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ABSTRACT  
Fabry disease (FD) is a rare, X-linked monogenic metabolic disorder caused by 
mutations in the α-galactosidase (αGal) coding gene – the GLA gene. The early-onset, 
multi-systemic FD classical phenotype is associated with absent or severe αGal 
deficiency but patients with higher levels of residual enzyme activity (REA) may have 
later-onset, more organ-restricted clinical presentations. The metabolic defect 
underlying FD is also thought to be the cause of a small-vessel cerebrovascular disease 
(CVD) associated with increased risk of stroke in young adults.  
The PortYStroke study – PAPER I – aimed to ascertain the prevalence of FD among 
Portuguese young adult incident stroke patients by GLA genotyping. From the 493 
patients who underwent genetic analyses, twelve had GLA missense mutations 
(p.Arg118Cys: n=6; p.Asp313Tyr: n=6). The estimated prevalence was 2.4% in the total 
cohort and 3.8% in the subset of patients with cryptogenic stroke. The αGal activity 
measured in leucocytes was subnormal in the hemizygous males and subnormal or low-
normal in the heterozygous females. None of those two GLA mutations is unequivocally 
associated with the classical FD phenotype, but both had been previously reported in 
patients with FD and were not found in over 400 X chromosomes of healthy Portuguese 
control subjects. The overall results demonstrated that despite a low diagnostic yield, 
screening for GLA mutations should probably be considered in different types of stroke 
and restricting investigation to patients with cryptogenic stroke may underestimate the 
true prevalence of FD in young patients with stroke.  
Post-hoc epidemiological analyses by screening available DNA samples from healthy 
cohorts of 360 males and 336 females, aged 18–45 years, allowed to calculate the allelic 
frequency of GLA Cys118 in the Portuguese population as ≈0.001 (1/1032), 95%CI 
<0.0001–0.006, and of GLA Tyr313 as 0.0019 (2/1032), 95%CI <0.0001–0.0075. As 
compared to the control population, the allelic frequencies of both GLA Cys118 and 
Tyr313 were significantly higher among the PortYStroke patients (=0.0087, 95%CI: 
0.004–0.019, Fisher’s exact test, respectively p=0.0185 and p=0.025). However, when 
the PortYStroke patients aged 45 years or less (n=204; 118 males) were entered as cases 
in a pair-matched case-control analysis, with healthy adult bone marrow donors used as 
gender- and age-matched controls, the estimated odds ratio for the risk of stroke among 
carriers of GLA p.Arg118Cys did not reach statistical significance. Taken together, 
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these findings suggest that subnormal αGal enzyme activity might be a quantitative, 
metabolic modulator of the multifactorial risk of CVD.  
Along with the epidemiological analyses outcomes, PAPER II presents the clinical, 
biochemical and histopathology data obtained from 22 individuals of Portuguese and 
Spanish ancestry carrying the Cys118 allele, including 3 homozygous females. Cases 
were identified either on the differential diagnosis of possible FD manifestations and on 
case-finding studies (n=11; 4 males), or on unbiased cascade screening of probands' 
close relatives (n=11; 3 males). This paper also includes microsatellite haplotyping 
studies in Portuguese individuals suggesting that the C>T transition underlying the 
emergence of p.Arg118Cys is a relatively frequent mutational event, in accordance with 
its location at a CpG dinucleotide. The critical review of these data suggests that the 
GLA p.Arg118Cys variant does not segregate with FD clinical phenotypes in a 
Mendelian fashion, but might indeed be a modulator of the multifactorial risk of CVD.  
The 5’-untranslated region (5’UTR) of the GLA gene shows a remarkable degree of 
variation with three common single nucleotide polymorphisms (SNPs) at nucleotide 
positions c.-30G>A, c.-12G>A and c.-10C>T. A fourth polymorphism at c.-44C>T, co-
segregating in cis with the c.-12A allele, was additionally identified in the PortYStroke 
study. The allelic frequencies of the GLA 5’-UTR SNPs did not significantly differ 
among three different Portuguese cohorts – (i) 256 index cases referred for FD 
screening by GLA genotyping (118 males); (ii) 504 patients with first-ever stroke before 
55 years old (308 males); and (iii) 382 healthy subjects (218 males) –, and were similar 
to those determined in other European populations. In vivo, the c.-30A allele is 
associated with higher enzyme activity in plasma, whereas c.-10T is associated with 
moderately decreased enzyme activity in leucocytes. Limited data suggest that c.-44T 
might be associated with increased plasma αGal activity. PAPER III describes the 
experimental assays performed with a luciferase reporter system in order to assess the 
relative modulatory effects on gene expression of the different GLA 5’UTR 
polymorphisms, as compared to the wild-type sequence, in four different human cell 
lines. Group-wise, the relative luciferase expression patterns of the various GLA variant 
isoforms differed significantly in all four cell lines, as evaluated by non-parametric 
statistics, and were cell-type specific. Some of the post-hoc pairwise statistical 
comparisons were also significant, but the effects of the GLA 5’UTR polymorphisms 
upon the luciferase transcriptional activity observed in vitro did not consistently 
replicate the in vivo observations. The data suggest that the GLA 5’UTR polymorphisms 
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are possible modulators of the αGal expression. Further studies are needed to elucidate 
the biological and clinical implications of these observations, particularly to clarify the 
effect of these polymorphisms in individuals carrying GLA variants associated with high 
REA, with no or mild FD clinical phenotypes.  
Deficient αGal activity leads to intracellular accumulation of globotriaosylceramide 
(Gb3) and related glycosphingolipids, which is the pathologic hallmark of FD. Recent 
data have shown that the deacylated derivative of Gb3 – globotriaosylsphingosine (lyso-
Gb3) – is possibly involved in the pathogenesis of FD and might be a clinically useful 
biomarker of its metabolic load. PAPER IV reports the results of the assays of Gb3 and 
lyso-Gb3 and related analogs in plasma and/or urine samples of 12 clinically well-
characterized subjects carrying several different GLA variant alleles associated with a 
wide range of residual αGal activities. Urinary Gb3 was measured by HPLC–MS/MS; 
plasma and urinary lyso-Gb3 and related analogs were measured by UPLC–MS/MS. 
The lyso-Gb3 analog at m/z 836 was found at increased levels only in patients 
manifesting clinically severe heart disease, irrespective of the pathogenicity of the GLA 
variant they carried. This finding suggests that this lyso-Gb3 analog might be an earlier 
biomarker of progressive heart disease, nonspecific of the FD cardiomyopathy. The 
results also suggest that urinary Gb3 might be a specific biomarker of kidney 
involvement in FD, but this possibility deserves further study. Individual profiles of Gb3 
and lyso-Gb3 and related analogs closely correlated with the phenotypic data for each 
subject, discerning the female patient with classical FD from the two patients with well-
established FD cardiac variants, as well as those carrying non-pathogenic (or of low 
pathogenicity) GLA variants, including the 5’UTR c.-10C>T SNP and the p.Arg118Cys.  
There are over 750 pathogenic variants identified in the GLA gene. The PortYStroke 
study cDNA-based GLA genotyping protocol was developed for time and cost-
effectiveness purposes and, afterwards, was applied for the first-tier 
screening/diagnostic test for FD in our laboratory. PAPER V reports that more than 
20% of the patients with CVD and/or left ventricular hypertrophy (LVH) referred for 
FD screening showed alternatively spliced transcripts of GLA cDNA involving exon 3. 
Additionally, it reports that such non-canonical transcripts are physiologically expressed 
at trace levels in healthy individuals and that their expression in leukocytes markedly 
increases in blood samples kept at room temperature for 48 hours before RNA 
extraction. Production of alternatively spliced GLA transcripts might be involved in the 
regulation of GLA gene expression, and its deregulated overexpression, particularly if 
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restricted to specific cells or tissues, might be the cause of organ-limited Gb3 pathology. 
Elucidation of the molecular mechanisms underlying the production of the non-
canonical GLA transcripts warrants further investigation, as it may contribute important 
new data to the understanding of the molecular pathology of FD and Gb3-related 
disorders.  
In summary, molecular analysis of the GLA gene for screening patients presenting with 
stroke and other likely manifestations of FD, frequently reveals sequence variants of 
unknown significance which are associated with a wide range of variation in the in vitro 
REA. The pathogenicity of these variants should be meticulously scrutinized, by 
detailed clinical evaluation and specific biochemical assays, ideally by ascertaining their 
phenotypes in hemizygous carriers. Some of these variants are associated with high 
REA and possibly modulate the risk of CVD. The combination of two or more of these 
variants, as well as their presence in individuals carrying GLA mutations known to be 
associated with mild, later-onset FD, may alter the phenotype of these patients.  
  
7 
 
RESUMO 
A Doença de Fabry (DF) é uma doença monogénica rara ligada ao cromossoma X 
causada por mutações no gene que codifica a α-galactosidase (αGal) – o gene GLA. As 
primeiras manifestações do fenótipo clássico começam na infância ou adolescência, são 
de envolvimento multissistémico, e estão associadas à ausência total ou a níveis 
residuais de atividade enzimática da αGal. Doentes com níveis de atividade enzimática 
menos reduzidos podem apresentar um fenótipo variante de apresentação tardia com 
manifestações clinicas restritas a determinados órgãos. O defeito metabólico subjacente 
à DF também é considerado causa de doença cerebrovascular de pequenos vasos 
estando associado ao risco aumentado de Acidente Vascular Cerebral (AVC) em adultos 
jovens.  
O estudo PortYStroke – ARTIGO I  – visou determinar a prevalência da DF em adultos 
jovens Portugueses com o 1º AVC através da genotipagem do gene GLA. Dos 493 
doentes que realizaram análise genética, doze apresentaram mutações do gene GLA do 
tipo missense (p.Arg118Cys: n=6; p.Asp313Tyr: n=6). A prevalência estimada destas 
mutações no total de doentes foi de 2,4%, e de 3,8% no subgrupo de doentes com AVC 
criptogénico. A atividade da αGal em leucócitos revelou-se subnormal nos homens 
hemizigotos, e subnormal ou no limite do normal nas mulheres heterozigotas. 
Nenhumas das duas mutações referidas está inequivocamente associada com a DF, mas 
ambas foram previamente reportadas em doentes com DF e não foram encontradas em 
mais de 400 cromossomas X de controlos saudáveis Portugueses. Na sua globalidade, 
os resultados demonstraram que apesar da baixa frequência a pesquisa de mutações no 
gene GLA deve ser considerada para os diferentes tipos de AVC, dado que restringir a 
investigação aos doentes com AVC criptogénico pode subestimar a verdadeira 
prevalência da DF em adultos jovens com AVC. 
Na sequência do estudo PortYStroke, as frequências dos alelos GLA Cys118 e GLA 
Tyr313 na população Portuguesa foram estimadas respetivamente em ≈0.001 (1/1032) e 
≈0.002 (2/1032), por genotipagem de 360 amostras de DNA de controlos saudáveis 
masculinos e em 336 femininos, com idades compreendidas entre os 18 e os 45 anos. 
Por comparação à população controlo as frequências alélicas do GLA Cys 118 e do GLA 
Tyr 313, foram significativamente mais altas nos doentes PortYStroke (=0.0087, 
95%CI: 0.004–0.019, teste exato de Fisher, respetivamente p=0.0185 e p = 0.025). No 
entanto, ao introduzir os casos PortYStroke com idades inferiores a 45 anos (n=204; 
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118 homens) numa análise emparelhada caso-controlo com dadores de medula adultos 
como controlos saudáveis correspondentes em sexo e idade, o odds ratio estimado para 
o risco de AVC em portadores da GLA p.Arg118Cys não atingiu significância 
estatística. Em conjunto, estes achados sugerem que a atividade subnormal da enzima 
αGal pode funcionar como um modulador metabólico quantitativo do risco multifatorial 
da doença vascular cerebral (DVC). 
Além dos resultados da análise epidemiológica post hoc, o ARTIGO II apresenta dados 
clínicos, bioquímicos e histopatológicos obtidos a partir de 22 indivíduos com 
ancestrais Portugueses e Espanhóis portadores do alelo Cys118, incluindo 3 mulheres 
homozigotas. Os casos foram identificados em estudos de rastreio em doentes de risco 
ou de diagnóstico diferencial de possíveis manifestações da DF (n = 11; 4 homens), ou 
em estudos em cascata dos familiares próximos ao probante (n = 11, 3 homens). Este 
artigo também inclui estudos de haplotipagem com microssatélites feitos em indivíduos 
Portugueses sugerindo que a transição do nucleótido C>T, que está na base da 
p.Arg118Cys, é um evento mutacional relativamente frequente, em conformidade com o 
facto de estar localizada num dinucleótido CpG. A revisão critica destes dados sugere 
que a variante GLA p.Arg118Cys não segrega com os fenótipos clínicos da DF de forma 
Mendeliana mas pode ser moduladora do risco multifatorial da DVC. 
A região 5’ não traduzida (5’-untranslated region, 5’UTR) do gene GLA apresenta um 
grau de variação notável com três polimorfismos nucleotídicos nas posições c.-30G>A, 
c.-12G>A e c.-10C>T. Um quarto polimorfismo na posição c.-44C>T, co-segregando 
em cis com o alelo c.-12A, foi adicionalmente identificado no estudo PortYStroke. As 
suas frequências alélicas foram analisadas em três grupos da população Portuguesa (i) 
256 casos índice com diagnóstico clinico de DF (118 homens); (ii) 504 doentes com o 
primeiro AVC antes dos 55 anos (308 homens); e (iii) 382 indivíduos saudáveis (218 
homens), e não apresentaram diferenças significativas. Quando comparados com 
estudos epidemiológicos feitos noutras populações os resultados das frequências alélicas 
destes polimorfismos nucleotídicos na população Portuguesa são idênticos. In vivo, o 
alelo c.-30A está associado a atividade enzimática elevada no plasma, enquanto o alelo 
c.-10T está associado com uma atividade enzimática leucocitária moderadamente 
diminuída. Os poucos dados disponíveis sugerem que o alelo c.-44T possa estar 
associado com um aumento da atividade da αGal no plasma. O ARTIGO III descreve os 
ensaios feitos com um sistema repórter de luciferase com o objetivo de medir os efeitos 
modulatórios dos vários polimorfismos da GLA 5’UTR na expressão génica 
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relativamente à sequência original, em quatro linhas celulares diferentes. Avaliados 
pelos testes não paramétricos de comparação de grupos múltiplos, os padrões da 
expressão relativa da luciferase correspondentes aos vários polimorfismos 5’UTR do 
gene GLA diferiram significativamente em todas as quatro linhas celulares, sendo 
específicos de tipo celular. Algumas das comparações post hoc usando análise 
estatística emparelhada também foram significativas, mas os efeitos dos polimorfismos 
GLA 5’UTR sobre a transcrição da luciferase observados in vitro não replicam de forma 
consistente as observações in vivo. Os dados sugerem que os polimorfismos GLA 
5’UTR são moduladores da expressão da αGal. Serão necessários mais estudos para 
esclarecer as implicações biológicas e clínicas destas observações, em particular para 
clarificar o seu efeito em indivíduos portadores das variantes do gene GLA associadas a 
atividade enzimática residual elevada, sem ou com um fenótipo clínico de DF 
moderado. 
A acumulação intracelular de glicosfingolípidos, em particular de globotriaosilceramida 
(Gb3), resultante de atividade enzimática deficitária da αGal é considerada o principal 
fator patogénico na DF. Dados recentes mostram que a forma desacilada da Gb3, 
também designada globotriaosilesfingosina (liso-Gb3), está possivelmente envolvida na 
patogénese da DF e pode ser um biomarcador da sobrecarga metabólica de elevada 
importância clínica. O ARTIGO IV reporta as análises de Gb3 e de liso-Gb3 e análogos, 
feitas em amostras de plasma e/ou urina de 12 indivíduos, clinicamente bem 
caracterizados, portadores de diferentes variantes alélicas do gene GLA associadas a um 
vasto espectro de atividades enzimáticas residuais da αGal. A Gb3 urinária foi medida 
por HPLC–MS/MS e a liso-Gb3, e respetivos análogos, presentes no plasma e na urina 
foram medidos por UPLC–MS/MS. O análogo da liso-Gb3 em m/z 836 foi encontrado 
em níveis aumentados apenas em doentes com manifestações clinicas de doença 
cardíaca grave, independentemente da patogenicidade da variante do gene GLA de que 
eram portadores. Tal facto sugere que este análogo da liso-Gb3 pode ser um marcador 
precoce de doença cardíaca progressiva, não específico da cardiomiopatia associada à 
DF. Os resultados deste estudo também realçam o Gb3 urinário como um possível 
marcador específico do envolvimento renal na DF, mas esta possibilidade requer mais 
estudos. Os perfis individuais de Gb3 e liso-Gb3 e respetivos análogos relacionam-se 
intimamente com os dados fenotípicos de cada indivíduo, distinguindo claramente o 
doente com variante clássica de DF dos dois doentes com variantes cardíacas assim 
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como todos os outros sem DF contando com os portadores da c.-10C>T e da 
p.Arg118Cys. 
Estão identificadas mais de 750 mutações no gene GLA. O protocolo de genotipagem do 
cDNA do gene GLA utilizado no estudo PortYStroke foi desenvolvido com o propósito 
de ser eficaz do ponto de vista económico e de consumo de tempo, e após a sua 
otimização foi aplicado ao diagnóstico de rotina da DF no nosso laboratório. O 
ARTIGO V reporta que mais de 20% dos doentes com DVC e/ou hipertrofia ventricular 
esquerda referidos para diagnóstico genético de DF apresentavam transcritos 
alternativos do gene GLA envolvendo o exão 3. Adicionalmente, reporta que tais 
transcritos não canónicos são expressos fisiologicamente a níveis vestigiais em 
indivíduos saudáveis, e a sua expressão em leucócitos aumenta consideravelmente em 
amostras mantidas à temperatura ambiente durante 48h antes da extração do RNA. A 
produção de transcritos alternativos do gene GLA pode estar envolvida na regulação da 
expressão génica, e a sua sobreprodução desregulada, particularmente em algumas 
células ou tecidos, pode ser causa de patologia secundária a acumulação de Gb3, 
limitada a órgãos específicos. A elucidação dos mecanismos moleculares que estão na 
base desta produção de transcritos não canónicos carece de investigação suplementar já 
que pode contribuir com dados importantes para a melhor compreensão da patologia 
molecular da DF e doenças relacionadas com a acumulação de Gb3. 
Em suma, o rastreio de DF por genotipagem revela frequentemente variantes de 
significado patogénico incerto do gene GLA que, estando na origem de uma vasta gama 
de valores de atividade residual da enzima αGal, podem estar associadas a fenótipos 
atenuados ou parciais de DF. Algumas destas variantes estão associadas com atividade 
enzimática residual relativamente elevada, podendo contribuir para o risco multifatorial 
de DVC. A concomitância de duas ou mais destas variantes num mesmo indivíduo, ou a 
sua presença em indivíduos portadores de variantes do gene GLA conhecidas como 
associadas a formas tardias de DF podem ser, respetivamente, causa de expressão 
clínica atenuada de DF ou de alteração do fenótipo clínico esperado naqueles doentes. 
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INTRODUCTION 
FABRY DISEASE 
Fabry disease (FD, OMIM 301500) is an inherited X-linked disorder that results from 
absent or deficient activity of the lysosomal hydrolase α-galactosidase A (αGal; EC 
3.2.1.22) [1, 2]. This enzyme defect impairs the catabolism of neutral 
glycosphingolipids, predominantly of globotriaosylceramide (Gb3), which progressively 
accumulate in the endothelium and smooth muscle cells of blood vessels, as well as in 
the heart, the kidney and the nervous system. The lifelong accumulation of the non-
degraded glycosphingolipids is the pathogenic basis of FD but the precise 
pathophysiologic mechanisms that lead to clinical manifestations are not entirely clear 
[3]. Although the enzyme deficiency is multisystemic [4], FD presents a considerable 
clinical heterogeneity, even within families. Patients are commonly classified into two 
major phenotypic groups according to the absence or presence of significant residual 
enzyme activity (REA) and the characteristics of the associated clinical manifestations: 
the classical phenotype and the atypical variants, the latter including the renal [5], the 
cardiac [6], and the more recently described, but still tentatively defined, 
cerebrovascular variant [7]. Like in other X-linked disorders, the affected males usually 
present the most severe clinical phenotypes while females have more variable, usually 
milder phenotypic expressions with later onset [1, 2].  
Diagnosis of FD in hemizygous males can be conclusively made by the demonstration 
of marked αGal deficiency in vitro, most commonly in leukocytes, plasma or dried 
whole blood spots; enzyme analysis may occasionally be helpful to identify 
heterozygotes, but is often inconclusive due to random X-chromosomal inactivation, 
making molecular testing (i.e. genotyping) mandatory for the diagnosis of FD in 
females [1, 2, 4]. 
 
Historical narrative 
The first clinical descriptions of the illness that would later become known by the 
current eponym designation were independently published in 1898 by William 
Anderson, in England [8], and Johannes Fabry, in Germany [9]. The major clinical 
finding in both cases was a peculiar, diffuse angiokeratomatous skin rash, leading to the 
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suspicion that they suffered from a predominantly dermatological condition [10]. 
However, the presence of proteinuria in his patient led Anderson to postulate that 
abnormal vessels might also be present in the kidneys as well as in the skin, as a 
manifestation of a more generalized disorder. Fabry characterized the skin lesions as 
small vessel aneurisms and eventually coined the descriptive name angiokeratoma 
corporis diffusum for the clinical condition. In later follow-up publications on the same 
patient, Fabry reported the development of proteinuria and his demise from lung disease 
at the age of 43 years [11].  
During the next decades, a number of clinicians made important contributions to the 
phenotypic description of the disease, which appeared to consist mainly of pain in the 
hands and feet (“acroparesthesias”), multiple cutaneous angiokeratomas, corneal 
dystrophy, angina pectoris, and impaired renal function, with uraemia being the major 
cause of death [10, 12].  
Pompen et al. [13] reported the first autopsy studies of patients with angiokeratoma 
corporis diffusum in 1947. Based on the observation of abnormal cytoplasmic vacuoles 
in many different types of cells throughout the body – which was particularly prominent 
in the wall of arterial blood vessels, the heart and the kidneys –, they postulated that the 
disease might be a generalized storage disorder. Other major post-mortem findings were 
cardiac hypertrophy and scarring of the kidneys, with glomerular sclerosis and 
interstitial fibrosis. The lipid nature of the accumulated material was subsequently 
established by Scriba [14] who, a few years later, in collaboration with Hornbostel [15], 
histologically confirmed the diagnosis of angiokeratoma corporis diffusum on a living 
patient, by examination of a skin biopsy.  
Shortly after the recognition that angiokeratoma corporis diffusum was a familial 
disorder, Opitz identified its X-linked recessive inheritance by pedigree analysis [16]. In 
1963, Sweeley and Klionsky isolated and characterized two novel neutral 
glycosphingolipids from the kidney of an affected male, with Gb3 present in much 
higher amount, and classified the disease as a sphingolipidosis. In 1967, Brady et al. 
[17] identified the metabolic defect in FD as a deficiency in a lysosomal galactosyl 
hydrolase required for the catabolism of Gb3. Three years later, Kint [18] reported that 
the leukocytes of male FD patients were deficient in α-galactosidase A, an enzyme that 
specifically hydrolysed terminal, non-reducing galactosyl(α14) moieties from 
glycolipids and glycoproteins. The identification of the biochemical defect underlying 
FD permitted the development of laboratory methods for measuring the enzyme activity 
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in cells and body fluids, allowing the specific diagnosis of hemizygous males and the 
presumptive identification of heterozygous females [19], as well as prenatal diagnosis 
of affected male foetuses [20]. The background hydrolytic activity against Gb3 observed 
in affected males was eventually attributed to a second glycosidase, later identified as α-
N-acetylgalactosaminidase but then named α-galactosidase B [21], which possesses 
partial α-galactosidase activity. The way was opened for the development of enzyme 
replacement as a specific therapy for FD and the results of pilot trials with intravenous 
infusion of normal plasma [22] or of highly purified enzyme extracted from human 
placental tissue [23] reported in the early 70’s, provided proof of concept.  
The next major steps in the understanding of FD were the isolation of the full-length 
complementary DNA (cDNA) encoding the human αGal, in 1986 [24], followed by the 
establishment of the complete genomic sequence of the human GLA gene, in 1989 [25]. 
This allowed the identification of the disease–causing mutations and the introduction of 
genetic testing as a standard diagnostic tool, which has particular relevance for the 
recognition of the heterozygous females, as well as for prenatal and pre-implantation 
diagnoses.  
The advancements in bioengineering technologies in the last 40 years have provided the 
pharmaceutical industry with the capabilities for large-scale manufacturing of functional 
recombinant human glycoproteins of therapeutic interest. Two forms of recombinant 
human αGal, respectively agalsidase alfa e agalsidase beta, have proved clinically useful 
[11, 26-28] and were granted approval for enzyme replacement therapy (ERT) of FD in 
2001. While there is evidence that long-term ERT can halt disease progression, 
particularly when started at early stages [29, 30], the importance of non-specific 
adjunctive and supportive therapies, especially for patients with established or 
irreversible complication of the disease, should not be overlooked. To avoid the 
inconveniences of life long bi-weekly intravenous infusions of agalsidase and some of 
their pharmacologic limitations – namely the inability to cross the blood-brain barrier –, 
the development of specific oral therapies for FD, either by using pharmacological 
chaperones to rescue responsive mutations [31] or inhibitors of glucosylceramide 
synthase for substrate reduction [32], is a major focus of current investigation. 
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Clinical manifestations 
The clinical manifestations of the classical phenotype of FD are the expression of the 
underlying involvement of multiple organ systems. The presenting and more 
distinguishing symptoms are periodic dysesthesias – that may be highly painful –, in the 
hands and feet (“acroparesthesias”); vascular skin lesions (angiokeratomas), most 
typically distributed to the periumbilical region, lower abdomen and thighs; decreased 
or absent sweating (hypo- or anhidrosis), leading to exercise and heat intolerance, and to 
recurrent febrile episodes; characteristic corneal (cornea verticillata) and lenticular 
opacities; and nonspecific gastrointestinal symptoms [1, 2]. Although these features do 
not influence lifespan, most of them have a profound impact on quality of life and self-
esteem of FD patients. In contrast, a number of other FD-related progressive renal, 
cardiac and cerebrovascular complications considerably decrease the life expectancy of 
untreated males and females. In the United Kingdom, the median cumulative survival of 
FD patients from classically affected families has been estimated as 50 and 70 years, 
respectively for males and females, representing reductions of 20 and 15 years in 
comparison to the general population [33, 34].  
The renal involvement in patients with FD may be suspected by the appearance of 
albuminuria and/or decreased glomerular filtration rate (GFR) [35]. Renal 
manifestations of FD occur early in life, often starting in the 2nd or 3rd decade [2], 
preceding the development of significant cardiac or cerebrovascular complications. In 
the untreated affected males, renal function gradually declines, eventually resulting in 
end-stage renal disease (ESRD) requiring dialysis or renal transplant by the 5th decade 
of life [1].  
Cardiac symptoms are common in adult FD patients, including dyspnoea, chest pain, 
palpitations and syncope [36]. These symptoms are mainly related to the development 
of progressive cardiac hypertrophy typically involving the left ventricular wall and the 
interventricular septum, conduction abnormalities and arrhythmias [2, 36]. The left 
ventricular hypertrophy (LVH) may compromise the cardiac output, resulting in 
decreased exercise tolerance, and rhythm abnormalities may be the cause of sudden 
death and require implantation of a cardioverter defibrillator or a pacemaker. Atrial 
fibrillation is a major nonspecific cause of cardioembolic stroke in patients with FD [37, 
38].  
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Another of the life-threatening complications of FD is the cerebral vasculopathy [39]. 
Transient ischaemic attacks (TIA) and ischaemic strokes are the most prevalent types of 
cerebrovascular events in patients with FD, but cerebral haemorrhages and cerebral 
venous thromboses have also been reported [38]. Stroke was the first serious FD 
complication experienced by many FD patients, many of whom were not aware of their 
underlying condition [39]. The cerebrovascular manifestations of FD result primarily 
from multifocal small–vessel involvement [1] and although stroke occurs in both the 
anterior and the posterior arterial territories, as well as in cortical and subcortical 
locations, the proportion of patients with involvement of the posterior circulation is 
higher among FD patients than in other stroke populations [38]. Repeated cerebral 
infarctions may lead to cognitive dysfunction and vascular dementia [40, 41]. The 
recurrence rate for cerebrovascular events in FD patients have been reported to be 76% 
in males and 86% in females, with death rates of 55% and 40%, respectively [42]. The 
FD-related renal and cardiac diseases exacerbate the risk of cerebrovascular 
complications: for instance, it has been demonstrated that FD patients with relatively 
stable GFR had fewer strokes than those with more rapidly progressing chronic kidney 
disease [43]. Neuroimaging features of cerebrovascular involvement in FD include 
white matter lesions; dolichoectasia, most typically of the basilar artery; and the 
"pulvinar sign", a T1 magnetic resonance imaging (MRI) hyperintensity of the posterior 
thalamus [37, 44].  
Atypical variants have few or none of the hallmark symptoms of classical FD, and have 
manifestations confined predominantly to one organ system, most frequently to the 
heart. In contrast to their classically affected counterparts in whom αGal activity is 
extremely low or absent, atypical variants are associated with residual αGal activity that 
varies between 2 and 20% of normal [2]. Possibly for this reason, the atypical variants 
recapitulate the respective organ features present in the classical variant with the 
exception of the endothelial disease which is usually absent in the presence of high 
residual enzymatic activity. Patients with atypical variants exhibit symptoms much later 
in life (4th to 6th decades) than patients with classical disease and are often identified 
serendipitously. Notably, many individuals diagnosed with the cardiac variant have 
mild proteinuria, secondary to podocyte Gb3 storage [1, 45]. 
Although many of the affected females are relatively asymptomatic and have a normal 
lifespan, up to 20% of those enrolled at a global FD registry experienced major 
18 
 
cerebrovascular, cardiac, or renal complications events, at a median age of 46 years 
[46].  
 
Epidemiology 
Classic FD is a rare pan-ethnic disorder with an estimated prevalence in new-born males 
ranging from 1 in 40,000 to 1 in 60,000 [1, 47]. The reported frequencies in the general 
population vary from 1 in 476,000 [48] to 1 in 117,000 [49] but these figures may 
largely underestimate the true prevalence. In the last 20 years, large scale screening 
studies of patients on haemodialysis [5, 50, 51], or with unexplained LVH or 
hypertrophic cardiomyopathy [6, 52], or presenting with cryptogenic stroke [7], allowed 
the identification of many previously undiagnosed patients with attenuated, more organ-
limited forms of FD. New-born screening programs have found unexpectedly high 
prevalences of the disease, reaching 1:3,100 in Italian males [53], with the overall allelic 
frequency of GLA mutations associated with later-onset forms of FD exceeding by 11:1 
ratio that of mutations associated with classic FD. Founder mutations may explain the 
particularly high prevalence of FD observed in certain populations: for example, in the 
Chinese population of Taiwan, where the birth prevalence of FD is approximately 
1:1,368 male neonates, ~80% of the cases carry a single intronic mutation associated 
with a late-onset cardiac variant of FD [54].  
The cardiac variant is the most widely reported atypical variant of FD, denoting patients 
presenting with cardiac manifestations in the absence of overt systemic involvement 
[55-57]. In a pivotal Japanese study, 7 (3%) of 230 unselected patients with LVH had 
clinically unsuspected FD [6]. Reports suggesting that FD should be considered in all 
cases of unexplained hypertrophic cardiomyopathy [52, 58, 59] have resulted in 
effective screening efforts to diagnose FD in high-risk adult patient populations.  
There are also reports of hemizygous males with disease manifestations confined to the 
kidney. Renal variants have been identified among ESRD Japanese patients on chronic 
dialysis who had been misdiagnosed with chronic glomerulonephritis [5]. Those 
patients had absent or low αGal activity and were subsequently found to have 
pathogenic GLA gene mutations. Such findings suggest that FD may be underdiagnosed 
among ESRD patients on renal replacement therapies – i.e., dialysis or transplant. Yet, 
their detection is important since these patients may develop severe cardiac or 
cerebrovascular complications. In a large case-finding study among Portuguese patients 
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on haemodialysis, the prevalence of FD among the ≅2500 screened males was 0.0016, 
but its diagnosis had been missed in three of the four identified patients [60].  
The existence of a cerebrovascular variant of FD remains controversial [37, 38] and the 
results obtained from several FD screening studies among stroke populations are 
diverse. While in some of these studies no patient with FD was identified [61, 62] others 
have reported FD in 0.5% to 3.9% of the stroke population [7, 63-66]. 
Taken together, these data suggest that FD, particularly the attenuated later-onset 
phenotypes presenting with nonspecific clinical manifestations, may be overlooked in 
many cases, requiring a high index of suspicion to be correctly diagnosed in individual 
patients.  
 
The GLA gene 
The human GLA gene is a housekeeping gene located at the long arm of the X 
chromosome (Xq22.1). The genomic region spans over 10.12kb and comprises seven 
exons, ranging in size from 92 to 291 nucleotides. The size of the introns varies between 
0.2kb to 3.7kb [24, 25] and all exon and intro boundaries follow the GT/AG rule. The 
GLA gene is one of the most Alu-rich human genes and all the 12 Alu-repetitive 
elements, which represent about 30% of the gene, are located within the introns.  
Many putative regulatory elements have been identified in the promoter region of the 
GLA gene, including sequences similar to TATA and CCAAT boxes, consensus 
sequences for the GC box, and several possible sites for the binding of enhancers [67]. 
Apart the regulatory elements and repeats, the GLA promotor also contains a CpG 
island – CpG islands are CG-rich DNA stretches commonly found in housekeeping 
genes, where their unmethylated status keep the genes active [68]; on the other hand, 
methylation of CpG islands of X-linked genes is one of the mechanisms thought to be 
involved in the random inactivation of one of the X-chromosomes in females [69].  
The 5’-untranslated region (5’UTR) of the GLA gene shows a remarkable degree of 
genetic variation. Three single nucleotide polymorphisms (SNPs) have been commonly 
identified in healthy individuals of several ethnically different populations [70-73], 
including the Portuguese [74], at positions c.-10(C>T), c.-12(G>A) and c.-30(G>A), 
counting backwards from the first nucleotide of the AUG start codon. At the NCBI 
Single Nucleotide Polymorphism Database (dbSNP), these SNPs are respectively 
identified as rs2071225, rs3027585 and rs3027584 [http://www.ncbi.nlm.nih.gov/snp/; 
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last accessed on April 1, 2016]. Another GLA 5’UTR variant, at position c.-44(C>T), 
has so far been identified only in Portuguese subjects [63]. The dbSNP lists an 
additional common GLA 5’UTR SNP, at position c.-8(C>G), identified as rs371291716, 
but this variant has never been reported in Portuguese individuals.  
As compared to the wild-type (WT) allele, the c.-30A allele is associated with 
significantly increased plasma αGal activity [70, 75], the c.-10T allele is associated with 
significantly decreased activity of αGal in leukocytes [74, 76] and limited data suggest 
that the c.-44T allele might be associated with increased plasma αGal activity [63]. In 
contrast, the c.-12(G>A) SNP seems to have no effect upon GLA gene expression [74].  
The GLA 5’UTR contains a binding site for methylated DNA-binding protein 
(MDBP)/RFX1-4 transcription factor family [77, 78], as well as partially overlapping 
binding motifs for the NFκB and Ets transcriptional regulatory factors [70, 75], and 
protein ligands to these sites are probably involved in the transcriptional regulation of 
GLA gene expression [70, 75, 79]. 
The GLA mRNA is 1,45kb long and, for a human nuclear-encoded mRNA, has the 
unusual feature of lacking a 3'-untranslated sequence [80], with the polyadenylation 
signal included in the coding region and the stop codon immediately followed by the 
poly-A tail.  
More than 750 disease-causing GLA mutations are reported at the Human Gene 
Mutation Database – HGMD® [http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GLA; last 
accessed on April 1, 2016], most of them being private to single families. The GLA 
gene mutations identified in FD patients may be pathogenic by affecting the synthesis, 
the intracellular processing, or the stability of αGal, or by compromising its catalytic 
activity. Although the correlations between the level of αGal enzyme activity measured 
in vitro and the type of GLA mutations or sequence variants are not entirely clear, some 
broad generalizations can be made: (i) point mutations that compromise the active site 
of the enzyme lead to loss of enzyme activity and are associated with the classic FD 
phenotype [81]; (ii) conservative missense mutations are associated with significantly 
higher REA as compared to non-conservative missense mutations or with nonsense, 
deletion or insertion mutations [82]; (iii) point mutations that affect buried residues in 
the hydrophobic core of αGal lead to folding defects in the enzyme and reduce its 
stability, thereby decreasing the amount of active enzyme transported to the lysosome 
[81] – this class comprises the largest group of disease-causing mutations and can be 
associated with either the classic or variant FD phenotypes; (iv) mutations associated 
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with the later-onset FD phenotypes tend to be more solvent-accessible than the 
mutations that cause the classic phenotype [81]; finally, (v) two deep intronic mutations 
in exon 4 lead to the abnormal transcription of a cryptic exon in intron four, the severity 
of the clinical phenotype being correlated with the ratio of the wild type versus the 
abnormally spliced GLA mRNA isoforms since the latter are thought to undergo 
nonsense mediated decay. 
 
The α-galactosidase A 
The αGal mRNA transcript encodes a 50kDa precursor polypeptide of 429 amino acids, 
including a 31-residue signal sequence, which is removed during the folding of the 
protein in the endoplasmic reticulum (ER) [83]. The αGal precursor is glycosylated 
during translation and subsequently transported to the Golgi apparatus where it is 
recognised by the mannose-6-phosphate receptors, which mediate vesicular transport 
and delivery into lysosomes. The processed mature lysosomal αGal monomers have a 
molecular weight of 46kDa [83]. The αGal monomers contain three N-linked complex 
carbohydrates and five disulfide bonds and associate as homodimers to form the mature 
functional αGal enzyme, which has a native molecular weight of approximately 101kDa 
[84]. The circulating isoform of αGal contains 10-12 sialic acid residues, whereas the 
placental form has only one or two [84]: these negatively-charged sialic acid residues 
are presumably responsible for the prolonged circulatory half-life of the plasma enzyme, 
escaping liver uptake by asialoglycoprotein receptors [85].  
The three-dimensional structure of human αGal was elucidated by x-ray crystallography 
[81]. The crystal structure showed that each monomer is composed of two domains: the 
N-terminal domain, containing the active site, is a classic (β/α)8 barrel; and the C-
terminal domain contains eight antiparallel β strands packed into a β sandwich. 
Residues 32-330 comprise the N-terminal domain, and residues 331-429 fold into the C-
terminal antiparallel domain [81].  
 
Pathophysiology 
The lysosomal hydrolytic activity of αGal is critical for the normal catabolism of neutral 
glycosphingolipids [17, 18] and its deficiency causes the accumulation of undegraded 
substrates, especially of Gb3 and of its deacylated derivative globotriaosylsphingosine 
(lysoGb3) [86]. The progressive storage of Gb3 in cells and tissues triggers an array of 
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secondary pathogenic cascades eventually leading to cellular dysfunction [87, 88] and to 
inflammatory and/or fibrotic phenomena [89]. In vitro studies have shown that lysoGb3 
is a potent competitive αGal inhibitor, induces proliferation of smooth muscle cells, and 
may have deleterious effects on the intima and media of small arterioles [86]. However, 
the relationship between glycosphingolipid storage and the advent of symptoms is not 
clear. For instance, in the knockout mice model of FD the extensive deposition does not 
result in clinical symptoms during the animal normal life-span [90].  
The FD-associated vasculopathy underlying the diverse vascular phenotypes described 
in FD patients apparently results not only from glycosphingolipid accumulation but also 
from a variety of other secondary factors, including inflammatory response, which may 
be triggered in response to abnormal endothelial and vessel wall function. It has been 
hypothesised that the FD vasculopathy is associated with abnormalities of blood 
components, of blood flow and of the vessel wall (Virchow's Triad) leading to vascular 
dysfunction [3]. Furthermore, the pathophysiological responses to glycosphingolipids 
storage are possibly heterogeneous in different vascular beds, and the microvascular 
endothelial cells seem to be affected earlier and more severely than those of larger 
vessels [91]. This FD-related vasculopathy might be exacerbated in individuals who 
have other prothrombotic risk factors [92]. In fact, lifestyle-related factors like smoking, 
obesity and dyslipidaemia [93], as well as genetic modifiers like interleukin-6, protein 
Z, angiotensin promoter, angiotensin II receptor type I polymorphisms and others [94], 
could add to the risk of stroke in young FD patients.  
Lysosomal Gb3 storage is found in various cells of the heart, including cardiomyocytes, 
conduction system cells, valvular fibroblasts, vascular endothelial cells and vascular 
smooth muscle cells. However, the amount of stored Gb3 by itself does not explain the 
observed increase of cardiac mass [55]: apparently, the progressive lysosomal Gb3 
storage leads to cellular malfunctioning that, in turn, activates common signalling 
pathways leading to hypertrophy, apoptosis, necrosis and fibrosis, ultimately explaining 
the clinical, electrophysiological and histopathological manifestations that characterize 
the natural history of cardiac FD [36].  
The renal involvement is characterized by glycosphingolipid deposits in many cell types 
in the renal glomerulus (particularly in podocytes, mesangial cells and endothelial 
cells), tubular epithelial cells (particularly of the distal nephron), and vascular cells 
(endothelial cells of capillaries, veins and arteries, and vascular smooth muscle cells) 
[35]. Histologically, the progression of kidney disease is characterized by nonspecific 
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glomerulosclerosis, tubular atrophy, and interstitial fibrosis [95]. The vascular 
involvement, with progressive luminal narrowing and consequent ischaemia, is one of 
the major mechanisms of renal injury in FD: in this regard, the renal vasculature is 
similar to the coronary and cerebral vessels, in which the deposition of Gb3 is associated 
with premature vascular disease. Accumulation of Gb3 within the podocytes constitutes 
a second important mechanism of kidney injury: by disturbing the physiology of the 
glomerular filtration barrier, podocyte involvement is in the genesis of albuminuria and 
glomerulosclerosis [96-98]. Finally, the deposition of Gb3 within tubular epithelial cells 
and in interstitial capillaries may lead to focal tubular atrophy and interstitial fibrosis.  
The neurological manifestations of FD involve both peripheral nervous system and 
central nervous system (CNS), with Gb3 accumulation found in dorsal root ganglia and 
Schwann cells, as well as deposits in CNS neurons [99, 100]. But the abnormal neuronal 
accumulation of glycosphingolipids seems to have little clinical effect on the natural 
history of FD, with the possible exception of some reported mild cognitive 
abnormalities [101]. The main involvement of the CNS is attributable to the cerebral 
vasculopathy, with an increased incidence of stroke. Major factors in the 
pathophysiology of FD-associated ischaemic stroke include the progressive increase in 
the intima-media thickness of the carotid artery, abnormalities of the cerebrovascular 
autoregulation and vasoreactivity leading to dysfunction of the cerebral circulation, and 
dolichoectasia of large cerebral arteries, particularly of the vertebrobasilar territory. 
Ischaemic stroke may also result from cardiac embolism, as a complication of the 
arrhythmias that frequently occur in patients with FD related-cardiomyopathy [37, 38]. 
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EPIDEMIOLOGICAL CONTEXT AND AIMS OF THE THESIS 
Stroke in young adults is an important cause of morbidity and mortality worldwide 
[102, 103] . Despite extensive investigation, the aetiology of stroke in young adults 
remains to be determined in up to 25% to 50% of cases [102, 103]. In Portugal 
(population approximately 10 million), there are an estimated 3000 new cases of stroke 
occurring every year in people aged 18 to 55 years, and stroke is still the leading overall 
cause of mortality, accounting for about 20% of all deaths.[104]  
Patients with FD develop a complex cerebral vasculopathy, characterized by 
abnormalities in blood vessel walls, blood components, and altered blood flow, making 
them more prone to ischaemic cerebrovascular disease (CVD) [3, 37, 38]. As a 
consequence, young adult FD patients have an increased risk of stroke since young 
adulthood [1, 4, 105]. Stroke in FD frequently occurs before the diagnosis of the 
underlying disease and in the absence of other clinical events, making the recognition of 
its aetiology particularly difficult [7, 39]. 
We hypothesised that under the particular epidemiological circumstances of the 
Portuguese population, with a strong environmental pressure favouring the development 
of CVD, hypomorphic GLA variants might be associated with a higher risk of stroke as 
compared to other European populations. The methodological design of the 
PortYStroke study, which used GLA genotyping as the case-finding diagnostic tool, 
allowed us to determine the prevalence of GLA variants among incident Portuguese 
young adult stroke patients of both genders [63] . The aim of this Thesis was to 
characterize at the molecular, biochemical and clinical levels the GLA variants 
identified in that study, as well as a number of other variants identified in additional 
young adult Portuguese stroke patients, and to establish clinically meaningful genotype-
phenotype correlations. 
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PAPER I 
Mutations of the GLA gene in young patients with stroke: the 
PORTYSTROKE study – screening genetic conditions in PORTuguese 
Young STROKE patients. 
Stroke 2010; 41:431-436. 
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Mutations of the GLA Gene in Young Patients With Stroke
The PORTYSTROKE Study—Screening Genetic Conditions in
PORTuguese Young STROKE Patients
Miguel Viana Baptista, MD; Susana Ferreira, BSc; Teresa Pinho-e-Melo, MD; Marta Carvalho, MD;
Vítor T. Cruz, MD; Ca´tia Carmona, MD; Fernando A. Silva, MD; Assunc¸a˜o Tuna, MD;
Miguel Rodrigues, MD; Carla Ferreira, MD; Ana A.N. Pinto, MD; Andre´ Leita˜o, MD;
Joa˜o Paulo Gabriel, MD; Sofia Calado, MD; Joa˜o Paulo Oliveira, MD, PhD; Jose´ M. Ferro, MD, PhD;
on behalf of the PORTYSTROKE Investigators
Background and Purpose—Fabry disease is an X-linked monogenic disorder caused by mutations in the GLA gene. Recent
data suggest that stroke in young adults may be associated with Fabry disease. We aimed to ascertain the prevalence
of this disorder among young adult patients with stroke in Portugal by GLA genotyping.
Methods—During 1 year, all patients aged 18 to 55 years with first-ever stroke, who were admitted into any of 12
neurology hospital departments in Portugal, were prospectively enrolled (n625). Ischemic stroke was classified
according to Trial of Org 10172 in Acute Stroke Treatment criteria. Alpha-galactosidase activity was further assayed
in all patients with GLA mutations.
Results—Four hundred ninety-three patients (mean age, 45.4 years; 61% male) underwent genetic analyses: 364 with ischemic
stroke, 89 with intracerebral hemorrhage, 26 with subarachnoid hemorrhage, and 14 with cerebral venous thrombosis. Twelve
patients had missense GLA mutations: 9 with ischemic stroke (p.R118C: n4; p.D313Y: n5), including 5 patients with an
identified cause of stroke (cardiac embolism: n2; small vessel disease: n2; other cause: n1), 2 with intracerebral
hemorrhage (p.R118C: n1; p.D313Y: n1), and one with cerebral venous thrombosis (p.R118C: n1). Leukocyte
-galactosidase activity was subnormal in the hemizygous males and subnormal or low-normal in the heterozygous females.
Estimated prevalence of missense GLA mutations was 2.4% (95% CI, 1.3% to 4.1%).
Conclusions—Despite a low diagnostic yield, screening for GLA mutations should probably be considered in different
types of stroke. Restricting investigation to patients with cryptogenic stroke may underestimate the true prevalence of
Fabry disease in young patients with stroke. (Stroke. 2010;41:431-436.)
Key Words: gene  GLA  stroke  young
Stroke in young adults is an important cause of morbidityand mortality worldwide.1,2 In Portugal (population ap-
proximately 10 million), it is estimated that up to 3000 new
cases occur every year in the population aged 18 to 55 years.3
Despite extensive investigation, the cause of stroke in young
adults remains to be determined in up to 25% to 50% of
cases.1,2
Fabry disease (FD) is a rare X-linked lysosomal storage
disorder associated with increased risk of stroke in young
adults.4–7 The classical phenotype presents with early derma-
tologic, ophthalmologic, and peripheral nervous system in-
volvement. Renal, cardiac, and cerebrovascular complica-
tions are major causes of morbidity and mortality in adults.
Late-onset atypical phenotypes have also been reported.4
Because its clinical recognition requires a high index of
suspicion, the diagnosis of FD is often delayed or missed.5
Early diagnosis became particularly important because en-
zyme replacement therapy may prevent the late renal and
cardiac complications6,7 and seems to have a beneficial effect
on abnormal cerebral blood flow.8,9
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The underlying metabolic defect in FD is a deficiency of
lysosomal -galactosidase (Gal) due to mutations in the
Gal gene locus (GLA) located at Xq22.4,10 Deficient Gal
activity ultimately leads to widespread intracellular accumu-
lation of globotriaosylceramide and related neutral glyco-
sphingolipids, including in vascular endothelial and smooth
muscle cells.4,7 Mutations have been described throughout all
7 GLA exons and most families have private mutations.4,10
Typical for X-linked disorders, FD has a more variable and
usually milder and later phenotypic expression in females.4–7
A recent prospective study of cryptogenic stroke in young
adults (n721), using an Gal enzyme assay for screening,
suggested that up to 1.2% of patients with stroke 55 years
of age might have FD.11 However, the GLA mutations
identified in these cases were never reported. Moreover, in a
smaller retrospective study of similar patients (n103), no
GLA mutations were found in any of the subjects who had
low enzyme activity.12 The PORTuguese Young STROKE
Patients (PORTYSTROKE) study was designed to screen for
genetic disorders in young patients with stroke. We report the
results of GLA mutational analysis as the screening approach
to FD.
Methods
The PORTYSTROKE clinical protocol and the data collection and
storage procedures were approved respectively by the ethics com-
mittee of each participating hospital and by the Portuguese authority
for data protection. A computer database for online data entry was
specifically developed and monitored by an independent clinical
research organization. Individual patient records included demo-
graphic data, history of vascular risk factors, medical history, family
history emphasizing the classical features of FD, and the clinical and
brain imaging (CT or MRI) characteristics of stroke. Ischemic stroke
(IS) was classified according to the Trial of Org 10172 in Acute
Stroke Treatment (TOAST) criteria.13 The molecular genetics labo-
ratory was blinded as to the clinical and imaging data of each patient.
Patients
From November 1, 2006, through October 31, 2007, all patients aged
18 to 55 years presenting with first-ever stroke, admitted to neurol-
ogy departments in any of 12 major Portuguese hospitals, were
eligible for this study. Patient enrollment for genotyping required
written informed consent.
Laboratory Methods
Venous blood samples for molecular genetic analyses were collected
in tubes containing 5% edetate and mailed to the laboratory at room
temperature. Genomic DNA (gDNA) samples were extracted from 1
mL of blood with the Citogene Blood Kit (Citomed, Lisbon,
Portugal) and banked at 4°C. Leukocyte pellets were prepared from
5 mL of blood and frozen at 80°C until used for RNA extraction.
Total cellular RNA was extracted using the RNeasy Mini Kit
(Qiagen, Hilden, Germany).
Two partially overlapping cDNA fragments, together comprising
1371 nucleotides of the 1418-nucleotide sequence of GLA messenger
RNA, were amplified from the RNA samples by reverse transcrip-
tion–polymerase chain reaction (PCR). The cDNA reverse
transcription-PCR amplicons contained a common sequence in their
respective 3 and 5 terminals, corresponding to part of exon 4. When
the cDNA could not be obtained, all 7 GLA exons and respective
exon/intron boundaries were PCR-amplified from the gDNA sam-
ples. The reverse transcription-PCR and PCR products were purified
and automatically sequenced in forward and reverse directions.
Details of these laboratory methods have been formerly published.14
The reference GLA gDNA and cDNA nucleotide sequences, respec-
tively GenBank Version X14448.1 and RefSeq Version NM_000169.2,
were obtained from the National Center for Biotechnology Information
(Bethesda, Md; www.ncbi.nlm.nih.gov/entrez/). Mutations detected in
the original GLA cDNA or gDNA analyses were confirmed in a
duplicate PCR amplification of the corresponding exon using the stored
gDNA samples.
A second blood sample for Gal enzyme assays was obtained
from all patients in whom a GLA mutation was identified. Plasma
and leukocyte activities of Gal were measured using a standard
fluorometric method.15 Normal range values for Gal enzyme
activity were 6 to 19 nmol/h/mL in plasma and 36 to 80 nmol/h/mg
in leukocytes.
In carriers of missense GLA mutations that were associated with
subnormal enzyme activity, multiplex ligation-dependent probe am-
plification (SALSA MLPA kit P159 GLA; MRC-Holland, Amster-
dam, The Netherlands) was additionally used to rule out the presence
of coexisting gross gene deletions and/or duplications that might
have been missed by gDNA or cDNA sequencing.
Control Population and Screening
To estimate the frequency in the general population of the missense
GLA mutations found in the stroke patient cohort, we used banked
gDNA samples of 130 (50 males) undergraduate medical students
aged 20 to 25 years, of 40 fertile males, aged 25 to 35 years, and of
130 (95 males) volunteer bone marrow donors, aged 25 to 45 years.
These control subjects were screened for the relevant GLA mutations
(see “Results”) by restriction enzyme analysis. To this end, endo-
nucleases HinfI and Hpy188III were selected with the NEBcutter
software (http://tools.neb.com/NEBcutter2/), respectively to identify
alleles p.R118C and p.D313Y. GLA exons 2 and 6 were PCR-
amplified as described14 and the digestion of the corresponding
amplicons was carried out according to the instructions of the
enzyme manufacturer (New England BioLabs, Hitchin, UK). In the
restriction analyses, gDNA samples of p.R118C or p.D313Y het-
erozygous carriers from the patient cohort were used as positive
controls.
Statistical Analyses
Parametric and nonparametric statistical analyses, as appropriate,
were performed with the SPSS software, Version 15.0. The preva-
lence of GLA gene mutations among patients and the corresponding
allele frequencies among healthy control subjects were estimated
using 95% CIs.16 Demographic and clinical data were summarized
using descriptive statistics. Comparisons of risk factors, personal
background, and family history were done according to demographic
characteristics (sex and age) and the presence or absence of GLA
gene mutations. The relative prevalence of GLA mutations was
compared for patients with or without evidence of small vessel
disease (lacunar stroke or leukoencephalopathy) and according to the
presence or absence of hypertension. The hypothesis that stroke in
the posterior circulation might have been relatively more frequent in
patients with missense GLA mutations7,17 was also specifically
addressed. A significance level of 0.05 was assumed for all
statistical tests.
Results
During the enrollment period, a total of 625 patients were
eligible for inclusion. Of these, 15 refused consent, 21 died
before inclusion, and 96 were lost for other reasons. There-
fore, the study cohort comprised 493 patients (61% males)
with a mean age of 45.4 years. The Table summarizes
demographic and clinical features of the enrolled patients. IS
occurred in 364 patients, intracerebral hemorrhage in 89,
subarachnoid hemorrhage in 26, and cerebral venous throm-
bosis (CVT) in 14.
Screening for GLA mutations was based on cDNA se-
quence analysis in 68% of the cases. As detailed in the Figure,
we identified one noncoding (g.1136CT in the 5-
untranslated region of exon 1) and 2 missense GLA mutations
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(p.R118C in exon 2, p.D313Y, in exon 6) in 10 patients with
IS (p.R118C: n4, 2 males; p.D313Y: n5, 3 males;
g.1136CT: n1, male), in 2 males with intracerebral
hemorrhage (p.R118C: n1; p.D313Y: n1), and in 2
females with CVT (p.R118C: n1; g.1136CT: n1). The
gDNA nucleotide changes corresponding to mutations
p.R118C and p.D313Y were, respectively, g.5251CT and
g.10645GT. MLPA analysis did not show gross gene
deletions or duplications in any of these patients.
Because leukocyte Gal activity was normal or above
normal in patients with mutation g.1136CT, their carriers
were not included in prevalence estimates. Leukocyte Gal
activity was subnormal in males and subnormal to low
normal in females with p.R118C and p.D313Y mutations.
The allelic frequencies of both the p.R118C and the p.D313Y
mutations were 0.0087 (6 of 686; 95% CI: 0.0035 to 0.0194)
and did not differ significantly between genders; none of
these mutations was identified in more than 400 X chromo-
somes of healthy control subjects (95% CI: 0.0000 to 0.0111).
The combined prevalence of GLA missense mutations in
the patient cohort was 2.4% (12 of 493; 95% CI: 1.4% to
4.3%) and showed no significant gender difference (2.3% in
males versus 2.6% in females). The prevalence of each
mutation was similar among the patients (1.2%) and did not
differ significantly between genders. The combined preva-
lence of GLA missense mutations among patients with IS was
2.5% (9 of 364; 95% CI: 1.2% to 4.7%). The combined
prevalence of GLA missense mutations among patients with
cryptogenic IS was 3.9% (4 of 104; 95% CI: 1.2% to 9.8%),
which did not significantly differ in comparison to patients
with an identified cause of stroke.
None of the patients carrying identical GLA mutations
were of the same family. The type and median number of
vascular risk factors, the characteristics of the stroke event,
and the prevalence of classic features of FD in the medical
history or family history did not significantly differ between
patients with GLA mutation and those without.
Among patients with IS or intracerebral hemorrhage, the
frequency of stroke in the posterior circulation was signifi-
cantly higher in those carrying missense GLA mutations
(Fisher exact test, P0.02). This was particularly evident in
patients with mutation p.R118C, of whom 80% (4 of 5) had
a stroke event in the territory of posterior circulation.
In patients presenting with IS and brain imaging evidence of
small vessel disease (lacunar stroke or leukoencephalopathy),
the overall prevalence of missense GLA mutations was 4.6% (6
of 132; 95% CI: 1.9% to 9.8%), increasing to 7.0% (4 of 57;
95% CI: 2.3% to 17.2%) in patients without hypertension and to
12.5% (3 of 24; 95% CI: 3.5% to 31.8%) in normotensive
patients with stroke in the posterior circulation.
Discussion
To our knowledge, this was the first study in which FD was
prospectively screened in a large cohort of unselected young
patients with stroke. We reasoned that not limiting eligibility
to cryptogenic stroke might decrease selection bias and would
be more appropriate to identify possible interactions between
GLA mutations and environmental risk factors, particularly
for populations with a very high prevalence of stroke, like the
Portuguese. This was also the first time that mutational
analysis was used to screen for FD in a large cohort with the
same sensitivity for both genders, overcoming the limitations
of Gal activity assays to diagnose FD in females.5 Exon
deletions and duplications as well as point mutations involv-
ing the last 16 amino acids of the Gal protein might have
been missed with our genotyping strategy. However, the
gross defects are rare and have been described in patients with
classic FD rather than in association with atypical pheno-
types, and no pathogenic GLA point mutations have been
reported in the last 15 amino acids of the enzyme (Human
Table. Demographic and Clinical Characteristics of the
Patient Cohort
Total
GLA
R118C
GLA
D313Y
GLA
(Total)
Study sample
No. of patients 493 6 6 12
Male 300 (60.9) 3 (50.0) 4 (66.7) 7 (58.3)
Age, years 47.0 41.0 46.5 43.0
Risk factors
Hypertension 233 (47.3) 4 (66.7) 1 (16.7) 5 (41.7)
Diabetes 74 (15.0) 0 (…) 1 (16.7) 1 (8.3)
Cardiac disease 54 (11.0) 1 (16.7) 1 (16.7) 2 (16.7)
Hyperlipidemia 222 (45.0) 4 (66.7) 1 (16.7) 5 (41.7)
Smoking 181 (36.7) 3 (50) 1 (16.7) 4 (33.3)
Alcohol 238 (48.3) 4 (66.7) 3 (50.0) 7 (58.3)
Oral contraception 87 (45.1) 2 (66.6) 0 (…) 2 (40.0)
Hormonal replacement 1 (0.52) 0 (…) 0 (…) 0 (…)
Median no. 2.0 2.5 1.0 2.0
History
Cutaneous disease 25 (5.1) 1 (16.7) 0 (…) 1 (8.3)
Ophthalmologic disease 45 (9.1) 1 (16.7) 0 (…) 1 (8.3)
Renal disease 37 (7.5) 1 (16.7) 0 (…) 1 (8.3)
Neuropathic pain 7 (1.4) 0 (…) 0 (…) 0 (…)
Family history
Stroke 215 (43.6) 2 (33.3) 2 (33.3) 4 (33.3)
Cardiac disease 179 (36.3) 3 (50.0) 3 (50.0) 6 (50.0)
Renal disease 48 (9.7) 1 (16.7) 0 (…) 1 (8.3)
Stroke
Ischemic 364 (73.8) 4 (66.7) 5 (83.3) 9 (75.0)
Cardiac embolism 80 1 1 2
Large vessel disease 55 … … …
Small vessel disease 98 1 1 2
Other known cause 27 1 … 1
Unknown cause 104 1 3 4
Intracerebral hemorrhage 89 (18.1) 1 (16.7) 1 (16.7) 2 (16.7)
Subarachnoid hemorrhage 26 (5.3) 0 (…) 0 (…) 0 (…)
CVT 14 (2.8) 1 (16.7) 0 (…) 1 (8.3)
Leukoencephalopathy 76 (15.4) 1 (16.7) 2 (33.3) 3 (25.0)
Posterior circulation 101 (20.5) 4 (66.6) 2 (33.3) 6 (50.0)
Modified Rankin Scale 2 135 (27.4) 3 (50.0) 2 (33.3) 5 (41.7)
Numbers in parentheses are percentages.
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Gene Mutation Database, HGMD; www.hgmd.cf.ac.uk/ac/
gene.php?geneGLA, accessed October 1, 2009).
The prevalence of GLA missense mutations was 2.4% in
the overall cohort and 3.8% in the subset of patients with
cryptogenic stroke. These results are comparable to those of
previous screening programs of atypical FD among patients
with cryptogenic stroke11 or with idiopathic left ventricular
hypertrophy.18–21 Except for stroke in the posterior arterial
territory, which was more frequent among patients with GLA
mutations, there were no significant demographic and clinical
differences between patients with GLA mutations and those
without. Of note, reporting of personal or family history of
possible complications of FD was no different in the 2
groups. The finding of GLA mutations in patients with
intracerebral hemorrhage was not surprising, because these
are a recognized cerebrovascular complication of FD,22 but
CVT had never been reported in association with FD.
Although a single case does not allow to conclude that Gal
deficiency is a risk factor for CVT, various abnormalities in
cerebral blood flow and in the walls of intracranial vessel
have been identified that are not exclusive of arterial sys-
tem7,17 and might contribute to a higher risk of CVT. In the
large observational Fabry Registry database, the diagnosis of
FD was established at later ages in patients who had stroke
than in patients who did not.22 Moreover, most patients with
stroke had not experienced renal or cardiac events before their
first stroke. These data are in accordance with our own
findings and suggest that the classical features of the disease
may be absent or more subtle in these patients. Furthermore,
the finding of GLA missense mutations in several patients
who had a concurrent cause of stroke by TOAST criteria
(Figure 1) suggests that screening of FD among patients with
stroke should not be restricted to the cryptogenic cases.
Evidence of small vessel disease (lacunar stroke or leukoen-
cephalopathy) without hypertension in young patients with IS
should prompt the search for FD, particularly when the stroke
occurs in the posterior circulation.
None of our patients carried a GLA mutation unequivocally
associated with the classical FD phenotype, but the 2 mis-
sense mutations that were identified have been previously
reported in patients with FD and were not found in over 400
X chromosomes of healthy Portuguese control subjects.
Figure. Alpha-galactosidase leukocyte and plasma enzyme activities in patients with missense GLA gene mutations. The normal ranges
for leukocyte and plasma -galactosidase activities are shadowed at the background. The clinical and brain imaging features of the
stroke event and the relevant details of the history and of the family history of each patient are also summarized.
434 Stroke March 2010
 by on May 9, 2011 stroke.ahajournals.orgDownloaded from 
However, given the 95% CI for their estimated prevalence in
the general population, we cannot formally exclude that
p.R118C and p.D313Y are low-frequency, missense single
nucleotide polymorphisms, as previously suggested for the
p.D313Y allele.23
Mutation p.R118C was identified in a single case among
37 104 males enrolled in an Italian newborn screening pro-
gram24 but was not present in over 400 X chromosomes from
normal control subjects.24 However, in contrast to our find-
ings, the neonate carrying this mutation had 5% residual
enzyme activity. Experimental data suggest that mutation
p.R118C behaves similarly to other known late-onset GLA
mutations.24 Mutation p.R118C has also been reported in a
Portuguese family presenting with a mild clinical phenotype,
including angiokeratomas in a young adult female25 who had
no histological evidence of globotriaosylceramide deposition
in the kidney. Furthermore, the predominant association with
stroke in the posterior circulation indirectly supports a patho-
genic role for this mutation in cerebrovascular disease.
Mutation p.D313Y was first described in a patient with the
classical FD phenotype,26 but its pathogenic role has been
subsequently challenged.23,27 Studies in transfected cells char-
acterized the D313Y enzyme as a pH-sensitive variant associ-
ated with pseudodeficiency of Gal activity in plasma.23 None-
theless, in recent screenings of FD among patients with
idiopathic left ventricular hypertrophy, mutation p.D313Y
was regarded as either pathogenic19,20 or nonpathogenic.21
Unfortunately, none of these studies provided histological
evidence confirming or excluding the diagnosis of Fabry
cardiomyopathy in such patients and the issue of whether
mutation p.D313Y is pathogenic still remains open.
In our cohort, males with either the p.R118C or the
p.D313Y mutation had comparable plasma Gal activities
(approximately 40% the normal mean) with average leuko-
cyte activity, respectively, of approximately 35% and approx-
imately 50% of the normal. Of note, plasma Gal expression
in several of these subjects was within the relatively high
range observed in Japanese patients with a cardiac variant of
FD.28 Although Gal expression was comparatively higher in
leukocytes, the difference in the relative levels of Gal
activity in the leukocyte and plasma assays that we observed
in p.D313Y hemizygous males was much lower than ex-
pected from available in vitro data.23 In contrast to previous
reports of classically affected patients with FD,23,27 none of
our patients carried an additional missense GLA mutation in
cis with mutation p.D313Y.
None of the clinical trials of enzyme replacement therapy
with recombinant Gal enrolled patients with substantial
residual enzyme activity and there is no conclusive evidence
that enzyme replacement therapy initiated in adulthood de-
creases the risk of stroke in patients with classic FD.7
Therefore, no recommendations regarding enzyme replace-
ment therapy for the patients identified in this study can be
issued at this time.
The pathogenic mechanisms of stroke in FD are uncertain.7
Our findings suggest that GLA mutations associated with
relatively high residual Gal activity may add to the risk of
stroke in young adults, possibly by contributing to the
underlying multifactorial pathogenesis rather than through a
classic Mendelian effect. Alternatively, it might be speculated
that a late-onset cerebrovascular variant of FD is associated
with relatively high levels of residual Gal activity. These
data need further confirmation in properly designed case–
control and family segregation studies.
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Abstract Lysosomal a-galactosidase A (aGal) is the
enzyme deficient in Fabry disease (FD). The 50-untranslated
region (50UTR) of the aGal gene (GLA) shows a remark-
able degree of variation with three common single nucleo-
tide polymorphisms at nucleotide positions c.-30G>A,
c.-12G>A and c.-10C>T. We have recently identified in
young Portuguese stroke patients a fourth polymorphism, at
c.-44C>T, co-segregating in cis with the c.-12A allele.
In vivo, the c.-30A allele is associated with higher enzyme
activity in plasma, whereas c.-10T is associated with
moderately decreased enzyme activity in leucocytes. Lim-
ited data suggest that c.-44T might be associated with
increased plasma aGal activity. We have used a luciferase
reporter system to experimentally assess the relative
modulatory effects on gene expression of the different
GLA 50UTR polymorphisms, as compared to the wild-type
sequence, in four different human cell lines. Group-wise,
the relative luciferase expression patterns of the various
GLA variant isoforms differed significantly in all four cell
lines, as evaluated by non-parametric statistics, and were
cell-type specific. Some of the post hoc pairwise statistical
comparisons were also significant, but the observed effects
of the GLA 50UTR polymorphisms upon the luciferase
transcriptional activity in vitro did not consistently replicate
the in vivo observations.
These data suggest that the GLA 50UTR polymorphisms
are possible modulators of the aGal expression. Further
studies are needed to elucidate the biological and clinical
implications of these observations, particularly to clarify the
effect of these polymorphisms in individuals carrying GLA
variants associated with high residual enzyme activity, with
no or mild FD clinical phenotypes.
Introduction
Insufficient activity of lysosomal alpha-galactosidase A
(aGal; EC 3.2.1.22) impairs the catabolism of several
neutral glycosphingolipids, particularly of trihexosylcer-
amide (Kint 1970). Accumulation of these glycosphingo-
lipids in the endothelium and smooth muscle cells of blood
vessels, as well as in the heart, the kidney and the nervous
system, is the pathologic hallmark of Fabry disease (FD,
OMIM #301500) (Desnick et al. 2001). The severity of the
clinical phenotype of FD is roughly related to residual
enzyme activity (REA) of aGal, as assayed in vitro: the
lower the REA, the earlier is the age of onset and the more
severe and multi-systemic are the clinical manifestations,
while in patients with higher levels of REA the resultant
phenotypes are more organ restricted (Germain 2010).
The primary transcript of the aGal gene (GLA) contains
an unusually polymorphic 50-untranslated region (50UTR)
of 110 nucleotides, encoded by exon 1 (Nucleotide
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database, National Center for Biotechnology Information –
NCBI, reference sequence: NM_000169.2; http://www.
ncbi.nlm.nih.gov/nuccore/NM_000169.2; National Library
of Medicine, Bethesda, MD, USA). Three single nucleotide
polymorphisms (SNPs) respectively identified by reference
numbers rs2071225, rs3027585 and rs3027584 at the NCBI
SNP database (dbSNP, http://www.ncbi.nlm.nih.gov/snp/),
which result from cytosine-to-thymine (C>T) or adenine-
to-guanine (G>A) transitions at cDNA nucleotide positions
c.-10(C>T), c.-12(G>A) and c.-30(G>A), counting back-
wards from the translation initiation codon, are relatively
common in several ethnically different populations (Davies
et al. 1993; Saifudeen et al. 1995; Wu et al. 2011; Ferri et al.
2012), including the Portuguese (Oliveira et al. 2008a). The
dbSNP lists three additional GLA 50UTR SNPs, at positions
c.-8(C>G), c.-18(T>C) and c.-105(A>G), respectively
identified as rs371291716, rs545597063 and rs3027583,
but these variants have never been reported in the
Portuguese population. Another GLA 50UTR variant at
c.-44(C>T), not yet registered at the dbSNP, was identified
in young Portuguese stroke patients (Baptista et al. 2010),
co-segregating in cis with the c.-12A allele.
Compared to the wild-type (WT) allele, the c.-30A
allele is associated with increased plasma aGal activity
(Saifudeen et al. 1995; Fitzmaurice et al. 1997), the c.-10T
allele is associated with decreased activity of aGal in
leukocytes (Oliveira et al. 2008a, b) and the c.-44T allele
might be associated with increased plasma aGal activity
(Baptista et al. 2010). Contrastingly, the SNP c.-12(G>A)
seems to have no effect upon GLA gene expression
(Oliveira et al. 2008a).
Because the GLA 50UTR contains a binding site for
methylated DNA-binding protein (MDBP)/regulatory factor
X (RFX) transcription factor family (Zhang et al. 1990;
Samac et al. 1998), as well as partially overlapping binding
motifs for the nuclear factor kappa-B (NFkB) and E-26
(Ets) transcriptional regulatory factors (Saifudeen et al.
1995; Fitzmaurice et al. 1997), it has been previously
suggested that protein ligands to these sites might be
involved in the regulation of GLA gene expression
(Saifudeen et al. 1995; Fitzmaurice et al. 1997). Since the
SNPs c.-10(C>T) and c.-30(G>A) involve nucleotides
respectively located at each of those binding sites, they
might act as polymorphic modulators of GLA gene
expression, with possible clinical relevance particularly in
males carrying GLA sequence variants associated with high
REA.
To compare the relative impact upon in vitro gene
expression of each of the GLA 50UTR SNPs that have been
identified in the Portuguese population, we have carried out
luciferase reporter assays in several human cell lines of
distinct embryological origins, representing some of the cell
types that are critically involved in the pathogenesis of FD.
Materials and Methods
A detailed description of the laboratory methods is
available online (Supplementary Information and Supple-
mentary Tables 1 and 2).
Synopsis of the Laboratory Protocol
Five genomic DNA (gDNA) samples from adult males
known to carry either the GLA 50UTR WT sequence or one
of the four SNPs identified in the Portuguese population
were obtained from an anonymised biorepository. The five
distinct isoforms were amplified by polymerase chain
reaction (PCR) and the amplicons were inserted into the
HindIII site of the pGL3-Control Vector (pGL3 Luciferase
Reporter Vectors; Promega, Madison, WI, USA). The
pGL3-Control Vector contains a cDNA encoding a modi-
fied firefly luciferase (luc+) under the control of the Simian
virus 40 (SV40) promoter. The recombinant pGL3 vectors
were transiently transfected into each of four human cell
lines of different embryological origin: (1) human embryo-
nic kidney, HEK-293 (Shaw et al. 2002); (2) human
cervical carcinoma, HeLa (Macville et al. 1999); (3) human
dermal microvascular endothelial cells, HDMEC (Richard
et al. 1999); and (4) human T cell lymphoblast-like, Jurkat
(Schneider et al. 1977). A plasmid (pCDNA3.3-LacZ;
Invitrogen, Life Technologies, Carlsbad, CA, USA) con-
taining the Escherichia coli (E. coli) b-galactosidase gene
(pGAL) was used as an internal control for transfection
efficiency. The relative luciferase activity (RLA) of
each sample was calculated as the ratio of luciferase to
b-galactosidase luminometric readings. A minimum of nine
independent successful co-transfection experiments were
analysed per cell type.
To allow comparisons between independent experiments
in each cell type, a normalised RLA (nRLA) was calculated
by dividing the RLA calculated for each sample by the
average RLA of the WT construct vector samples of the
corresponding experiment.
Statistical Analyses
The non-parametric Kruskal–Wallis one-way analysis of
variance by ranks was used as the first-tier statistical testing
for significant differences in the nRLA raw data of the
various GLA 50UTR vector constructs, in each cell type.
As this test does not identify where the observed
differences occur or how many differences actually occur,
further statistical analyses were based on parametric testing
with one-way analysis of variance (ANOVA) and post hoc
Dunnett’s test. To this end, outlier raw RLA data points
were first excluded by the fourth-spread method, as
recommended by other investigators (Jacobs and Dinman
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2004), the nRLA values were expressed as percentage of
the WT nRLA (nRLA%), and the natural logarithms of the
latter values were used for the statistical analyses.
A two-sided significance level of <0.05 was assumed
for all the statistical tests except for post hoc Dunnett’s test
where one-sided p-values were used instead. All statistical
analyses were performed with the SPSS software, Version
19.0.
Results
HDMEC cells with more than 12 subculture passages
showed non-uniform and significantly slower doubling
rates, with more erratic transfection efficiencies (data
not shown). For that reason, only the RLA assays obtained
in younger cell cultures were validated for the final
analyses.
Table 1 Non-parametric statistical analysis by the Kruskal–Wallis test of the normalised relative luminometric activity (nRLA) of the five GLA
50UTR plasmid vector constructs in four different cell lines
GLA 50UTR plasmid vector
constructs
Cell lines
HEK-293 HeLa HDMEC Jurkat
N
Mean rank
(nRLA) N
Mean rank
(nRLA) N
Mean rank
(nRLA) N
Mean rank
(nRLA)
WT 13 20.54 16 38.03 15 45.23 15 45.17
c.-10T 13 46.62 16 48.28 15 39.77 15 27.07
c.-12A 13 30.92 16 28.69 15 26.73 15 27.83
c.-30A 13 25.96 12 10.00 15 48.60 9 23.94
c.-44T 13 40.96 16 60.38 15 29.67 15 46.57
Total (N) 65 76 75 69
Kruskal–Wallis test
Chi-square (df ¼ 4) 16.652 41.993 11.501 15.831
Asymptotic significance 0.002 0.000 0.021 0.003
WT wild-type, N number of experiments validated per each cell line, df degrees of freedom
Table 2 One-way analysis of variance (ANOVA) of the natural logarithms of the normalised relative firefly luciferase activities expressed as a
percentage of the wild-type (nRLA%), comparing the means of the five GLA 50UTR plasmid vector constructs in four different cell lines
Cell lines
ANOVA results
Sum of squares df Mean square F p-value
HEK-293 Between groups 2.184 4 0.546 3.615 0.010
Within groups 9.062 60 0.151
Total 11.246 64
HeLa Between groups 10.423 4 2.606 22.796 0.000
Within groups 8.116 71 0.114
Total 18.538 75
HDMEC Between groups 1.401 4 0.350 3.721 0.009
Within groups 6.305 67 0.094
Total 7.706 71
Jurkat Between groups 1.005 4 0.251 4.278 0.004
Within groups 3.641 62 0.059
Total 4.646 66
df degrees of freedom
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The distributions of the nRLA of the five GLA 50UTR
constructs, as evaluated by non-parametric statistics
(Table 1), differed significantly in all cell types. By the
fourth-spread method, one of the WT and one of the c.-44T
allele data point values obtained in the Jurkat cells, as well
as three of the c.-30A allele data point values obtained in
the HDMEC cells, were classified as outliers and removed
from the dataset for the subsequent parametric statistical
analyses. ANOVA was performed on the normalised,
log-transformed nRLA% data, with results similar to the
non-parametric statistical approach (Table 2). Post hoc
parametric statistical analyses showed that the SNPs c.-12
(G>A) and c.-30(G>A) were associated with significantly
lower nRLA%, respectively in HDMEC (p ¼ 0.002)
and HeLa (p < 0.000) cells, while the SNPs c.-10(C>T)
and c.-44(C>T) were associated with significantly higher
nRLA%, respectively in HEK-293 (p ¼ 0.032) and HeLa
(p < 0.000) cells. In the Jurkat cells, none of the GLA
SNPs was associated with a statistically significant differ-
ence in nRLA%, but both the c.-10T (p ¼ 0.067) and
c.-12A (p ¼ 0.086) alleles showed a trend to lower activity
(Fig. 1).
Discussion
Luciferase-based genetic reporter assays are a standard
in vitro approach to study DNA sequences and molecular
processes that control gene expression, in various cellular
contexts (Brogan et al. 2012). Herein we report the results
of luciferase expression assays designed to investigate the
relative efficiency of four different human GLA 50UTR
SNPs, in comparison to the WT sequence, as potential
modulators of gene expression. One of the most common
research applications of chimeric genetic reporter systems is
in the analysis of cis-acting elements, like gene promoters;
however, to the best of our knowledge, the functional
consequences of the 50UTR SNPs upon GLA gene
expression have never been assayed in this manner. Overall,
our results are consistent with the working hypothesis,
based on observations in vivo that some of the minor
50UTR SNPs alleles significantly affect aGal activity levels
(Saifudeen et al. 1995; Fitzmaurice et al. 1997; Oliveira
et al. 2008a, b), and provide indirect evidence that the
human GLA 50UTR indeed contains sequences that are
involved in the regulation of gene expression. These data
Fig. 1 Normalised luciferase/b-galactosidase luminometric ratios of
the GLA 50UTR sequence variant isoforms c.-10T, c.-12A, c.-30A and
c.-44T, expressed as percent of wild-type (WT), in HEK-293, HeLa,
HDMEC and Jurkat human cell lines. The average bars are shown
with the upper limit of the standard error of the mean. As explained in
the text, the c.-44T allele was present in cis with the c.-12A allele. All
pairwise comparisons between each of the variant alleles and the WT
GLA 50UTR isoform that reached statistical significance in the post
hoc analyses are shown in the charts, with the corresponding one-
sided Dunnett’s test p-value
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also demonstrate, for the first time, that the 50UTR-
dependent modulation of GLA gene expression may vary
among different cell types. The expression of alternative
50UTRs represents an evolutionary gain of transcriptional
and translational control pathways, allowing tissue-specific
expression patterns and expanding the repertoire of expres-
sion from a single gene locus (Barrett et al. 2012).
Although GLA is a housekeeping gene, aGal activity levels
vary greatly from organ to organ and in different cell types
(Brady et al. 1967; von Scheidt et al. 1991). It is possible
that either transcription factors (TF) or RNA-binding
proteins (RBP) that bind to specific sequences in the GLA
50UTR contribute to the regulation of GLA gene expression
in a tissue-specific manner.
The three common SNPs of the human GLA 50UTR were
originally described in 1993 with a combined minor allele
frequency of 10% in the British population (Davies et al.
1993). Because they were neither translated nor part of the
mRNA Kozak consensus sequence for translation initiation,
they were regarded as biologically neutral, but subsequent
studies showed that the c.-30A allele was associated with
increased aGal activity in plasma (Saifudeen et al. 1995)
and the c.-10T allele with decreased aGal activity in
leukocytes (Oliveira et al. 2008a, b), as compared to the
corresponding WT alleles. Since the GLA 50UTR c.-10 and
c.-30 positions are within binding sites respectively for the
MDBP and the NFkB and Ets families of TF, the effect of
those two nucleotide transitions upon aGal expression
in vivo might be mediated by modulation of transcriptional
activity.
On electrophoretic mobility shift assays (EMSA), bind-
ing of nuclear extract proteins to synthetic oligonucleotides
containing the GLA 50UTR NFkB/Ets binding site, either
with a G or an A at the position corresponding to c.-30, was
significantly less when adenine was present (Saifudeen
et al. 1995), showing that the WT sequence has higher
affinity to the putative NFkB/Ets ligands. Furthermore,
in vitro translation of mRNAs from cloned WT and c.-30A
alleles resulted in similar levels of aGal protein, indicating
that the G>A transition does not enhance translation
(Fitzmaurice et al. 1997), and studies performed on aGal
derived from the WT and the c.-30A alleles, partially
purified from plasma and lymphoblasts, revealed that the
high plasma activity was not due to altered post-transla-
tional processing (Fitzmaurice et al. 1997). Overall, these
findings suggest that the GLA 50UTR c.-30G>A transition
results in enhanced transcription, presumably by interfering
with the binding of negatively acting TF which normally
decrease aGal expression in various cells (Fitzmaurice et al.
1997).
Surprisingly, the c.-30A allele was not associated with
higher protein expression in comparison to the WT allele, in
any of the four cell types assayed in our luciferase reporter
studies. Since plasma aGal most probably has a multiplicity
of cellular sources (Fitzmaurice et al. 1997; Warnock 2005),
a possible explanation for the inconsistency between the
in vivo observations and the experimental in vitro data
might be that none of the cell types used in our reporter
studies is the right model to assay the 50UTR-related
modulation of GLA gene expression at the transcriptional
level, at least for cells that most significantly contribute to
the pool of circulating aGal protein. Therefore, testing
additional cell types, ideally representing highly vascular-
ised tissues that are particularly rich in aGal activity, like
the spleen and the liver (Brady et al. 1967), might help to
clarify these discrepancies.
Both the c.-12(A>G) and the c.-10(C>T) SNPs are
located within the GLA 50UTR MDBP consensus sequence,
respectively, at its first and third nucleotide positions
(Zhang et al. 1990), but only the c.-10(C>T) SNP seem
to affect enzyme expression in vivo (Oliveira et al. 2008a).
The amount of aGal identified by western blot analyses of
leukocyte protein extracts was significantly lower in
carriers of the c.-10T allele as compared to carriers of the
WT allele (Oliveira et al. 2008b). Experimental data (Samac
et al. 1998) have shown that sequence changes that increase
the affinity of the GLA 50UTR MDBP binding site for its
cognate ligands exert a strong repressive effect upon gene
expression. Furthermore, a C>T transition in the third
nucleotide position of a MDBP binding site in the human
cytomegalovirus significantly increased ligand binding,
resulting in 10-fold reduction of reporter gene expression
(Schneider et al. 1977). However, to the best of our
knowledge, no EMSA studies have ever been performed
with the human GLA 50UTR MDBP binding site, to assess
the relative affinities of the c.-10(C > T) alleles. Although
the human GLA 50UTR c.-12(G>A) SNP does not seem to
change aGal expression in vivo, at least in plasma and
leukocytes (Oliveira et al. 2008a), studies in the MDBP
binding site of plasmid pBR322 have shown that the A>G
transition in its first nucleotide position significantly
increased the binding of MDBP extracted from the human
placenta (Macville et al. 1999).
The results of our luciferase reporter assay studies are
consistent with the hypothesis that the G>A transition at c.-
12 has indeed a biological effect on gene expression. It is of
note that in HDMEC and Jurkat cells the GLA c.-10T and
c.-12A alleles are associated with relatively lower reporter
gene expression as compared to the WT alleles, but in
HEK-293 and HeLa cells the c.-10T allele is associated
with increased reporter gene expression. The trend for a
lower reporter gene expression associated with the c.-10T
allele in the Jurkat cells is in agreement with the decreased
leukocyte aGal activity observed in vivo (Oliveira et al.
2008a). The lack of statistical significance of all the post
hoc analyses of the relative luciferase reporter expression
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data in the Jurkat cells, as well as of some of the
comparisons made in other cell types, can be attributed
to statistically underpowered datasets. Confirmation of the
present findings should be made using larger datasets of
validated reporter gene expression readings per cell type,
possibly using a dual reporter assay for better control of
experimental normalisation (Jacobs and Dinman 2004).
The relative luciferase expression profile of the four
human GLA 50UTR SNPs, as normalised to the WT
sequence, was different for each of the transfected cell
lines in our experimental protocol. The diverse embryolog-
ical lineages of HEK-293 (Shaw et al. 2002), HeLa
(Macville et al. 1999), HDMEC (Richard et al. 1999), and
Jurkat (Schneider et al. 1977) cells are a logical explanation
for this finding, as the GLA gene may be under different
constitutive expression regulation on different cells.
To identify other potential TF binding sites in the GLA
50UTR, we queried the Transcription Factor Database
(TRANSFAC). According to TRANSFAC, the c.-12G and
the c.-10C nucleotides are both part of a consensus binding
motif for zinc finger C4-type domains of nuclear receptors
(ZFC4-NR), particularly the estrogen receptor alpha (ER-
a), and the G>A and C>T transitions at those positions
result in the loss of ZFC4-NR binding affinity. Similarly,
the G>A transition at the c.-30 nucleotide, which is part of
a conserved consensus binding sequence for both the Ets
and the adenovirus E2 promoter binding (E2F) families of
TF, also suppresses the site ligand affinity. On the other
hand, the C>T transition at the c.-44 nucleotide creates a
novel ZFC4-NR binding site, particularly for hepatocyte
nuclear factor-4-alpha (HNF-4a). It is of note that, in the
Portuguese population, the c.-44T allele has been found
exclusively in cis with the c.-12A allele: therefore, the
results of our luciferase reporter assays represent the
in vitro combined effects of the two nucleotide transitions.
By predicting binding sites from position weight matrix
in the database of RNA-binding specificities (RBPDB), the
G>A transition at the c.-30 nucleotide results in the loss of
binding affinity with the eukaryotic translation initiation
factor 4B (EIF4B), but no changes are reported for the c.-10
(C>T) and the c.-12(G>A) SNPs. On the other hand a
C>T transition at the c.-44 nucleotide originates a novel
binding site to KH-type splicing regulatory protein.
According to these results either the transcriptional machin-
ery or post-transcriptional events, or both, might be
influencing the gene expression.
In conclusion, as assessed in vitro by luciferase reporter
assays, the various GLA 50UTR SNPs modulate the gene
expression in a manner that seems to be cell-type specific.
The biological context and clinical implications of these
observations are not yet clear, and further studies will be
necessary to elucidate such questions. This may be of
particular relevance considering the recent data suggesting
that subnormal aGal activity levels above the range of
enzyme insufficiency associated with FD phenotypes may
be a risk factor in the pathogenesis of sporadic Parkinson
disease (Wu et al. 2008, 2011) and stroke (Baptista et al.
2010). Although the 50UTR-related modulation of GLA
gene expression is not anticipated to be of much relevance
for male patients carrying pathogenic mutations associated
with very low or absent aGal activity, elucidation of the
specific cellular contexts and of the molecular mechanisms
underlying the effect of GLA 50UTR SNPs, particularly of
the negatively acting, might be clinically relevant in
individuals with several other GLA genotypes. First: in
patients with later-onset, organ-limited FD phenotypes,
because most of such cases are associated with GLA
mutations leading to altered enzyme stability (Garman
2007), which makes the final amount of aGal protein
available in each tissue more dependent of the local gene
expression profile. Second: in females coinheriting a
negatively acting GLA 50UTR SNP in trans with a
pathogenic GLA mutation, the compound heterozygosity
may significantly decrease the REA and aggravate the
clinical phenotype since the aGal activity would be
subnormal in all cells, irrespective of which of the two X
chromosomes is inactivated. Third: in individuals carrying
GLA variants associated with small decreases in REA,
which otherwise would not be the cause of FD clinical
phenotypes – like the p.Arg118Cys (Ferreira et al. 2015)
and the p.Asp313Tyr (Yasuda et al. 2003; Niemann et al.
2013) – the additive effect of a negatively acting GLA
50UTR SNP in cis could decrease REA into the typical
range of mutations associated with later-onset phenotypic
variants of FD (Ferreira et al. 2015), thereby modifying the
expected phenotype. This might also affect the probability
of identifying individuals carrying such mutations in large
case-finding studies of FD among high-risk patients, when
the primary screening method is based on aGal activity
analysis. Finally, at the population level, the inadvertent
inclusion of carriers of nonneutral GLA 50UTR SNPs in
cohorts of healthy individuals used to define the normal
laboratory ranges of aGal activity will affect the values of
the upper limit in plasma, like the c.-30A allele, and of the
lower limit in leukocytes, like the c.-10T allele.
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SUPPLEMENTARY MATERIAL 
Five genomic DNA (gDNA) samples known in advance to carry either the GLA 5’UTR 
WT sequence or one of the four SNPs identified in the Portuguese population had been 
obtained from peripheral blood leukocytes of adult males under informed and written 
consent. The five distinct isoforms were amplified by polymerase chain reaction (PCR) 
using the primers described in Table 1 of the Supplementary material. The resultant 
amplicons were 134-nucleotide long and included a HindIII restriction site at their 
extremity (Table 1 Supplementary material). To confirm the effectiveness of the 
amplification reaction, the PCR products were checked by capillary electrophoresis in a 
QIAxcel® System (Quiagen, Hilden, Germany).  
Preparation and cloning of the luciferase reporter vector constructs  
A total of 100 µl of each distinct PCR product was digested with 1 µl of HindIII (New 
England Biolabs, Ipswich, MA, U.S.A.) and purified with Agencourt AMPure XP 
(Beckman Coulter, Brea, CA, U.S.A.), according to the manufacturer’s instructions.  
Purified amplicons of each of the GLA 5’UTR isoforms were inserted into the HindIII 
site of the pGL3-Control Vector (pGL3 Luciferase Reporter Vectors; Promega, Madison, 
WI, U.S.A.) using a T4 DNA Ligase (NZYTech, Lisboa Portugal). The pGL3-Control 
Vector contains a cDNA encoding a modified firefly luciferase (luc+) under the control 
of the SV40 promoter and a β-lactamase gene conferring ampicillin resistance in 
Escherichia coli (E. coli). The recombinant pGL3 vectors were cloned in NZYStar 
Competent E. coli Cells (NZYTech), grown on ampicillin-containing Luria broth (LB) 
agar plates. Positive clones were selected and the plasmid DNA isolated with GenElute 
Plasmid Miniprep Kit (Sigma-Aldrich, St. Louis, MO, U.S.A.), according to 
manufacturer’s instructions, and quantified in a NanoDrop 2000C UV-Vis 
spectrophotometer (Thermo Scientific, Waltham, MA, U.S.A.). Plasmid purity was 
checked by ultraviolet (UV) light absorbance measurements at wavelengths 230 nm, 260 
nm and 280 nm and only those with absorbance ratios of ~1.8 at 260/280 nm and >1.95 
at 260/230 nm were subsequently used for transfection. All plasmids were validated by 
DNA sequencing.  
Cell lines, cell culture, transfection reagents and internal control  
Five different cell lines were selected for the luciferase expression assays: (i) Mouse 
neuroblastoma x Rat dorsal root ganglion neuron hybrid, ND7/23 (Raymon et al 1999); 
(ii) human embryonic kidney, HEK-293 (Shaw et al 2002); (iii) human cervical 
carcinoma, HeLa (Macville et al 1999); (iv) human dermal microvascular endothelial 
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cells, HDMEC (Richard et al 1999); and (v) human T cell lymphoblast-like, Jurkat 
(Schneider et al 1977). The cells were cultured at 37 oC in a humidified 5% CO2 incubator 
(Water-Jacketed, US Autoflow Automatic CO2 Incubator; NuAire, Plymouth, MN, 
U.S.A.), using standard laboratory procedures (Phelan 2007) and the applicable 
manufacturer’s recommendations (Table 2 - Supplementary material). The ND7/23 cells 
were only used in preliminary experiments to optimize the laboratory conditions for the 
subsequent comparative assays of luciferase expression under control of the various 
human GLA 5’UTR isoforms. The ND7/23, HEK-293 and Hela cells were transfected 
with FuGENE (Promega) while the HDMEC and Jurkat cells were transfected with 
Lipofectamine LTX (Life Technologies; Carlsbad, CA, U.S.A.), following the 
manufacturer’s protocols. A plasmid (pCDNA3.3-LacZ; Invitrogen, Life Technologies) 
containing the E. coli β-galactosidase gene (pGAL) was used as an internal control for 
transfection efficiency. 
The preliminary experiments made in ND7 cells showed that plasmid samples with 
absorbance ratios at 260/230 nm <1.95 were unreliable for transfection (data not shown). 
In these cells, the amount of plasmid DNA in the diluted aliquots used for transfection 
was also checked by quantitative PCR (qPCR) and all exhibited the same qPCR cycle 
thresholds (data not shown), demonstrating that they indeed contained similar amounts 
of plasmid DNA.  
Co-transfection protocols and luminometric β-galactosidase and luciferase 
expression assays  
The HEK-293 and HeLa cells were seeded overnight at 45% confluence onto 96-well 
plates and co-transfected with 120 ng of the pGL3 vector reporter construct and 30 ng of 
pGAL per well. The HDMEC cells were seeded overnight onto 24-well plates at 70% 
confluence and co-transfected with 400 ng of the pGL3 vector reporter construct and 100 
ng of pGAL per well.  
To prepare the Jurkat subcultures for transfection, cell number and viability were 
determined in a Countess Automated Cell Counter (Invitrogen), using a trypan blue 
staining technique, according to the protocol recommended by the manufacturer. The 
cells were initially grown in penicillin/streptomycin-free RPMI-1640 medium 
(Biochrome), in 24-well plates, at about 80% confluence (~1x105 cells/well), and were 
immediately co-transfected with 400 ng of the pGL3 vector reporter construct and 100 ng 
of pGAL per well; in order to avoid transfection-related antibiotic cytotoxicity, 
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penicillin/streptomycin was added to each well only after 3 hours of incubation, to the 
final concentration of 1%.  
After transfection, the HEK-293, HeLa and Jurkat cells were incubated for 24 hours, 
while the HDMEC cells needed longer incubation (48 hours). At the end of the incubation 
time, the culture medium was removed from the monolayer cultures (i.e. HEK-293, HeLa, 
HDMEC), cells were washed in situ with 1x phosphate-buffered saline (PBS) and then 
lysed with 35 µl of Luciferase Cell Culture Lysis reagent (Promega). In the case of the 
Jurkat cells, the subcultures were pipetted into eppendorf tubes and the culture medium 
was removed following centrifugation for 10 minutes, at 200 x g / 4 ºC; the cells were 
then washed with PBS and the tubes centrifuged for 5 minutes, at 200 x g / 4 ºC; finally, 
PBS was removed and the cell lysis reagent added.  
A 15 µl aliquot of each cell lysis extract was mixed with 2.5 mg/ml of the β-galactosidase 
substrate O-nitrophenyl-β-D-galactopyranoside (ONPG; Sigma-Aldrich), in a PBS 
containing 25mM magnesium chloride and 1mM DTT. The Luciferase Assay Reagent 
(Promega) was added to a second 15 µl aliquot of the cell lysates and the luminescence 
of each sample was measured immediately afterwards.  
Both absorbance at 420nm and luminescence were determined in an Infinite 200 PRO 
(Tecan, Männedorf, Switzerland), according to the manufacturer’s instructions.  
 
Table 1(Supplementary material). Primer sequences and their coordinates according to GenBank® GLA gDNA nucleotide 
sequence version X14448.1 (NCBI, Bethesda, MD, U.S.A.; www.ncbi.nlm.nih.gov/nuccore/x14448.1).  
Primer code Primer oligonucleotide sequence Primer coordinates 
Gla-5´UTR S 5’- [CCCAAGCTT]GGATAACCGTCCCAGTTGCCAG -3’ 1046_1067 
Gla-5´UTR AS 5’- [GGGAAGCTT]TGTCACGGTGACCGGACAGC -3’ 1160_1179 
Gla-5´UTR -10 AS 5’- [GGGAAGCTT]TGTCACGGTAACCGGACAGC -3’ 1160_1179 
Gla-5´UTR -12 AS 5’- [GGGAAGCTT]TGTCACGGTGATCGGACAGC -3’ 1160_1179 
The primer nucleotide sequences shown between brackets are complementary to the HindIII site of the pGL3 vector subsequently 
used for transfection, respectively in sense (S) or antisense (AS) directions. The remaining sequences are complementary to the WT, 
the c.-10(C>T) or the c.-12(G>A) isoforms of the human GLA 5’UTR. Using the same genomic reference sequence, the ATG start 
codon corresponds to nucleotide positions g.1180–1182.  
The PCR protocol consisted of an initial denaturation step at 94ºC for 5 minutes, followed by 40 cycles of denaturation, annealing 
and elongation, respectively at 94 ºC for 20 seconds, 67ºC for 20 seconds and 72 ºC for 30 seconds, and a terminal elongation step at 
72 ºC for 10 minutes. All primers were used at 10 pmol/µl. Each 50 µl of the individual PCR reaction mixture contained 2 µl of 
template DNA (100 ng/µl), 5 µl buffer 10X, 4 µl MgCl2 (25mM), 2 µl of a 10 mMol dNTP mix (100 mM dNTP Set; Invitrogen, 
Life Technologies, Carlsbad, CA, U.S.A.), 2 µl of the sense and antisense set of primers at 25 pmol/µl, and 0,4 µl recombinant Taq 
DNA Polymerase (5 U/µl; Thermo Scientific, Vilnius, Lithuania).  
Table 2(Supplementary material). Cell lines and cell culture methods and procedures.  
Cell lines Origin and characteristics Cell culture conditions 
ND7/23 Mouse neuroblastoma x Rat neurone hybrid Dulbecco's modified Eagle's medium (DMEM; Sigma-
Aldrich) supplemented with 10% fetal bovine serum (FBS), 
1% GlutaMAX (Gibco, Life Technologies) and 1% 
penicillin/streptomycin (Gibco).  
Monolayer culture; medium replaced every 2-3 days; passages 
at <90% confluence.  
HEK-293 Human embryonic kidney  
(continuous cell line obtained by adenovirus 
transformation of normal embryonic kidney cells; 
have many properties of immature neurons) 
HeLa Human cervical carcinoma  
(immortal epithelial cell line derived from an 
adenocarcinoma of the cervix) 
HDMEC Human dermal microvascular endothelial cells  
(isolated from the dermis of juvenile foreskin; 
comprise blood and lymphatic microvascular 
endothelial cells) 
Endothelial Cell Basal Medium-2 (EBM®-2; Lonza, 
Walkersville, MD, U.S.A.) supplemented with Endothelial 
Cell Growth Medium-2 (EGMTM-2; Lonza).  
Monolayer culture; medium replaced every 2-3 days; passages 
at <70% confluence.  
Jurkat Human T cell lymphoblast-like  
(immortalized line of T lymphocyte cells established 
from the peripheral blood of a patient with T cell 
leukemia) 
RPMI-1640 medium (Biochrome, Cambridge, U.K.), with 
10% FBS, 1% GlutaMAX (Gibco), 1% penicillin/streptomycin 
(Gibco).  
Suspension culture; medium replaced every 2-3 days; passages 
at <80% confluence.  
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Lyso-Gb3 analogsRecent data have shown that lyso-Gb3, the deacylated derivative of globotriaosylceramide (Gb3), is possibly
involved in the pathogenesis of Fabry disease (FD) and might be a clinically useful biomarker of its metabolic
load. To test this hypothesis, we assayed Gb3 and lyso-Gb3 and related analogs in plasma and/or urine samples
of 12 clinically well-characterized subjects carrying several different GLA variant alleles associated with a wide
range of residual α-galactosidase A activities. Urinary Gb3 was measured by HPLC–MS/MS; plasma and urinary
lyso-Gb3 and related analogs were measured by UPLC–MS/MS.
Individual profiles of Gb3 and lyso-Gb3 and related analogs closely correlated with the phenotypic data for each
subject, discerning the classical FD patient from the two patients carrying cardiac variants as well as those from
all the others without FD. The lyso-Gb3 analog at m/z 836 was found at increased levels only in patients
manifesting clinically severe heart disease, irrespective of the pathogenicity of the GLA variant they carried.
This finding suggests that this lyso-Gb3 analog might be an earlier biomarker of progressive heart disease, non-
specific of the FD cardiomyopathy. The possibility that urinary Gb3 is a specific marker of kidney involvement
in FD deserves further study.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Fabry disease (FD) (OMIM no. 301500) is a glycosphingolipidosis
caused by mutations affecting the X-linked GLA gene [1,2], which
codes for lysosomal alpha-galactosidase A (α-Gal, EC 3.2.1.22). Deficient
α-Gal activity leads to lysosomal accumulation of glycosphingolipids
(GSL), particularly globotriaosylceramide (Gb3) and its deacylated
derivative, globotriaosylsphingosine (lyso-Gb3), which are the patho-
logic hallmarks of FD. The involvement of vascular smooth muscle
cells and endothelia of cardiomyocytes and of kidney epithelial cells is
critical for the development of the late, but clinically nonspecific, cere-
brovascular, cardiac and renal complications of FD. However, the path-
ogenic mechanisms leading to stroke, to left ventricular hypertrophytica, Faculdade de Medicina,
, 4200-319 Porto, Portugal.
ichel.boutin2@usherbrooke.ca
lnunes@med.up.pt (J.P. Nunes),
ass.edu (S. Garman),(LVH) and cardiomyopathy, and to progressive chronic kidney disease
(CKD), which are the major causes of morbidity and mortality in adult
FD patients, remain unclear. Specifically, the pathophysiology of the sys-
temic vasculopathy that characterizes FD, the homeostatic regulatory
pathways affected by lysosomal GSL accumulation and the molecular
mediators involved in these processes are still poorly understood [3–6].
In males, the clinical severity of FD broadly correlates with the level
of in vitroα-Gal residual enzyme activity (REA) measured in leukocytes
or plasma [7]. The classical multisystemic early onset phenotype, pre-
senting with acroparesthesias, angiokeratomas and impaired sweating,
which is more typically observed in young boys and adolescents, is
caused by α-Gal mutations usually with ≤1% REA [7]. Mutations with
REA in the range of N1–10% of normal are associated with organ-
limited, later-onset renal and/or cardiac phenotypes. Heterozygous
females present more variable clinical phenotypes and are usually less
severely affected than the hemizygous males [6,8], showing no clear-
cut genotype–phenotype correlations, including with REA. Further-
more, the distribution of α-Gal enzyme activities measured in hetero-
zygous females with pathogenic GLAmutations partially overlap those
observed in healthy females, potentially leading to many false negative
diagnoses [9]. This is, at least in part, attributable to the metabolic
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[10]. As a major consequence of this phenomenon, genetic molecular
testing is mandatory for a conclusive diagnosis of FD in females, while
inmales the laboratorymeasurement ofα-Gal enzyme activity is highly
reliable for both diagnostic and screening purposes [2,11].
Specific treatment for FD, by enzyme replacement therapy (ERT)with
genetically-engineered human α-Gal preparations (Agalsidase-alfa,
Replagal from Shire; and Agalsidase-beta, Fabrazyme from Genzyme, A
Sanofi Division) has been in clinical use for more than a decade now
[12,13]. The extremely high cost of ERT, the questions regarding the
cost-effectiveness of ERT for FD [14,15], the efficacy of different dosing
regimens [16,17], and the impact of anti-agalsidase antibodies in classi-
cally affected males treated with ERT [18], make it urgent to identify
biomarker(s) that reliably allow the clinical monitoring of the response
to ERT and dose individualization, without the need for invasive diagnos-
tic procedures (e.g., heart or kidney biopsies).
Although Gb3 is the major GSL accumulated in FD patients, and its
quantitation in plasma and urine has been used for laboratory monitor-
ing of disease progression [17], the correlation between clinical symp-
toms of FD and levels of Gb3 is inconsistent: [17,19,20] for instance,
asymptomatic children with absent or very low α-Gal REA sometimes
show abnormally high plasma Gb3 levels, while clinically affected fe-
males generally have plasma Gb3 levels within the normal range. On
the other hand, urine Gb3 excretion, expressed as the Gb3/creatinine
concentration ratio, significantly correlated with gender, genotype,
and ERT status of FD patients [21], and the measurement of urine Gb3
concentration has been suggested as a potential marker of disease se-
verity and monitoring response to treatment in FD males [22], as well
as for high-risk screening [23]. However, other investigators have
questioned the usefulness of Gb3 as a biomarker in FD [24]. Although
the decrease in left ventricular mass (LVM) observed in response to
agalsidase treatment correlates with the decline of plasma Gb3 levels
only in women [18], the reduction in plasma and urinary Gb3 in the
first year of ERT predicts the hazard of developing white matter lesions
and stroke in both genders [18].
Lyso-Gb3 has recently been proposed as a key pathogenic mediator
of the onset and progression of some of FD complications [25]. In vitro,
lyso-Gb3 promotes the proliferation of smooth muscle cells [25], a bio-
logical effect that might contribute to the increase of carotid intima–
media thickness, in the absence of atherosclerotic lesions, observed in
adult FD patients [26], For monitoring the effect of ERT upon LVM and
the risk of cerebrovascular complications of FD, measurements of
plasma lyso-Gb3 levelswere performed, aswell as plasma Gb3 [18]. Fur-
thermore, while urine from healthy controls contained no detectable
lyso-Gb3, increases in urinary lyso-Gb3/creatinine ratio significantly cor-
related with the concentrations of Gb3, types of GLA mutation, gender
and ERT status [27].
More than 750 unequivocally pathogenic GLA mutations have al-
ready been described [Human Gene Mutation Database; last accessed
at http://www.hgmd.cf.ac.uk, March 1, 2015], most of which are private
to single families. However, the GLA sequence variants most frequently
identified in newborn screenings and in case studies of patients with
potential late complications of FD, are novel neutral variants or exonic
and intronic variants of unknown pathogenic significance (VUPS) [28].
In the absence of definite biomarkers of GSL tissue load in FD patients,
the interpretation of equivocal genotyping findings should be supported
by robust clinical and histopathological data, as well as co-segregation
studieswithin families, in order to avoid false assumptions of pathogenic-
ity [28,29].
Clear-cut increases in plasma lyso-Gb3 or Gb3 concentrations
have been acknowledged as an ancillary diagnostic criterion of FD
[28,29]. Moreover, the discovery and analysis of analogs of lyso-Gb3
in urine [30–33] and in plasma [34–37] have shown to be interesting
biomarkers for FD patients. In fact, urinary lyso-Gb3 analogs were
specifically increased in FD patients with cardiac variant mutations,
in whom urinary Gb3 and lyso-Gb3 was normal, particularly inchildren [33]. We hypothesized that the measurement of lyso-Gb3
and related analogs in plasma and urine might be helpful for the dif-
ferential diagnosis of GLA neutral variants and VUPS. To test this hy-
pothesis, we have measured lyso-Gb3 and related analogs in urine
[32] and in plasma [37] samples in clinically well-characterized pa-
tients carrying several different GLA variant alleles, associated with
a wide range of α-Gal REA.
2. Subjects, materials and methods
2.1. Case ascertainment, consent and protocol clinical evaluations
The majority of the subjects selected for this study were patients
who either presented with clinical phenotypes warranting the differen-
tial diagnosis of FD, or with decreased α-Gal enzyme activity on dried
blood spots (DBS), collected to screen for FD among adult patients pre-
senting with LVH, CKD or stroke of unclear aetiology. The remaining
cases were healthy individuals identified during family screening of se-
lected patients. Patients were originally diagnosed at specialized clinics
at the university, tertiary care hospital (São João Hospital Centre, Porto,
Portugal), or referred thereto from other hospitals, for expert clinical
and genetic evaluation. The blood and urine samples required for the
Gb3- and lyso-Gb3-related biomarker assays were collected after
obtaining specific informed consent from each enrolled subject.
Baseline evaluation included a detailed clinical history and physical
examination, as well as a review of the available relevant analytical and
echocardiographic data, paying particular attention to possible dermato-
logical (hypohidrosis, angiokeratomas), neuropathic (acroparesthesias),
cerebrovascular (transient ischaemic attack, stroke), cardiac (arrhyth-
mias, LVH, ischaemic heart disease) and renal (albuminuria, proteinuria,
azotaemia) manifestations of FD. All patients were referred to the oph-
thalmology clinic for slit-lamp examination, to screen for the typical cor-
neal dystrophy of FD (i.e., cornea verticillata) [23]. Thefinal diagnosiswas
classified according to previously suggested criteria [28].With the excep-
tion of an anuric patient, who had been on renal replacement therapy
(RRT) by haemodialysis (HD) for several years, the plasma creatinine
concentration (pCr), the urinary albumin/creatinine ratio (UACR) and
urinary sediments were evaluated in all individuals, to diagnose and
stage CKD according to the guidelines of the “Kidney Disease: Improving
Global Outcomes (KDIGO)” initiative [38]. The glomerular filtration rate
was estimated (eGFR) from pCr by the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation [39].
2.2. GLA gene sequence analysis, laboratory assessment of α-galactosidase
activity and bioinformatic analyses
GLA gene mutations and sequence variants were identified by di-
rect sequencing of polymerase chain reaction (PCR) or reverse
transcription-PCR (RT-PCR) products, using a conventional Sanger
method [40]. The blood sample processing and analytical protocols
used for GLA genotyping have been previously reported [40]. GLA se-
quence changes are described according to the most recent recom-
mendations of the Human Genome Variation Society [HGVS; http://
www.hgvs.org/mutnomen/recs-prot.html].
The α-Gal enzyme activity in plasma, leukocytes or whole blood
(DBS) was measured by standard fluorometric assays, using 4-
methylumbelliferyl-α-D-galactopyranoside as the fluorescent
substrate, and N-acetyl-D-galactosamine as an inhibitor of α-N-
acetylgalactosaminidase activity [41]. Whenever necessary for prop-
er interpretation of the genotyping data, the diagnosis of α-Gal defi-
ciency in patients originally identified by decreased enzyme activity
on DBS testing was confirmed on a plasma or leukocyte α-Gal assay.
In vitro demonstration of marked α-Gal deficiency on a plasma or
leukocyte assay was considered as diagnostic in hemizygous males,
while the finding of a pathogenic GLAmutation was needed for con-
firmation of FD diagnosis in heterozygous females [2,11].
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stitutions caused by novel missense GLA variants on the structure and
function of α-Gal, bioinformatic tools were used: “MutationTaster2”
(accessed at http://www.mutationtaster.org/), “PolyPhen-2” (accessed
at http://genetics.bwh.harvard.edu/pph2/) and SIFT (accessed at
http://sift.jcvi.org). Variants were modelled onto the structure of wild-
type α-Gal, and the effect of the mutation on the α-Gal structure was
analyzed for the changes in chemical environment around the substitut-
ed amino-acid residue.2.3. Clinical and genetic characterization of the study cohort
The relevant demographic, clinical and genetic data from 12 individ-
uals enrolled in this study are summarized in Table 1. None of them re-
ported current or past history of acroparesthesias or of hypohidrosis, or
had typical FD angiokeratomas on physical examination of the skin, and
only patient (case I) showed cornea verticillata on slit-lampophthalmo-
logical examination.
Patient I was screened for FD at the age of 22 years and found to be
heterozygous for the nonsense GLAmutation p.Arg220Ter (or R220X)
that she inherited from her affected mother. The patient's leukocyte
α-Gal activity was moderately decreased (see Table 1), within the
usual range for FD females [1], but all her affected male relatives had
b1% REA, in agreement with the known association of this mutation
with the classical FD phenotype [1,42]. At 30 years of age, she was diag-
nosed with an unusual morphological presentation of FD cardiomyopa-
thy, as reported elsewhere [43]. At age 32 years, she remained clinically
asymptomatic and with normal UACR.
In patient II, LVHwasfirst noticed at the age of 58 years, in thework-
up of atypical acute chest pain, but its cause was attributed to long-
standing high blood pressure. The diagnosis of a cardiac variant of FD
was not recognized until 6 years later, when a screening DBS α-Gal
assay showed low REA (≈7% of the normal average) and GLA genotyp-
ing revealed hemizygosity for mutation p.Phe113Leu (or F113L), which
is associated with mild/attenuated cardiac phenotypes of FD [1,42]. At
age 64 years, the patient's echocardiogram showed severe concentric
LVH (maximum left ventricular wall thickness = 26mm), with systolic
anterior motion of the mitral valve; his renal function was normal
(pCr = 0.84 mg/dl), total proteinuria was quantified as 90 mg/day
and themicroscopic examination of urinary sediments did not showmi-
croscopic haematuria; and no significant vascular or white matter ab-
normalities were identified on the computed tomography scan of the
brain.Table 1
Demographic, clinical, biochemical and genetic characteristics of study subjects.
Case
identifier
Gender Age at genetic
diagnosis
Age at
sampling*
GLA gene
variant
α-Galactosidase
activity
I F 22 32 p.Arg220Ter (L) 25 nmol/h/mg
II M 63 64 p.Phe113Leu (S) 0.84 pmol/h/spot
III M 52 53 p.Asn215Ser (L) 4 nmol/h/mg
IV-P F 26 37 p.Arg118Cys (L) 44 nmol/h/mg
IV-Fa M 53 63 p.Arg118Cys (L) 25 nmol/h/mg
V-P F 33 38 p.Arg118Cys (L) 38 nmol/h/mg
V-Mo F 71 74 p.Arg118Cys ND
VI F 39 44 p.Arg118Cys (L) 40 nmol/h/mg
VII F 47 49 p.Asp83Asn (L) 45 nmol/h/mg
VII-Br¶ M 45 45 p.Asp83Asn (L) 73 nmol/h/mg
(P) 13 nmol/h/ml
VIII M 36 38 p.Asn228Ser (P) 9 nmol/h/ml
IX-P M 20 30 c.-10CNT (L) 68.4 nmol/h/mg
IX-Si F 23 34 c.-10CNT (L) 65.2 nmol/h/mg
Case identifiers: roman numerals refer to individual pedigrees, P = proband; Fa = proband's f
Gender identifiers: M =male/F = female. Ages reported in full years. (*) Age at the sampling
Missense exonic GLA gene sequence variants amino acid code: Arg = arginine; Phe = phen
aspartate; Ter = premature stop codon. CNT = cytosine to thymine transition.
(L) leukocyte assay; (P) plasma assay; (S) dried blood spot assay. ND: not determined. FD: FabThe diagnosis of FD in patient III wasmade at the age of 52 years, on
the electron-microscopy (EM) examination of a cardiac biopsy, which
had been obtained for the differential diagnosis of severe LVH (maxi-
mum left ventricular wall thickness = 19 mm). The histopathological
diagnosis was confirmed by the demonstration of low REA α-Gal on a
leukocyte assay (≈7% of the normal average) and the identification of
the pathogenic GLA missense mutation p.Asn215Ser (or N215S),
which is characteristically associated with a late-onset cardiac variant
of FD [1,42]. The patient reported history of poorly controlled severe hy-
pertension since the age of 38 years. Eight years later, on the screening
for additional cardiovascular risk factors following an acute coronary
syndrome, he was diagnosed with one-vessel coronary heart disease,
type 2 diabetes mellitus (T2DM) with non-proliferative diabetic
retinopathy, and combined hyperlipidaemia. Finally, at the age of
50 years, he had suffered a haemorrhagic stroke resulting in severe
right hemiparesis. A permanent pacemaker was implanted at age
52 years, for treatment of advanced atrioventricular block. At baseline
evaluation for systemic complications of FD, had CKD stage 3 (pCr =
1.7 mg/dl; GFR = 45 ml/min/1.73 m2) with UACR of 329 mg/g and
normal urinary sediments, but refused kidney biopsy for the differential
diagnosis of the aetiology of his kidney disease.
Patient IV-P was found to be heterozygous for the GLA VUPS
p.Arg118Cys (or R118C) on the diagnostic workup of multiple angio-
keratomas affecting the buttocks and upper thighs that she had first no-
ticed at the age of 22 years. Clinical details are described elsewhere [44].
Her father (case IV-Fa)was identified by cascade screening. Patients V-P
andVI,who are heterozygous for the sameGLAVUPS,were diagnosed in
a prospective FD case-finding study among incident adult stroke
patients aged up to 55 years [45]. Patient V-P's mother (case V-M),
was identified on cascade screening. Cases IV-Fa and V-Mo have been
thoroughly assessed for manifestations of FD but showed no major tar-
get organ complications attributable to the disease, respectively in their
7th and 8th decade of life [46]. The available clinical, biochemical and
histopathology data from individuals carrying the GLA p.Arg118Cys
variant strongly suggest that it does not co-segregate with FD clinical
phenotypes in a highly penetrant Mendelian fashion, but might rather
be amodulator of themultifactorial risk of cerebrovascular disease [46].
Patient VII, a 47-year-old female with history of T2DM and hyperten-
sion, was screened for FD for having suffered a cryptogenic ischaemic
stroke. Her α-Gal activity on a DBS assay was below the normal range
and the subsequent GLA genotyping identified a novel missense variant,
p.Asp83Asn (or D83N), consistently predicted to be non-pathogenic
change on bioinformatic analyses. The p.Asp83Asn substitution leads to
a small change on the surface of the α-Gal protein and is not expected(Normal
range)
Clinical phenotype leading to the genetic
diagnosis
Definite
diagnosis
(36–80) Family screening. Left ventricular non-compaction. Classical
(8.75–15.6) Hypertrophic cardiomyopathy. Non-classical
(36–80) Hypertrophic cardiomyopathy. Non-classical
(36–80) Angiokeratomas. No FD
(22–73) Family screening: father of case IV-P. No FD
(36–80) Stroke. No FD
Family screening: mother of case V-P. No FD
(36–80) Stroke. No FD
(36–80) Stroke. No FD
(36–80)
(6–19)
Family screening: brother of case VII-P. No FD
(6–19) Dilated cardiomyopathy; end-stage renal disease. No FD
(79–130) Stroke. No FD
(79–130) Family screening: sister of case IX-P. No FD
ather; Mo= proband's mother; Si = proband's sister; Br = proband's brother.
of plasma and urine for this study. (¶) Not included in the biomarker profile study.
ylalanine; Leu = leucine; Asn = asparagine; Ser = serine; Cys = cysteine; Asp =
ry disease.
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screening, one of her brothers, aged 45 years, was found to be hemizy-
gous for the sameGLA variant but showed nomanifestations whatsoev-
er of FD, and had normal plasma and leukocyte α-Gal activities
(Table 1). Their mother had died at age 55 years, from lung cancer,
with no history of any health problems attributable to FD.
Patient VIII, a 38-year-old man with end-stage CKD of unclear
aetiology and history of severe hypertension, who had been on regular
HD treatment since the age of 36 years, was eventually screened for
FD because of co-existent dilated cardiomyopathy. After the finding of
subnormal α-Gal activity on a DBS assay, GLA sequencing identified a
novel missense variant, p.Asn228Ser (or N228S). The p.Asn228Ser sub-
stitution leads to loss of two internal hydrogen bonds and the intro-
duction of a packing defect in the centre of the hydrophobic core of
the α-Gal protein and thus expected to cause a significant perturbation
to the structure (see Fig. 1B). Although this variant was consistently
predicted to be a pathogenic change also on bioinformatic analyses, a
confirmatory enzyme assay in plasma showed α-Gal activity within
the normal range, excluding FD as the cause of the patient's cardiac
dysfunction.
Patient IX-Pwas originally screened for FD in the etiologic investiga-
tion of recurrent ischaemic stroke in adolescence, as reported elsewhere
[40]. His leukocyte α-Gal activity was slightly, but consistently below
the normal reference range, and the only variation identified on se-
quencing all the GLA exons and exon–intron boundaries was the pres-
ence of a single nucleotide polymorphism (SNP) of the 5′-untranslated
region (5′UTR) of exon 1, resulting from a cytosine-to-thymine transi-
tion at position -10 in the cDNA (c.-10CNT). On family screening, his
healthy sister (case IX-Si), his healthy brother and their healthymother
were all found to be carriers of the same SNP [40]. At the age of 34 years,
case IX-Si remained in good health. The GLA c.-10CNT SNP is identifiedFig. 1. The alpha-galactosidase A (α-Gal) structure analyzed for the changes in chemical enviro
leads to a small change on the surface of theα-Gal protein. B. Thep.Asn228Ser (N228S) substitu
the centre of the hydrophobic core of the α-Gal protein.by the reference number rs2071225 at the SNP database of the National
Centre for Biotechnology Information (dbSNP; National Library of Med-
icine, NCBI; Bethesda, MD, U.S.A.; http://www.ncbi.nlm.nih.gov/snp)
and has been reported from several ethnically different populations
[40,47–49], with minor allele frequencies of 0.03 in the Portuguese
[50] and 0.05 in Britons [47].2.4. Blood and urine sample collection, processing, and shipment for
laboratory analysis of lyso-Gb3 and related analogs
Venous blood and urine samples were collected at a routine clinical
visit, before ERT was eventually started. No urine sample could be
obtained from patient VIII due to his anuric condition.
Lyso-Gb3 and analogs were quantified in plasma and urine samples,
whereas Gb33 was quantified only in urine. All analogs of lyso-Gb3 in
urine and in plasma were structurally elucidated and characterized as
modified sphingosine moieties [30,36]. For plasma separation, blood
was drawn by phlebotomy into a 6.0 mL BD Vacutainer® K2EDTA
tube (BD — Becton, Dickinson and Company, catalog number 367864;
Plymouth, United Kingdom). Blood samples were immediately centri-
fuged at 2250 g for 15 min, at 4 °C, and the plasma was pipetted into
2 mL plastic vials and kept frozen at−80 °C until shipment to the labo-
ratory. The urine specimens were collected from the midstream void
into plastic 150 mL sterile urine collection cups (Deltalab, catalog refer-
ence 409726; Barcelona, Spain). Immediately after collection, the urine
cup was vortexed and an aliquot of the well-mixed urine was pipetted
into a 15mLplastic tube and stored at−20 °C until shipment to the lab-
oratory. The plasma and urine samples were sent to the laboratory by
overseas express courier, in temperature-controlled packaging units,
at−20 °C.nment around the substituted amino-acid residue. A. The p.Asp83Asn (D83N) substitution
tion leads to loss of two internal hydrogenbonds and the introduction of a packing defect in
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and of Gb3 in urine
Urinary Gb3 was measured by high performance liquid chromatog-
raphy coupled to tandem mass spectrometry (Alliance-Quattro Micro
MS/MS; Waters Corporation, Milford, MA, United States of America)
according to a method previously published [21]. Lyso-Gb3 and related
analogs in urine and in plasma were measured by ultra-performance
liquid chromatography coupled to a tandemmass spectrometry system
(Acquity-UPLC I-Class Xevo TQ-S MS/MS; Waters) [32,37]. Creatinine
concentrations were quantified according to a method of isotope dilu-
tion using an ultra-performance liquid chromatography coupled to an
electrospray time-of-flight (UPLC-ESI-TOF) mass spectrometry system
[30]. The levels of all the urinary biomarkers were expressed as a ratio
to creatinine to normalize the concentration of urine [51].
3. Results
The results of biomarker quantification in plasma and urine samples
of 12 subjects enrolled in this study are presented in Table 2.
In plasma, lyso-Gb3 (mass/charge (m/z) ratio at 786) and its analogs
atm/z 802 andm/z 804were found at increased levels exclusively in pa-
tients with pathogenic GLA mutations (p.Arg220Ter, p.Phe113Leu and
p.Asn215Ser); the lyso-Gb3 analog atm/z 758 showed a similar pattern
but it was additionally detectable in one of the p.Arg118Cys heterozy-
gote (case IV-P); and the lyso-Gb3 analog at m/z 784 was detectable
only in patients with pathogenic mutations, but was found above the
normal reference range exclusively in the p.Asn215Ser hemizygote.
The lyso-Gb3 analog at m/z 820 was detectable at levels slightly above
the normal range in one of the individuals carrying non-pathogenic
GLA variants; at N2-fold above the upper limit of the normal range
(ULN) in the p.Arg220Ter heterozygote; and at N8-fold the ULN in the
two patients with the late-onset cardiac variants. The lyso-Gb3 analog
atm/z 836was detectable only in the three patientsmanifesting clinical-
ly severe heart disease, either cardiac variants of FD (cases II, III) or dilat-
ed cardiomyopathy of uncertain aetiology (case VIII).
In urine, lyso-Gb3 analogs at m/z 758, 774, 784, 800, 802, and lyso-
Gb3 (m/z= 786) itself were found at increased levels only in patients
with pathogenic GLA mutations, while Gb3 was within normal range
in the p.Asn215Ser hemizygote, but N4.5-fold above the ULN in the
p.Phe113Leu hemizygote and modestly increased in the p.Arg220Ter
heterozygote. In addition to the patients with pathogenic GLA muta-
tions, theurinary excretion of lyso-Gb3 analog atm/z 820was detectable
at a slightly increased level in one of the p.Arg118Cys heterozygotes
(case IV-P). Only the twomales with clinically severe heart disease car-
rying pathogenic GLAmutations showed increased urinary excretion of
lyso-Gb3 analog atm/z 836, at N1.5-fold the ULN.
4. Discussion
Overall, the plasma and urine biomarker panels broadly differentiat-
ed patients with known pathogenic GLA mutations from individuals
carrying VUPS, including exonic variants that either moderately affect
(p.Arg118Cys) or do not affect (p.Asp83Asn, p.Asn228Ser) α-Gal en-
zyme activity, as well as from individuals carrying a functional GLA 5′
UTR SNP (c.-10CNT).
The plasma and urinary biomarker profiles observed in the female
with the GLA p.Asp83Asn variant was entirely normal. Although
the p.Asp83Asn variant has been regarded as a pathogenic mutation
by the investigators of large-scale screening studies of FD among
European stroke patients [52] and Spanish HD patients [53], that as-
sumption has not been supported by intrafamilial segregation analyses
and/or kidney pathology data. In agreement with the in silico pre-
dictions, the results of our clinically unbiased family study strongly sug-
gest that GLA p.Asp83Asn is instead a non-pathogenic exonic variant. In
the structural analysis of α-Gal, the p.Asp83Asn appears to be a smallperturbation in the protein, suggesting that the enzyme could have
nearly wild-type activity.
The only abnormality identified in the panel of plasma biomarkers in
themalewith theGLA p.Asn228Ser variantwas the presence of the lyso-
Gb3 analog at m/z 836, which is undetectable in healthy controls. The
normal lyso-Gb3 level and of all its other analogs is in agreement with
the result of a confirmatory α-Gal enzyme assay in plasma and does
not corroborate the bioinformatic and structural modelling predictions
of pathogenicity. It is of note that lyso-Gb3 analog at m/z 836 was also
detected in the plasma of two patients diagnosed with cardiac variants
of FD, but was not found neither in the p.Arg118Cys hemizygote male,
who showed minimal LVH, probably not related to α-Gal deficiency
[46], nor in the p.Arg220Ter heterozygote female, who presented left
ventricular noncompaction, probably as an earlymanifestation of cardi-
ac involvement by FD [43]. This finding is particularly interesting in
view of the results of a recent study showing that elevated urinary
Gb3 excretion is associatedwith near-termmortality in non-FD patients
with advanced stages of heart disease [54]. Further studies with an in-
creased number of patients will be needed to elucidate whether an in-
creased plasma level of lyso-Gb3 analog atm/z 836 might be an earlier
biomarker of progressive heart disease.
A brother and sister carried the GLA 5′UTR SNP c.-10CNT. Hemizy-
gous and heterozygous carriers of the minor c.-10T allele have an aver-
age ≈25% lower leukocyte α-Gal activity, as compared to males and
females with the wild-type c.-10C or c.-10CC genotypes [40,50]. The
pattern of plasma and urinary biomarkers exhibited by the two siblings
was similar to the p.Asp83Asn heterozygote. The marginal increase
above normal range upper limit of the plasma lyso-Gb3 analog at m/z
820 observed in patient IX-P most probably is clinically meaningless.
Four females and one male carried the GLA p.Arg118Cys variant,
whose minor allele is associated with average residual leukocyte α-
Gal activities of≈30% and≈60% of the normal mean, respectively in
hemizygous males and heterozygous females [46]. The male (case IV-
Fa) and two of the females (cases V-P, VI) had normal patterns of plas-
ma and urinary biomarkers. In patient IV-P, the detection of minimal
amounts of lyso-Gb3 analog atm/z 758 in plasma and of lyso-Gb3 analog
atm/z 820 in urine is probably clinically insignificant. The normal con-
centrations of lyso-Gb3 in plasma and urine, and of Gb3 in the urine, ob-
served in case IV-P, are in agreementwith the results of a kidney biopsy
obtainedwhen shewas29 years old,whichdid not showany signs of FD
nephropathy or of abnormal accumulation of Gb3 [55]. Further evidence
that the GLA p.Arg118Cys variant does not cause FD nephropathy was
the lack of GSL deposits observed by the EM examination of a kidney bi-
opsy from a 42-year-old hemizygous male [46].
The p.Phe113Leu and p.Asn215Ser hemizygotes typically presented
with FD cardiac variants. Both patients exhibited rather similar bio-
marker patterns in plasma and urine, with the exceptions of the plasma
concentrations of lyso-Gb3 analog atm/z 784 and of urinary Gb3 excre-
tion levels. The lyso-Gb3 plasma levels were, respectively, ≈40% and
≈20% of the lowest levels observed in Dutch [56,57] or Japanese [58]
males with classic FD, and roughly of the same order of magnitude
than those reported in Chinese patientswith a late-onset cardiac variant
of FD, which is particularly common in Taiwan [59]. Like in the Dutch
[56] and the Chinese [59] cohorts, the plasma concentrations of lyso-
Gb3 observed in our patients with the p.Phe113Leu or the p.Asn215Ser
mutation reflected the severity of LVH; conversely, none of the lyso-
Gb3 analogs detected in plasma correlated better with the severity of
LVH than the plasma levels of lyso-Gb3.
Remarkably, the urinary Gb3 excretion was N4.5-fold above the
ULN in the p.Phe113Leu hemizygote, who showed only minimal
proteinuria, but was within the normal reference range in the
p.Asn215Ser hemizygote, who presented with CKD stage 3. As this
patient also had T2DM and diabetic retinopathy, diabetic nephropa-
thy might be the underlying cause of CKD. A kidney biopsy would be
critical to clarify the differential diagnosis but unfortunately could
not be obtained.
Table 2
Plasma and urinary tandem mass spectrometry biomarker results of the 12 studied subjects carrying GLA gene variants.
Plasma biomarkers [nmol/L] Urinary biomarkers [µg/mmol Cr]
Lyso–Gb3
m/z 786
Analog 
758
Analog 
784
Analog 
802
Analog 
804
Analog 
820
Analog 
836
Gb3
Lyso–Gb3
m/z 786
Analog 
758
Analog 
774
Analog 
784
Analog 
800
Analog 
802
Analog 
820
Analog 
836Case
identifier
Gender
GLA gene
variant
I F p.Arg220Ter 7.45 0.01 0.06 0.02 1.55 0.75 0 36 67 10 35 22 23 168 85 44
II M p.Phe113Leu 22.17 0.04 0.20 0.13 3.07 2.76 0.35 116 13 35 259 50 74 474 168 101
III M p.Asn215Ser 11.05 0.26 4.00 2.98 2.21 2.28 0.20 8 16 1 77 14 32 227 116 97
IV–P F p.Arg118Cys 0.38 0.01 0 0 0 0.07 0 9 0 0 0 0 0 9 15 45
IV–Fa M p.Arg118Cys 0.37 0 0 0 0 0.19 0 15 0 0 0 0 0 0 0 9
V–P F p.Arg118Cys 0.47 0 0 0 0 0.16 0 14 0 0 0 0 0 9 0 24
V–Mo F p.Arg118Cys 0.61 0 0 0 0 0.30 0 10 0 0 0 0 0 12 0 31
VI F p.Arg118Cys 0.37 0 0 0 0 0.20 0 8 0 0 0 0 0 4 6 20
VII F p.Asp83Asn 0.41 0 0 0 0 0.26 0 0 0 0 0 0 0 0 0 8
VIII M p.Asn228Ser 0.30 0 0 0 0 0.24 0.21 – – – – – – – – –
IX–P M c.–10C>T 0.36 0 0 0 0 0.32 0 4 0 0 0 0 0 0 0 15
IX–Si F c.–10C>T 0.53 0 0 0 0 0.30 0 3 0 0 0 0 0 6 0 22
Reference values
(Patients >18 years)
Normal ranges Normal ranges
0–2.4 0 0–0.9 0 0 0–0.3 0 0–25 0 0 0 0 0 0–17 0–14 0–55
Case identifiers: roman numerals refer to individual pedigrees, P = proband; Fa = proband's father; Mo = proband's mother; Si = proband's sister. Gender identifiers: M =male/F = female. Cr = creatinine.Missense exonic GLA gene sequence
variants are described according to the amino acid single letter code:
Arg = arginine; Phe = phenylalanine; Leu = leucine; Asn = asparagine; Ser = serine; Cys = cysteine; Asp = aspartate; Ter = premature stop codon. CNT = cytosine to thymine transition.
Abnormal biomarker levels are marked as shaded cells.
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102 S. Ferreira et al. / Clinica Chimica Acta 447 (2015) 96–104It has been previously argued that the urine levels of Gb3 cannot be
used as a marker of FD in patients with the p.Asn215Ser mutation [24].
This was based on the observation that only three of seven males and
none of five females carrying that mutation had elevated urinary Gb3
levels, but no data were reported regarding the kidney disease pheno-
type of those patients.
The GLA p.Asn215Sermutationwas originally identified in unrelated
asymptomatic individuals or mildly affected patients with late-onset
manifestations primarily confined to the heart [60]. A recent study has
shown that a paediatric Fabry patient cohort with the p.Asn215Ser
mutation presents normal urinary Gb3 and lyso-Gb3 levels but show ab-
normal levels of the urinary analogs [33]. In the United Kingdom, the
GLA p.Asn215Ser mutation was identified in three of the five unrelated
men diagnosed with FD on the prospective screening of patients pre-
senting with unexplained LVH at ≥40 years of age (n = 79), but in
none of those who were diagnosed at b40 years of age (n = 74) [61].
Males who are hemizygous for this GLA p.Asn215Ser may present
with renal dysfunction at advanced age, with the kidney biopsy show-
ing predominant involvement of podocytes and minimal or absence of
GSL deposits in other cell types [62], but only exceptionally [63] has
the p.Asn215Ser mutation been identified in FD case-finding studies
among HD patients. Indeed, the GLA p.Asn215Ser mutation was not de-
tected in any of 13 large-scale studies screening for FD among patients
on RRT that were carried out before 2010 (summarized at [64,65]),
nor in any of those that have been published subsequently [53,66–70],
adding up to more than 20,000 RRT patients screened and more than
30 newly diagnosed carriers of pathogenic GLA mutations. Mutation
p.Asn215Serwas also not identified in any of the large stroke patient co-
horts of the multinational European “Stroke in Young Fabry Patients
study” (n = 5023) [52], the “Belgian Fabry study” (n = 1000) [71],
the “Stroke Prevention in Young Men Study” (n = 558) [72] and the
“PORTYSTROKE study — Screening Genetic Conditions in Portuguese
Young Stroke Patients” (n = 493) [45]. Overall, these data suggest
that GLA mutation p.Asn215Ser might not be associated with severe,
renal or cerebrovascular complications of FD. The same holds true for
the epidemiology of GLAmutation p.Phe113Leu, which has never been
identified in FD case-finding studies among stroke or RRT patients, ex-
cept in one of the three newly diagnosed FD patients, among the 2012
males enrolled in the Portuguese screening of HD patients (Ferreira, S.
& Oliveira, J. P., personal observation).
Theoretically, relatively hydrophilic biomarkers of systemic GSL
metabolic load, like lyso-Gb3 [25], might be filtered and reabsorbed in
the kidney [57] andwould be expected to be found at increased concen-
trations in plasma and urine of FD patients. On the other hand, lipophilic
biomarkers, like Gb3 [25], reach the urinemainly in desquamated tubu-
lar cells and possibly also in podocytes [20,22], and may better reflect
the GSL kidney tissue load [22]. These postulates are in agreement
with our present findings and deserve further investigation, particularly
in correlation with kidney biopsy data.
In the heterozygous female for the p.Arg220Ter mutation, the plas-
ma levels of lyso-Gb3 and of most of its analogs were abnormally high,
while the lyso-Gb3 analogs atm/z 784 and 836were respectively within
the normal range or undetectable. The plasma lyso-Gb3 concentration
was of the same order of magnitude of the levels previously reported
for Dutch [56,57], Japanese [58] and Chinese [59] females carrying GLA
mutations associated with the classical phenotype of FD. The urinary
biomarker profile of the p.Arg220Ter female in this study showed an in-
creased level of excretion for all analogs, except for the analog at m/z
836, which was within the normal values. This urinary lyso-Gb3 profile
was similar to that of the p.Phe113Leu hemizygote but with significant-
ly lower amounts of all the analytes except for lyso-Gb3, which was de-
tected at 4- to 5-fold higher concentration. The patient's lyso-Gb3 urine
levels were within the range observed in Dutch males with classic FD
[57].
In conclusion, the plasma and urine lyso-Gb3 profiles closely corre-
lated with the phenotypic data for each study subject, supporting thecontention that they may constitute clinically useful biomarkers of FD.
Our findings are in line with those of Smid et al. [73], who showed
that plasma lyso-Gb3 is a reliable diagnostic tool to discern classical FD
from subjects without FD, and first describe a similar relationship be-
tween lyso-Gb3 analogs and the phenotypic expression of GLA muta-
tions and variants.
The hypothesis that increased levels of plasma and (possibly) uri-
nary lyso-Gb3 analog atm/z 836 are an earlier biomarker of progressive
heart disease, and that urinary excretion of Gb3 is a specific biomarker of
FD nephropathy, warrants further research studies [74] with larger,
carefully selected cardiac and renal patient cohorts.Conflict of interest declaration
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PAPER V 
Individuals with normal GLA gene sequence may present abnormally 
spliced alpha-galactosidase mRNA transcripts. 
Gene Cell and Tissue. 2016 January; 3(1):e34386.  
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OVERALL DISCUSSION AND CONCLUSIONS  
The major purpose of the research projects leading to this Thesis was to characterize the 
GLA gene variants identified in Portuguese patients presenting with CVD, including at 
the molecular structural and functional levels, as well as to describe their biochemical 
features, genotype-phenotype correlations and population genetics.  
Based on the results of several large case finding studies among patients presenting with 
cryptogenic stroke [7, 64, 65] and on the Fabry Registry data [39] it has been suggested 
that there might be a cerebrovascular phenotype of Fabry disease with no signs of organ 
involvement besides stroke and TIA, or with these manifestations preceding the 
development of any other complications attributable to the disease.  
Our own interest in the relationship between GLA gene variants and the risk of CVD 
was originally driven by the clinical observation of an adolescent male presenting with 
recurrent stroke, who showed mildly to moderately decreased αGal activity in 
leukocytes in association with hemizygosity for the GLA 5’UTR c.-10(C>T) SNP 
(rs2071225) [76]. However, the hypothetical c.-10(C>T)-related risk of CVD did not 
segregate as a Mendelian trait within the patient’s family. We had further demonstrated 
that c.-10(C>T) SNP causes a decrease in the amount of the enzyme identifiable by 
western blot in leucocyte protein extracts, thereby explaining the observed enzyme 
deficiency [76]. This was in agreement with the observation of decreased GLA mRNA 
levels in males hemizygous for the c.-10(C>T) [106]. 
The frequency of the c.-10(C>T) in the general Portuguese population (0.03) was 
similar to that described in Britons (0.05) and its relationship with lower αGal activity 
in leucocytes was confirmed in healthy volunteers of both genders [74]. Notably, in the 
“1000 Genomes – A Deep Catalog of Human Genetic Variation” database the allelic 
frequency of rs2071225 reported for several south Asian populations varies between 
0.28 and 0.4 
[http://browser.1000genomes.org/Homo_sapiens/Variation/Population?db=core;g=ENS
G00000102393;r=X:100652791-100662913;v=rs2071225;vdb=variation;vf=1473867].  
The GLA 5’UTR is remarkably polymorphic, with two other SNPs commonly identified 
in Caucasians, including in the Portuguese population, respectively designated as 
c.-12(G>A) (rs3027585) and c.-30(G>A) (rs3027584) [71]. Although the c.-12(G>A) 
does not apparently have any functional impact on leucocytes or plasma αGal enzyme 
activity [74], the c.-30(G>A) is associated with increased αGal activity in plasma [75]. 
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A possible explanation for the observed effects of both c.-10(C>T) and c.-30(G>A) 
upon enzyme activity is their location within DNA protein-binding regions that may be 
involved in the transcriptional regulation of the GLA gene expression [70, 79]. 
The PortYStroke study was designed as a FD case-finding study among young adult 
Portuguese patients presenting with a first-ever stroke [63]. Unlike preceding studies 
that also aimed to determine the prevalence of FD as a previously unsuspected cause of 
stroke, enrollment in the PortYStroke study was not limited to patients with cryptogenic 
ischaemic stroke and the screening for FD was based on GLA genotyping in all cases. 
No FD cases, either due to classic or cardiac variant GLA mutations, were identified in 
the PortYStroke study. The upper limit of the estimated 95% confidence interval for the 
prevalence of FD (0.9%) in the PortYStroke study was 25% lower than the 1.2% 
prevalence of FD in young stroke patients estimated by Rolfs et al. [7], which was the 
figure used to calculate the PortYStroke cohort size. Unfortunately, Rolfs et al. did not 
publish the GLA variants identified in their patients. Nevertheless, two missense GLA 
variants associated with moderately decreased αGal activity – p.Arg118Cys (R118C) 
and p.Asp313Tyr (D313Y) –, with a cumulated prevalence of 2.4% in the PortYStroke 
cohort, had significantly higher allelic frequencies among the young stroke patients than 
in the healthy Portuguese population. Moreover, among the patients with ischaemic 
stroke or intracerebral haemorrhage, the involvement of the posterior circulation 
territory was significantly higher in the carriers of GLA mutations, particularly of the 
p.Arg118Cys. These findings are particularly relevant given the higher prevalence of 
CVD involving the vertebro-basilar and posterior arterial territories among patients with 
FD as compared to the general stroke population. Of note, the allelic frequency of 
c.-10(C>T) in stroke patients and healthy controls did not significantly differ, 
suggesting that the lower αGal enzyme activity observed in the former does not increase 
the CVD risk. None of the comparable studies conducted in other populations, including 
Caucasians and African-Americans [62, 64-66], either contemporary with or subsequent 
to the PortYStroke study, confirmed the original findings of Rolfs et al. [7], but the 
different investigators had different interpretations about the nature and the pathogenic 
significance of the GLA variants found in their patients. However, the generalizability of 
the PortYStroke results to populations with a lower prevalence of CVD might be limited 
by the peculiar Portuguese epidemiological context: according to the multifactorial 
model for the aetiology and pathophysiology of stroke [107], the environmental and 
genetic factors contributing to the extremely high prevalence of CVD in Portugal [104] 
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might act synergistically with hypomorphic GLA variants, if mild to moderate decreases 
of αGal activity are, indeed, a metabolic risk factor for stroke. 
There are some controversial opinions about the pathogenic role of p.Asp313Tyr in FD 
[108], and this mutation has been reported to be associated with white matter lesions in 
the absence of other FD symptoms and considered potentially involved in neural tissue 
damage [109]. Nevertheless, the GLA p.Asp313Tyr had been generally characterized as 
a non-pathogenic pH-sensitive variant associated with pseudo-deficiency of αGal 
activity in plasma [110, 111], while the p.Arg118Cys had been identified in a single 
case among 37,104 newborn males enrolled in an Italian screening program. On the 
bases of molecular modeling and in vitro overexpression studies the p.Arg118Cys was 
classified as a late onset variant. In accordance to its location on a CpG island, and 
unlike most FD mutations which are private to single families, the p.Arg118Cys has 
been identified in apparently unrelated families of different geographic origins [65, 112-
117]. In the Portuguese population we identified five different microsatellite haplotypes 
segregating with the variant allele [118] supporting the hypothesis that multiple 
independent mutational events lie behind their occurrence in the population. 
Detailed phenotypic characterization of Portuguese and Spanish individuals carrying the 
GLA p.Arg118Cys variant, ascertained either on differential diagnostic workup for FD 
or through unbiased family screening, showed that this gene variant does not segregate 
with FD in a Mendelian fashion [118]. However it might constitute a metabolic risk 
factor for CVD, adding to other arteriosclerotic risk factors to increase the multifactorial 
risk of stroke, both in hemizygous males and heterozygous females [118]. The 
phenotype-genotype correlations observed in individuals carrying the p.Arg118Cys 
variant illustrate the dilemmas of making a diagnosis of FD in subjects with GLA 
variants of uncertain clinical significance, who are identified through the (intrinsically 
biased) screening of high-risk patient populations [108, 119-121], as the major late-
onset complications of FD are nonspecific and difficult to differentiate on clinical 
grounds alone, from the common forms of cerebrovascular, cardiac and renal disorders 
affecting the adult population [122, 123]. Electron microscopy examination of an 
endomyocardial or a kidney biopsy has been recently recommended as the gold-
standard to confirm the diagnosis of FD in adults with LVH or chronic kidney disease 
and a GLA gene variant of uncertain pathogenicity [108, 119-121]. However, such an 
approach is not possible to confirm FD-related cerebral vasculopathy in patients 
presenting with TIA or stroke.  
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The measurement of Gb3 and lysoGb3 in plasma and urine have been proposed as 
biomarkers of FD [86, 124-127]  and, particularly Gb3, has been used for laboratory 
monitoring of disease progression and response to ERT [128, 129]. However, its clinical 
utility has been questioned, particularly for non-classic patients [130-132]. Based on the 
promising data that have emerged from recent studies of lyso-Gb3 analogues in plasma 
and urine as biomarkers of FD [126, 133-136], we measured urinary Gb3, as well as 
lyso-Gb3 and related analogues in urine and plasma samples, of clinically well-
characterized patients carrying several different GLA variants associated with a wide 
range of αGal activity, including the p.Arg118Cys [137]. The major finding of this 
study was that the plasma and urinary biomarker panel clearly differentiated patients 
with known pathogenic GLA mutations from individuals carrying variants of unknown 
pathogenic significance (VUPS).  
Of note, coinheritance of p.Arg118Cys and the 5’UTR c.-10(C>T) apparently had 
additive effects upon leukocyte αGal activity measured in vitro [118]. This observation 
supported the assumption that GLA variants in the promoter region might be modulators 
of gene expression of hypomorphic variants. To test whether the various GLA 5’UTR 
SNPs identified in the Portuguese population indeed influenced the gene expression, we 
have used a standard luciferase reporter assay to measure the relative GLA gene 
expression in four embryologically distinct cell lines. The results of these studies 
confirmed our working hypothesis and have additionally shown that their modulatory 
effects upon gene expression are cell type specific.  
The great majority of GLA mutations associated to FD are missense or nonsense. Yet, 
5% of the pathogenic mutations in the GLA gene reported to HGMD are variants 
affecting the mRNA splicing most of them located at the donor and acceptor consensus 
splice site regions. To date, only two deep intronic GLA variants have been reported that 
perturb the splicing mechanism, resulting in the production of an alternatively spliced 
mRNA transcript, containing an additional 57bp exon between exons 4 and 5: IVS4 ds 
+919 G-A (HGMD Accession Number CS020811) [138]  and  IVS4 ds +861 C-T 
(HGMD Accession Number CS087458)  [139]. Although the alternatively spliced 
mRNA was also identified in normal controls, increased expression ratios of the 
alternatively spliced transcript correlated with low or very low αGal residual activity, in 
patients diagnosed with cardiac [138] or classic variants of FD [139]. 
We have serendipitously identified weakly regulated splicing signals leading to 
alternatively spliced mRNA GLA transcripts, most commonly with a deletion of 62bp 
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from exon 3 or a deletion of the entire exon 3. These transcripts are normally expressed 
at very low levels but are detectable in almost all blood samples when RNA is extracted 
more than 48h after collection. Dysregulation of molecular mechanisms controlling this 
process, particularly if restricted to specific cells or tissues, might be the cause of organ-
limited Gb3 pathology. 
The correlations between in vitro αGal residual activity, substrate accumulation and FD 
clinical phenotype are complex and still incompletely understood [3], and that other 
factors, besides the residual level of enzyme activity, play a crucial role in the 
pathogenesis of the disease [89]. It might also be possible that the in vitro αGal assays 
do not reflect the biological enzyme activity in vivo, thereby confounding the 
interpretation of genotype-phenotype correlations. As shown by our luciferase reporter 
assay studies, GLA gene expression might be under different molecular control systems 
in different cells types thus limiting the utility of plasma or leucocyte αGal enzyme 
assays to diagnose hypothetical patients with organ-limited Gb3 pathology [140]. In 
such cases, and in patients carrying  novel GLA variants or VUPS identified  in 
screenings of  high-risk population, histopathological [79, 120, 121, 140] or 
biochemical evidence of Gb3 accumulation [82, 141] in biopsies of affected tissues 
might be indispensable for correct diagnosis, particularly when comprehensive clinical 
assessment of hemizygous individuals identified by unbiased family screening is not 
possible or informative.  
The importance of the possible biological and clinical implications of our findings, 
namely (i) the differential 5’UTR-related regulation of GLA gene expression in different 
cell types, (ii) the relative loss of accuracy of the splicing mechanism of GLA mRNA in 
leukocytes when left standing at room temperature, and (iii) the possibility that 
hypomorphic alleles of the GLA gene are a metabolic risk factor for CVD, adding to the 
other major arteriosclerotic risk factors, warrant further investigation and elucidation of 
the underlying molecular mechanisms.  
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Summary
Background: The a-galactosidase gene (GLA) has
three single-nucleotide polymorphisms in the 5¶ un-
translated region of exon 1, respectively g.1150G>A,
g.1168G>A, g.1170C>T. The g.1150A allele is associ-
ated with increased plasma a-galactosidase (a-Gal)
activity in hemizygotes, while the others are regarded
as biologically neutral. The primary goal of this
investigation was to test the hypothesis, raised by a
clinical observation and results of a family study, that
the g.1170T allele polymorphism is associated with
lower a-Gal expression.
Subjects and methods: Plasma and leukocyte a-Gal
activities were assayed in unrelated healthy young
adults of both sexes, who had been genotyped for
GLA exon 1, and enzyme activity values in carriers of
any of the polymorphisms were compared to those of
individuals with the standard genotype; GLA exon 1
was genotyped in males who had a-Gal activity in
dried blood spots lower than 2 SD below the cohort
average.
Results and conclusions: Mean a-Gal leukocyte activ-
ity was õ25% higher in subjects with the g.1170C or
CC genotype than in those with the alternative
genotypes (p<0.05). The frequency of the g.1170T
allele in subjects with low a-Gal activity in dried blood
spots was 4-fold higher (p<0.05) than in the general
population. As in hemizygotes, the g.1150A heterozy-
gote identified in this study had plasma a-Gal activity
more than 2-fold above the normal mean. The g.1168A
allele did not affect enzyme activity. Surprisingly,
females with the standard GLA exon 1 genotype had
significantly higher plasma a-Gal activity than genet-
ically comparable males.
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Introduction
Human a-galactosidase (a-Gal; EC 3.2.1.22) is the
enzyme deficient in Fabry disease (OMIM #301500)
(Desnick et al 2001). The full sequence of the a-Gal
gene (GLA) has seven exons and extends for 12 463
base pairs on the long-arm of the X-chromosome
(Xq22.1) (Kornreich et al 1989). Exon 1 codes for the
initial 64 codons of the mRNA transcript but also
comprises 110 nucleotides preceding the start codon,
the 5¶ untranslated region (5¶ UTR). Three single-
nucleotide polymorphisms (SNPs) are known in this
region—g.1150G>A, g.1168G>A, g.1170C>T, respec-
tively at j30, j12 and j10 nucleotides counting
backwards from the start codon—which were original-
ly identified by single-strand conformation polymor-
phisms (SSCP) analysis (Davies et al 1993). Because
they are not translated and do not involve nucleotides
in the optimal context sequence of the start codon for
the initiation of mRNA translation (Kozak 1991),
these SNPs were regarded as neutral molecular
variants (Davies et al 1993). This theoretical assump-
tion was eventually challenged by the demonstration
that g.1150A hemizygotes had increased plasma a-Gal
activities, more than 3-fold above the normal mean, a
finding that was apparently due to transcriptional
upregulation of gene expression (Fitzmaurice et al
1997; Saifudeen et al 1995). However, genotype to
enzyme activity phenotype correlation studies have
never been reported with either the g.1168A>G or
the g.1170C>T and a formal demonstration that
these SNPs have no effect on GLA expression is still
lacking.
Decreased leukocyte a-Gal activity (õ45% of
normal mean) was detected in the diagnostic work-up
of a male teenager who had presented with idiopathic
cerebral ischemic small-vessel disease. On sequencing
all exons and the exon–intron boundaries of the GLA
gene, no mutation was found except for the g.1170T
allele. Within the patient_s family the g.1170C>T SNP
segregated with lower a-Gal activity levels, seemingly
in a co-dominant mode, an observation that led us to
postulate that the g.1170T allele decreases a-Gal
expression (Oliveira et al 2008).
To test this hypothesis in a larger number of
unrelated individuals, we genotyped GLA exon 1 in a
cohort of healthy young Portuguese adults and mea-
sured a-Gal enzyme activity in carriers of any of the 5¶
UTR SNPs and in male and female subjects with the
standard genotype. In addition, we screened for the
g.1170T allele among subjects who had shown a-Gal
activities in dried blood spots lower than 2 standard
deviations (SD) below the cohort mean and compared
its frequency in this group with that estimated in the
general population.
Subjects and methods
To screen for GLA 5¶ UTR SNPs and estimate their
allele frequencies in the Portuguese population, GLA
exon 1 was genotyped in a cohort of 50 male and 50
female unrelated healthy volunteers aged 20–25 years.
These individuals were pregraduate medical students,
received full information about the study protocol, and
gave formal consent for DNA analysis. All identified
carriers of the minor allele of any of the GLA 5¶ UTR
SNPs (Fcarriers_), and 10 males and 10 females
randomly selected among the subjects who had the
standard 5¶ UTR sequence (Fcontrols_), were invited to
donate an additional blood sample for a-Gal assays.
One g.1170T hemizygous male, as well as two males
and one female of the group of Fcontrols_, did not
attend the second blood sampling appointment. Blood
samples collected for the enzyme assays were sent to
the laboratory blind-coded as to the results of the
previous genotyping studies and were processed within
24 h of collection.
In addition, 30 anonymized archive dried blood spots
in filter paper (Fcases_) were randomly selected for
GLA exon 1 genotyping, among subjects who had
shown an a-Gal activity more than 2 SD below the
cohort average. This cohort was of a nationwide screen-
ing programme for Fabry disease in chronic haemodial-
ysis patients, which enrolled a total of 2212 males.
Samples from patients who received a final diagnosis of
Fabry disease or from subjects that also showed a low
b-galactosidase (b-Gal) activity were excluded before
selection of the subset for GLA genotyping.
JIMD Short Report #124 (2008) Online
Laboratory methods
Genomic DNA was extracted from leukocyte pellets
and from dried blood spots using standard laboratory
methods (Mullenbach et al 1989; Walsh et al 1991).
The following forward/reverse primers were used for
PCR amplification of GLA exon 1 (Madsen et al
1995): 5¶ATTGGTCTACCTCTGGGGATAACC/
5¶CGTTGAGACTCTCCAGTTCC. PCR amplifica-
tions were performed in a GeneAmp PCR System
9700 (Applied Biosystems, Foster City, CA, USA).
PCR reaction mixtures of 20 ml were prepared with
100 ng of template DNA, 2 ml buffer 10, 2 ml MgCl2
(25 mmol/L), 1 ml of a dNTP mix (100 mmol/L dNTP
Set, PCR grade, Invitrogen, Carlsbad, CA, USA),
10 pmol/L of the forward and the reverse primers,
and 0.5 U recombinant Taq DNA Polymerase (MBI
Fermentas, Vilnius, Lithuania). The PCR conditions
were as follows: initial denaturation for 5 min at 94-C;
35 cycles with denaturation at 94-C for 20 s, annealing
at 63-C for 20 s and extension at 72-C for 20 s;
terminal extension at 72-C for 10 min. The resultant
amplicon has 378 nucleotides, encompassing all the
5¶ UTR sequence and the translated sequence, as well
as 58 nucleotides of the 3¶ intronic flanking sequence.
The amplicons were screened by SSCP using the
GeneGel Excel 12.5/24 Kit (Amersham Biosciences,
Uppsala, Sweden). One ml of each PCR product was
mixed with 4 ml of a dilution buffer (10 mmol/L
EDTA, 0.1% SDS) and this solution was mixed with
an equal volume of loading buffer (96% formamide,
0.05% bromophenol blue, 0.05% xylene blue,
20 mmol/L EDTA). Following heat denaturation at
95-C for 5 min and snap-chilling on ice, a 6 ml aliquot
of each sample was loaded onto the 12.5% polyacryl-
amide gel. Electrophoreses were carried out at 10-C in
a GenePhor DNA Electrophoresis System (Amersham
Biosciences) using 3-hour runs at 600 V, 25 mA, and
15 W. Finally, the gels were fixed and silver-stained
using minor modifications of a reference method
(Bassam et al 1991), air-dried at 37-C and examined
visually.
Purified amplicons were obtained from the original
PCR products of individuals with any variant SSCP
pattern and from each of the Fcontrols_ by using the
GFX PCR DNA and Gel Band Purification Kit
(Amersham Biosciences). The purified amplicons were
sequenced in forward and reverse directions in an ABI
PRISM 310 Genetic Analyzer apparatus (Applied
Biosystems) using the ABI PRISM BigDye Termina-
tor v1.1 Cycle Sequencing Kit, and checked for
sequence variations.
Plasma and leukocyte activities of a-Gal were
measured using a fluorometric assay with 4-methyl-
umbelliferyl-D-galactoside as substrate (Svennerholm
et al 1979), in the presence of 0.1 mol/L N-acetylga-
lactosamine to inhibit a-N-acetylgalactosaminidase
activity (Mayes et al 1981). Leukocyte b-Gal activity
was measured as a control for sample quality.
Genetic databases, software
and website information
The GLA genomic and cDNA sequences used for
reference were those described at the National Center
for Biotechnology Information of the National Insti-
tutes of Health, USA (http://www.ncbi.nlm.nih.gov),
under GenBank accession numbers X14448 and
NM_000169.
The program FUTRscan_ (Pesole and Liuni 1999)
was used to search for known 5¶ UTR functional
elements, either in the regular or in the polymorphic
isoforms of the GLA mRNA.
Thermodynamic prediction of secondary structures
of the standard and the 5¶ UTR polymorphic GLA
mRNAs was done with the FRNAstructure_ software
(Mathews et al 2004), version 4.2. The GLA mRNA
nucleotide strings entered for computer analysis
contained the 110-nucleotide 5¶ UTR plus the start
codon, either with the standard sequence or with
appropriately substituted nucleotides at positions
g.1150, g.1168 and g.1170.
Statistical analysis
Allele frequencies were compared using the Fisher
exact test included in the FEpi Info for Windows_
statistical software (Dean et al 2002). Descriptive
statistics and comparisons of specific enzyme activities
and of enzyme activity ratios, expressed as mean T SD,
were done with FSPSS for Windows_ statistical soft-
ware, using the unpaired two-sample t-test. For all
statistical tests, p-values Q0.05 were considered not
significant (NS). One-sided p-values were calculated
for t-tests assessing the working hypothesis that the
g.1170T is associated with lower a-Gal activity in
leukocytes.
Results
Variant SSCP band patterns of the GLA exon 1 were
detected in five males and five females of the healthy
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volunteer cohort. DNA sequencing of the respective
amplicons showed that nine individuals (four males)
had 5¶ UTR SNP polymorphisms (Table 1) and one
male had a previously unreported exonic synonymous
point mutation (g.1227T>G/p.L16L). No homozygous
or double-heterozygous female for the minor 5¶ UTR
SNP alleles was detected.
Extraction of DNA from the filter paper was
unsuccessful in only one of the 30 archive dried blood
spots. Four of the remaining 29 Fcases_ showed a
variant SSCP pattern, which was confirmed as
corresponding to the g.1170T allele by DNA sequenc-
ing. The frequency of the g.1170T allele in this cohort
was significantly higher (p = 0.04) than in the healthy
volunteer cohort.
Enzyme analyses were carried out in 17 Fcontrols_
and in eight Fcarriers_ and these results are summa-
rized in Table 2. Leukocyte b-Gal activity was within
the normal laboratory range in all the samples. In
Fcontrols_, plasma a-Gal activity was significantly
different between the two sexes (p = 0.03). Extremely
outlying a-Gal activity values (3 SD below or above
the control group mean) were found in only two
individuals: a g.1170T hemizygous male who had a
value of 10.8 mkat/kg in the leukocyte assay, and a
g.1150A heterozygote female who had a value of
6.9 nkat/L in the plasma assay. However, these two
individuals respectively had plasma (3.0 nkat/L) or
leukocyte (31.2 mkat/kg) a-Gal activities within 1 SD
above the normal mean. In both, sequencing of all the
remaining GLA exons, including intronic flanking
sequences, excluded the presence of other mutations.
Although mean plasma a-Gal and leukocyte b-Gal
activities did not differ significantly, the a-Gal leuko-
cyte activity was õ25% lower in g.1170T carriers as
compared to Fcontrols_ (p = 0.02).
In silico analyses did not identify any 5¶ UTR
regulatory motifs in the a-Gal mRNA. Predicted
optimal secondary structures (Fig. 1) of the standard
and the polymorphic mRNAs were similar, with less
than 3.0 kcal/mol calculated free energy difference
between the g.1150G and the g.1150A isoforms, and
Table 1 Frequencies of the GLA 5¶ UTR SNPs in healthy Portuguese caucasians and in Britons, as estimated by SSCP
SNP Males (N) Females (N) Minor allele frequencies
Portuguese (chr) = 150 Britons (chr) = 101
g.1150G>A 0 1 0.007 0.02
g.1168G>A 1 2 0.02 0.03
g.1170C>T 3 2 0.03 0.05
(N): number of hemizygous males and of heterozygous females with the minor allele at each locus
(chr): number of chromosomes assayed in each study
Data in Britons reported by Davies et al (1993)
Table 2 Results of a-galactosidase and b-galactosidase enzyme assays in g.1170T carriers and in the control group
GLA 5¶ UTR
g.1170 genotype
N Leukocyte
a-galactosidase
activity (mkat/kg)
Leukocyte
b-galactosidase
activity (mkat/kg)
Leukocyte
a-Galactosidase
to b-galactosidase ratio
Plasma
a-galactosidase
activity (nkat/L)
C or CC 17 28.1T4.2* 89.7T24.0b 0.33T0.07d 2.6T0.7f
(males: C) 8 28.7T3.7a 98.9T29.8c 0.31T0.08e 2.2T0.5**
(min./max.) (23.2/34.5) (52.1/149.6) (1.5/2.9)
(females: CC) 9 27.5T4.7a 81.5T14.6c 0.34T0.06e 2.9T0.7**
(min./max.) (21.1/34.1) (57.1/102.6) (2.2/4.6)
T or CT 4 21.8T8.2* 85.5T35.6b 0.27T0.09d 2.5T0.6f
Independent samples t-test statistic:
*,**p<0.05;
a,b,c,d,e p=NS
* and d are of one-sided p-values
Normal range values, for the general population (established on a sample of 20 male and 20 female anonymous healthy adult
blood donors): 50–108 mkat/kg for b-Gal activity in leukocytes; 22–36 mkat/kg for a-Gal activity in leukocytes; and 2.3–9.9 nkat/L
for a-Gal activity in plasma. Conversion factors, SI to conventional units: mkat/kg protein3.6=nmol/h per mg protein; nkat/L
plasma 3.6=nmol/h per ml plasma
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less than 1.0 kcal/mol between the g.1170C and the
g.1170T isoforms.
Discussion
This study was designed to test the hypothesis that the
GLA g.1170C>T SNP modulates a-Gal expression, as
assessed by enzyme activity in leukocytes. Despite the
small number of cases included in the analyses, the
mean leukocyte a-Gal activity was significantly lower
in hemizygous and heterozygous carriers of the
g.1170T allele than in individuals with the standard
5¶ UTR gene sequence. The 4-fold higher frequency
of the g.1170C>T allele among subjects with sub-
normal a-Gal in dried blood spots, over the
estimated frequency in the general population, is
further evidence supporting the working hypothesis.
This study also confirms and expands the available
data on the functional consequences of the g.1150G>A
SNP. Similar to what has been previously described in
hemizygotes (Fitzmaurice et al 1997), the sole hetero-
zygote identified in the population screening had a
plasma a-Gal activity more than twice the mean of
Fcontrol_ females. The finding of normal leukocyte a-
Gal activity, along with high plasma activity, might be
explained by skewed X-chromosome inactivation of
the g.1150A allele in leukocytes and more even
inactivation pattern in other tissues also contributing
to the pool of circulating enzyme (Orstavik 2006).
Measuring plasma and leukocyte a-Gal activities in
g.1150A hemizygotes, besides avoiding the theoretical
confounding effect of X-chromosome inactivation,
would help to elucidate whether the increased a-Gal
activity is also observed in cell-based assays. Unfortu-
nately, such studies have never been reported and we
did not find any such hemizygotes in our screening.
Furthermore, the similarity of the frequency of the
g.1150A allele calculated in our study (õ0.007) and a
previous estimate in Americans (õ0.005), derived on
the assumption that the g.1150A allele would be found
only in males with plasma a-Gal activity more than 2-
fold above the normal average, is indirect evidence
that the g.1150A allele is indeed associated with high
a-Gal plasma enzyme activity.
The finding that all three carriers of the g.1168A
allele had normal leukocyte and plasma a-Gal activity
supports the prior assumption that the g.1168G>A has
no effect upon GLA gene expression.
As mRNA 5¶ UTR sequences are not translated, the
most plausible mechanism(s) underlying the impact of
the g.1150G>A and g.1170C>T SNPs on a-Gal expres-
sion would operate at transcriptional or translational
control. It is well established that 5¶ UTRs of
eukaryotic mRNAs play crucial roles in the posttran-
scriptional regulation of gene expression (Mignone
et al 2005; Wilkie et al 2003). Many functional ele-
ments in eukaryotic 5¶ UTR mRNA correspond to
short oligonucleotide tracts, which are binding sites for
various regulatory proteins (Davuluri et al 2000;
Fig. 1 Computer-predicted optimal secondary structures of the
standard (left), the g.1170T (middle) and the g.1150A (right) 5¶
UTR sequences of the a-Gal mRNA (calculated free energies
respectively of j34.2 kcal/mol, j32.0 kcal/mol and j31.3 kcal/mol).
The free energies of these structures are much lower than the
j50 kcal/mol required for inhibiting the progress of the scanning
ribosome in mRNA translation. In the drawings, g.1170 and g.1150
correspond to positions 101 and 81, respectively
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Kozak 1991; Pickering and Willis 2005). Another
important structural feature of mRNA 5¶ UTRs is the
formation of stable secondary structures which may
inhibit translation initiation by blocking the access of
the pre-initiation molecular complexes to the mRNA,
or its progress by resisting the unwinding activity of
the mRNA scanning molecular mechanism (Kozak
1991; Pickering and Willis 2005). Our in silico analyses
did not identify regulatory signal(s) in any of the a-Gal
mRNAs 5¶ UTR isoforms. In addition, the thermody-
namic free energies of their secondary structures did
not differ significantly and were much below the
j50 kcal/mol needed to impair translation by imped-
ing the progress of the scanning ribosome along the
mRNA (Kozak 1991; Pickering and Willis 2005). The
lack of structural translational inhibitory features in
the a-Gal mRNA 5¶ UTR is typical of mRNAs of
highly expressed genes, whose functional control
occurs mainly at the transcriptional level (Davuluri
et al 2000).
Although it has been suggested that a less stable 5¶
UTR stem–loop secondary structure in the g.1150A as
compared to the g.1150G mRNA (Fitzmaurice et al
1997) might be a mechanism contributing to the higher
a-Gal expression in carriers of the polymorphic allele,
our thermodynamic structural predictions, which were
based on the most recent version of the a-Gal mRNA,
do not support such an explanation.
Estimating the frequencies of the GLA 5¶ UTR
SNPs in the Portuguese population was not a primary
goal of our study. However, the total number of
unrelated X-chromosomes that we screened by SSCP
was the largest ever assayed for polymorphisms of
GLA exon 1. The allele frequencies of exon 1 SNPs
in this cohort did not differ significantly from
those reported in Britons (Davies et al 1993). In our
experience, SSCP is a sensitive method for the
identification of GLA 5¶ UTR SNPs, with a detection
rate of 100% for the g.1170C>T allele. A surprising
observation, which needs to be confirmed in an
adequately sized cohort, was the significantly higher
plasma a-Gal activity found in g.1170CC homozygotes
than in g.1170C hemizygotes, despite similar levels of
leukocyte activities. A sex difference in normal range
values could be a reason for the much lower sensitivity
of the plasma a-Gal assay in identifying females with
Fabry disease, as compared to the leukocyte assay
(Wilcox et al 2008), while in males the two assays can
be used interchangeably.
We did not investigate the molecular mechanisms
behind our findings, but some theoretical conjectures
are worth discussing. Transcriptional upregulation of
gene expression was suggested as the major explana-
tion for the high plasma a-Gal activity observed in
g.1150A males (Fitzmaurice et al 1997) because the
nucleotide transition occurred in a putative NF-kB/Ets
consensus binding site that was shown to inhibit
protein binding to the 5¶ UTR of the gene. Similarly,
the g.1168G>A and g.1170C>T SNPs are located
within a methylated DNA binding protein (MDBP)
consensus sequence, respectively at its first and third
nucleotide positions (Zhang et al 1990). The MDBP
site at the GLA 5¶ UTR was shown to have a strong
repressive effect on gene expression when its affinity
for MDBP was increased by various sequence changes
(Samac et al 1998). Interestingly, a C>T transition in
the third position of a consensus MDBP-binding
sequence in the human cytomegalovirus converted a
low-affinity methylation-independent MDBP site to a
high-affinity site, resulting in a significant increase in
MDBP binding and a 10-fold reduction of reporter
gene expression (Zhang et al 1995). However, site-
directed mutagenesis experiments in the methylation-
dependent MDBP consensus motif of plasmid pBR322
(Khan et al 1988) suggest that both the g.1168A and
the g.1170T alleles would moderately decrease MDBP
binding to the GLA 5¶ UTR site. The reason for these
contrasting data needs to be specifically addressed in
future experimental studies.
In both g.1150A and g.1170T carriers, a-Gal activity
levels were proportionally higher in plasma than in
leukocytes, relative to the normal reference ranges. A
possible explanation for this finding is the substantially
longer circulating half-life of the more sialylated
human plasma isozyme (Brady et al 1973; Desnick
et al 1979).
Finally, it is not clear why females may have higher
plasma a-Gal activity than males. Studies of over-
expression of human a-Gal cDNA in transfected
Chinese hamster ovary cells have not shown preferen-
tial routing of the enzyme to the extracellular space
except in highly amplified clones (Ioannou et al 1992).
At physiological levels of expression, a higher sialyla-
tion rate of the nascent a-Gal protein in female cells is
an attractive hypothesis. Sex-specific glycosylation
patterns have already been demonstrated in humans
(Lapid and Sharon 2006) and their possible occurrence
in a-Gal deserves further investigation.
As the small number of subjects included in our
study cohorts precludes any definite conclusions, the
findings report herein need to be confirmed in
adequately sized populations.
Acknowledgements This study was partially supported by a
grant from Genzyme Corporation. We thank Rob Pomponio,
PhD, Genzyme Corporation, for critically reviewing the
JIMD Short Report #124 (2008) Online
manuscript, and Hans Ebels, MD, Genzyme Europe BV, for
editorial assistance.
Parts of these data were presented at the F7th European
Round Table on Fabry Disease_, 27–28 October 2006, Barce-
lona, Spain, and published as an abstract in Clinical Therapeutics
2007; 9(Supplement A).
We are grateful to the medical students, the patient and his
relatives who have made this study possible.
References
Bassam BJ, Anolle´s GC, Gresshoff PM (1991) Fast and sensi-
tive silver staining of DNA in polyacrylamide gels. Anal
Biochem 196: 80–83.
Brady RO, Tallman JF, Johnson WG, et al (1973) Replacement
therapy for inherited enzyme deficiency. Use of purified
ceramidetrihexosidase in Fabry_s disease. N Engl J Med
289: 9–14.
Davies JP, Winchester BG, Malcolm S (1993) Sequence
variations in the first exon of alpha-galactosidase A. J Med
Genet 30: 658–663.
Davuluri RV, Suzuki Y, Sugano S, Zhang MQ (2000) CART
classification of human 5¶ UTR sequences. Genome Res 10:
1807–1816. doi:10.1101/gr.GR-1460R.
Dean AG, Arner TG, Sunki GG, et al (2002) Epi Infoi, A
Database and Statistics Program for Public Health Profes-
sionals. Atlanta, GA: Centers for Disease Control and
Prevention.
Desnick RJ, Dean KJ, Grabowski G, Bishop DF, Sweeley CC
(1979) Enzyme therapy in Fabry disease: differential in vivo
plasma clearance and metabolic effectiveness of plasma and
splenic a-galactosidase A isozymes. Proc Natl Acad Sci U S A
76: 5326–5330. doi:10.1073/pnas.76.10.5326.
Desnick RJ, Ioannou YA, Eng CM (2001) a-Galactosidase A
deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly
WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B,
assoc. eds. The Metabolic and Molecular Bases of Inherited
Disease, 8th edn. New York: McGraw-Hill, 3733–3774.
Fitzmaurice TF, Desnick RJ, Bishop DF (1997) Human alpha-
galactosidase A: high plasma activity expressed by the
j30G>A allele. J Inherit Metab Dis 20: 643–657. doi:10.1023/
A:1005366224351.
Ioannou YA, Bishop DE, Desnick RJ (1992) Overexpression of
human a-galactosidase A results in its intracellular aggre-
gation, crystallization in lysosomes, and selective secretion.
J Cell Biol 119: 1137–1150. doi:10.1083/jcb.119.5.1137.
Khan R, Zhang X-Y, Supakar PC, Ehrlich KC, Ehrlich M (1988)
Human methylated DNA-binding protein. Determinants of
a pBR322 recognition site. J Biol Chem 263: 14374–14383.
Kornreich R, Desnick RJ, Bishop DF (1989) Nucleotide
sequence of the human a-galactosidase A. Nucleic Acids
Res 17: 3301–3302. doi:10.1093/nar/17.8.3301.
Kozak M (1991) Structural features in eukaryotic mRNAs that
modulate the initiation of translation. J Biol Chem 266:
19867–19870.
Lapid K, Sharon N (2006) Meet the multifunctional and sexy
glycoforms of glycodelin. Glycobiology 16: 39R–45R.
doi:10.1093/glycob/cwj059.
Madsen KM, Hasholt L, Sørensen SA, Ferme´r ML, Dahl N
(1995) Two novel mutations (L32P) and (G85N) amongst
five different missense mutations in six Danish families with
Fabry_s disease. Hum Mutat 5: 277–278. doi:10.1002/
humu.1380050316.
Mathews DH, Disney MD, Childs JL, et al (2004) Incorporating
chemical modification constraints into a dynamic program-
ming algorithm for prediction of RNA secondary structure.
Proc Natl Acad Sci U S A 101: 7287–7292. doi:10.1073/
pnas.0401799101.
Mayes JS, Scheerer JB, Sifers RN, Donaldson ML (1981)
Differential assay for lysosomal alpha-galactosidases in
human tissues and its application to Fabry_s disease. Clin
Chim Acta 112: 247–251. doi:10.1016/0009-8981(81)90384-3.
Mignone F, Grillo G, Licciulli F, et al (2005) UTRdb and
UTRsite: a collection of sequences and regulatory motifs of
the untranslated regions of eukaryotic mRNAs. Nucleic
Acids Res 33: D141–D146. doi:10.1093/nar/gki021.
Mullenbach R, Lagoda PJL, Welter C (1989) An efficient salt–
chloroform extraction of DNA from blood and tissues.
Trends Genet 5: 391.
Oliveira JP, Ferreira S, Reguenga C, Carvalho F, Ma˚nsson JE
(2008) The g.1170C>T polymorphism of the 5¶ untranslat-
ed region of the human alpha-galactosidase gene is asso-
ciated with decreased enzyme expression—evidence from a
family study. J Inherit Metab Dis. doi:10.1007/s10545-008-
0972-0.
Orstavik KH (2006) Skewed X inactivation in healthy individ-
uals and in different diseases. Acta Paediatr Suppl 95: 24–29.
doi:10.1080/08035320600618783.
Pesole G, Liuni S (1999) Internet resources for the functional
analysis of 5¶ and 3¶ untranslated regions of eukaryotic
mRNA. Trends Genet 15: 378. doi:10.1016/S0168-
9525(99)01795-3.
Pickering BM, Willis E (2005) The implications of structured 5¶
untranslated regions on translation and disease. Semin Cell
Dev Biol 16: 39–47. doi:10.1016/j.semcdb.2004.11.006.
Saifudeen Z, Desnick RJ, Ehrlich M (1995) A mutation in the 5¶
untranslated region of the human alpha-galactosidase A
gene in high-activity variants inhibits specific protein
binding. FEBS Lett 371: 181–184. doi:10.1016/0014-
5793(95)00891-C.
Samac S, Rice JC, Ehrlich M (1998) Analysis of methylation in
the 5¶ region of the human alpha-galactosidase A gene
containing a binding site for methylated DNA-binding
protein/RFX1-4. Biol Chem 379: 541–544.
Svennerholm L, Hakansson G, Mansson JE, Vanier MT (1979)
The assay of sphingolipid hydrolases in white blood cells
with labelled natural substrates. Clin Chim Acta 92: 53–64.
doi:10.1016/0009-8981(79)90396-6.
Walsh PS, Metzger DA, Higuchi R (1991) ChelexT 100 as a
medium for simple extraction of DNA for PCR based
typing from forensic material. BioTechniques 10: 506–513.
Wilcox WR, Oliveira JP, Hopkin RJ, et al. (2008). Females with
Fabry disease frequently have major organ involvement:
lessons from the Fabry Registry. Mol Genet Metab 93: 112–
128. doi:10.1016/j.ymgme.2007.09.013.
Wilkie GS, Dickson KS, Gray NK (2003) Regulation of
mRNA translation by 5¶- and 3¶-UTR-binding factors.
Trends Biochem Sci 28: 182–188. doi:10.1016/S0968-
0004(03)00051-3.
Zhang X-Y, Asiedu CK, Supakar PC, et al (1990) Binding sites
in mammalian genes and viral gene regulatory regions
recognized by methylated DNA-binding protein. Nucleic
Acids Res 18: 6253–6260. doi:10.1093/nar/18.21.6253.
Zhang X-Y, Ni Y-S, Saifudeen Z, Asiedu CK, Supakar PC,
Ehrlich M (1995) Increased binding of a transcription factor
immediately downstream of a cap site of a cytomegalovirus
gene represses expression. Nucleic Acids Res 23: 3026–3033.
doi:10.1093/nar/23.15.3026.
JIMD Short Report #124 (2008) Online
120 
 
 
  
 
 
 
 
 
PAPER VII 
The g.1170C>T polymorphism of the 5'-untranslated region of the human 
alpha-galactosidase gene is associated with decreased enzyme expression - 
evidence from a family study. 
J. Inherit. Metabol. Dis. 2008 31 Suppl 2:S405-13. 
  
PA
PE
R
 
V
II 
122 
 
 
SHORT REPORT
The g.1170C>T polymorphism of the 5¶ untranslated region
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Summary Subnormal leukocyte !-galactosidase (!-Gal)
activity was found during evaluation of an adolescent
male with cryptogenic cerebrovascular small-vessel dis-
ease. The only molecular abnormality found was the
g.1170C>T single-nucleotide polymorphism (SNP) in
the 5¶ untranslated region of exon 1 in the !-Gal gene
(GLA). Historically, this polymorphism has been con-
sidered to be biologically neutral. To test the hypothesis
that the g.1170T allele might be associated with lower
!-Gal expression, we genotyped GLA exon 1 and
measured leukocyte and plasma !-Gal in the parents,
brother and sister of the index case. The g.1170T allele
co-segregated with a subnormal leukocyte !-Gal activity
in the three siblings. Although plasma enzyme activities
were within the normal range in all five relatives, the
ranking of their values suggested a dosage effect of
the g.1170T allele. Western blotting assays of leukocyte
protein extracts showed that the relative expression of !-
Gal in both the patient and his sister was significantly
lower than in sex-matched hemizygous or homozygous
controls for the g.1170C allele, either normalized to the
b-actin immunoblot expression or standardized to a
known amount of recombinant human !-Gal. These
family data, in combination with results from a recent
GLA SNP screening study among healthy Portuguese
individuals, suggest that the g.1170C>T SNP may be co-
dominantly associated with a relatively decreased GLA
expression at the transcription and/or translation level.
Larger population studies are needed to confirm these
findings and to test the hypothesis that the GLA
g.1170C>T may contribute to the multifactorial risk of
ischaemic small-vessel cerebrovascular disease.
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Introduction
Alpha-galactosidase (!-Gal, EC 3.2.1.22) is a lysosom-
al enzyme that cleaves terminal !-D-galactosyl residues
from neutral glycosphingolipids. In humans, absence
or severe deficiency of !-Gal activity causes accumu-
lation of globotriaosylceramide (GL-3) in a variety of
cell types and tissues, including vascular endothelial
and smooth-muscle cells. In most cases, progressive
GL-3 storage leads to the Fclassical_ phenotype of
Anderson–Fabry disease (AFD, OMIM #301500)
(Desnick et al 2001a). The !-Gal gene (GLA) localizes
to Xq22 and has seven exons (Bishop et al 1988;
Kornreich et al 1989). The 5¶ untranslated region
(5¶ UTR) of the first exon has a high degree of mole-
cular variation. Three 5¶ UTR single-nucleotide poly-
morphisms (SNPs) were first described in screening of
exon 1 for single-strand conformation polymorphisms
(SSCP): g.1150G>A, g.1168G>A, and g.1170C>T,
respectively at positions j30, j12 and j10, counting
backwards from the mRNA start codon (Davies et al
1993). In Britons, the frequencies of the minor
polymorphic alleles (g.1150A, g.1168A, g.1170T) were
estimated to be between 0.02 and 0.05 (Davies et al
1993). As they did not modify the normal !-Gal
peptide sequence or affect nucleotide residues in
positions known to modulate the initiation of transla-
tion in eukaryotes (Kozak 1991), these SNPs were
originally thought to be biologically neutral. However,
unusually high plasma !-Gal enzyme activities (>2.5
times the normal mean) were later reported in two
unrelated healthy males hemizygous for the g.1150A
allele (Fitzmaurice et al 1997; Saifudeen et al 1995).
The higher !-Gal expression in these individuals
correlated with an increased amount of circulating
enzyme (Fitzmaurice et al 1997; Saifudeen et al 1995).
This was attributed to the nucleotide substitution at
position g.1150 interfering with the binding of nega-
tively-acting transcription factors that normally de-
crease GLA expression in various cells (Fitzmaurice
et al 1997).
Here we report evidence from a family study that
the g.1170C>T SNP, which is also located in a putative
binding site for another transcription regulatory pro-
tein (Fitzmaurice et al 1997), may be associated with
decreased !-Gal expression.
Material and methods
Case presentation
A Portuguese caucasian young adult male was referred
for genetic evaluation because of premature ischaemic
small-vessel cerebrovascular disease (ISVCD), with a
first neurological event at age 12 years. Despite a com-
prehensive diagnostic work-up (Ganesan et al 2003),
the aetiology of the ISVCD remained elusive. Brain
imaging showed typical features of ISVCD (Hassan
and Markus 2000), including basal ganglia and internal
capsule infarctions, and progressive T2-weighted hy-
perintense focal lesions in the periventricular and
subcortical white and deep grey matter.
On screening for possible genetic aetiologies of
ISVCD, leukocyte !-Gal enzyme activity was found
to be 26 nmol/h per mg (normal range 36–80), but this
value had been interpreted as normal biological
variation. The patient had no suggestive clinical
manifestations of AFD and his family medical history
was irrelevant. On sequencing of all GLA exons,
including exon/intron boundaries and the critical
region of the promoter (Ashley et al 2002; Bishop
et al 1988), the only genomic variation found was the
g.1170C>T SNP.
Laboratory materials and methods
To test the hypothesis that the patient_s subnormal !-
Gal enzyme activity might be genetically related to the
g.1170C>T SNP, plasma and leukocyte !-Gal activities
were simultaneously assayed in the patient and in all
his first-degree relatives, and the latter were genotyped
for the g.1170C>T SNP. Subsequently, the !-Gal
protein was semi-quantified by western blot in the
patient and his sister (g.1170C/T heterozygote), and
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in three controls with the canonical GLA exon 1
sequence (details in Fig. 1). All subjects were fully
informed about the study protocol and gave formal
consent prior to blood sampling.
Genomic DNA was extracted by a salt–chloroform
method (Mullenbach et al 1989). Total cellular RNA
was extracted using the TriPure Isolation Reagent
(Roche Diagnostics Corporation, Basel, Switzerland).
Extraction of proteins, sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and
western blotting were performed with minor variations
of standard protocols (Maniatis et al 1989).
For protein extraction, leukocytes were lysed in a
buffer containing 50 nmol/L BisTris at pH 7.0, 1 nmol/
L EDTA, 0.25 mol/L aminocaproic acid and 0.1%
Nonidet P-40, and a Protease Inhibitor Cocktail in
dimethyl sulfoxide (DMSO) solution (Sigma-Aldrich,
St Louis, MO, USA), at final concentration of 1/500.
Agalsidase-beta (Fabrazyme, Genzyme Corpora-
tion, Cambridge, MA, USA) was used as a source of
recombinant human !-Gal (rh-!-Gal). A remnant
volume of approximately 500 ml (5 mg/ml) was
recovered from two commercial vials of Fabrazyme
that had been reconstituted in preparation for intra-
venous administration. This solution was further
diluted with water for injection to a final aliquot
concentration of 5 ng/ml.
The primers used for polymerase chain reaction
(PCR) and reverse transcription PCR (RT-PCR) were
synthesized by Thermo Electron Corporation (Ulm,
Germany). All thermocycling reactions were carried
out in a 96-well GeneAmp PCR System 9700 (Applied
Biosystems, Foster City, CA, USA). DNA sequencing
analyses were done in an ABI Prism 310 Genetic
Analyzer (Applied Biosystems).
SDS-PAGE was carried out in a Mini-PROTEAN 3
Electrophoresis Cell (Bio Rad Laboratories, Hercules,
CA, USA) and the electrophoresed proteins were
transferred to nitrocellulose membranes in a Mini
Trans-Blot Electrophoretic Transfer Cell (Bio Rad
Laboratories).
PCR amplification
Amplicons of the critical promoter region and of all
GLA exons were obtained from genomic DNA
samples, using the primers described in Table 1. PCR
was performed in 20 ml reaction mixtures containing
Fig. 1 Immunodetection of !-Gal in a western blot of leukocyte
proteins using a rabbit polyclonal anti-human !-Gal antibody as
primary antibody (see Laboratory Materials and Methods for
details). MagicMark XP Western Protein Standard (Invitrogen)
was used for molecular weight (MW) marking. Following
staining, the nitrocellulose membranes were digitally photo-
graphed at 19011212 pixel resolution and the OD of each
immunoblot was measured on the digital images using the Kodak
1D Image Analysis Software (Eastman Kodak Rochester, NY,
USA). SDS-PAGE lanes and corresponding GLA g.1170 geno-
types, from left to right: lane 1, healthy young adult female
(g.1170C/C); lane 2, healthy young adult male (g.1170C); lane 4,
rh-!-Gal, 5 ng; lane 5, patient_s sister (g.1170C/T); lane 7, index
patient (g.1170T). Lanes 3 and 5 were left void. In a duplicate assay
performed with 25 ng of rh-!-Gal, the relative sizes of the !-Gal
blots of the study subjects were similar to those above (data not
shown). Relative quantification of each !-Gal blot was estimated
by dividing the corresponding OD by the rh-!-Gal blot OD (lane
4). These !-Gal/rh-!-Gal OD ratios were, respectively, 0.69 (lane
1), 0.88 (lane 2), 0.28 (lane 6), 0.34 and (lane 7). In addition, the
ODs of the corresponding chromogenically stained western blots of
b-Actin in the same nitrocellulose membrane (data not shown)
were used to normalize the expression of !-Gal to a second
housekeeping gene. The !-Gal/b-Actin blots OD ratios were,
respectively, 6.2 (lane 1), 12.6 (lane 2), 1.6 (lane 6) and 2.4 (lane
7). Taken together, these data consistently showed that the two
carriers of the g.1170 allele had lower intracellular amounts of !-Gal
as compared to controls with the canonical GLA 5¶ UTR sequence
JIMD Short Report #128 (2008) Online
100 ng genomic DNA, 2 ml buffer 10, 2 ml MgCl2
(25 mmol/L), 1 ml of a 10 mmol/L dNTP mix
(100 mmol/L dNTP Set, PCR grade; Invitrogen,
Carlsbad, CA, USA), 10 pmol of each relevant primer,
and 0.5 U of recombinant Taq DNA Polymerase (MBI
Fermentas, Vilnius, Lithuania).
One-step RT-PCR amplification
Two partially overlapping RT-PCR amplicons were
amplified from the patient_s RNA, using the primers
described in Table 2. One-step RT-PCR 50 ml reaction
mixtures were prepared with 100 ng of template RNA,
Table 1 Primers and conditions used for PCR amplification
Primer code Primer oligonucleotide sequence Primer coordinatesa
GLA exons 1–7 and exon-intron boundaries
GLA1-F 5¶-ATTGGTCTACCTCTGGGGATAACC-3¶ 1030–1053
GLA1-R 5¶-CGTTGAGACTCTCCAGTTCC-3¶ 1432–1451
GLA2-F 5¶-TGAAATCCCAAGGTGCCTAA-3¶ 5010–5029
GLA2-R 5¶-GTGTTGGGATTACAGCGTGAG-3¶ 5366–5386
GLA3-F 5¶-ACCTGGTGAAGTAACCTTGTC-3¶ 7159–7179
GLA3-R 5¶-ACCATGGCCTCAAAGTTC-3¶ 7484–7501
GLA4-F 5¶-TTGGGAAGCTGAGACAGAAGA-3¶ 8116–8136
GLA4-R 5¶-GGGGAAGACACAAGGATGACT-3¶ 8597–8617
GLA5-F 5¶-GACGTTCAATCTGTAAACTCA-3¶ 10019–10039
GLA5-R 5¶-TCTCACATAAAGCCTCCTC-3¶ 10382–10400
GLA6-F 5¶-TGGGTCATCTAGGTAACTTTAAG-3¶ 10441–10463
GLA6-R 5¶-GCAAGAAGCTTTATTACTGATAGT-3¶ 10802–10825
GLA7-F 5¶-ACTATCAGTAATAAAGCTTCTTGC-3¶ 10802–10825
GLA7-R 5¶-TGAGCTTTTAAAGTGAATGGAGAA-3¶ 11311–11334
GLA promoter region
PromGLA-F 5¶-CCGCTCTGGTCTTCATCATCA-3¶ 706–726
PromGLA-R 5¶-CATAAATTTCCGCGGGTAACCT-3¶ 1139–1160
a GLA genomic DNA nucleotide coordinates according to GenBank sequence version X14448.1 (GI:31755), obtained at the NCBI
(http://www.ncbi.nlm.nih.gov/entrez/), using accession number X14448.
The analysed sequence of the GLA promoter region comprised all of its putative regulatory elements, including the TATA box-like
element TAATAA, the five CCAAT box sequences and the two GC box consensus sequences (Bishop et al 1988, Desnick et al
2001a). The ATG start codon corresponds to nucleotide positions g.1180–1182.
The number in primer codes refers to the targeted exon; F: forward primer, R: reverse primer. Primers GLA1-F, GLA1-R, GLA6-F,
GLA6-R, GLA7-F have been previously described (Madsen et al 1996) and the others were of our own design. The exon amplicons
included the critical nucleotide sequences of the respective exon/intron boundaries. All 110 nucleotides of the 5¶ UTR are included in
the PCR product for exon 1.
The PCR conditions were as follows: initial denaturation at 94-C for 5 min; 35 cycles with denaturation at 94-C for 20 s, annealing at
63-C (promoter and exon 1), 61.5-C (exon 2), 60-C (exons 3, 4) or 55-C (exons 5, 6, 7) for 20 s, and extension at 72-C for 20 s; terminal
extension at 72-C for 10 min.
Table 2 Primers and conditions used for RT-PCR amplification
Primer code Primer oligonucleotide sequence Primer coordinatesa
GLA/RT1-F 5¶-ATTTATGCTGTCCGGTCACC-3¶ 85–104
GLA/RT1-R 5¶-GGCTTTTGAAAGGGCCACAT-3¶ 732–751
GLA/RT2-F 5¶-TTGGCAGATGGTTATAAGCAC-3¶ 648–668
GLA/RT2-R 5¶-AAGTCTTTTAATGACATCTGCAT-3¶ 1371–1393
a Complementary DNA nucleotide position coordinates according to RefSeq sequence version NM_000169.2 (GI:125661058),
obtained at the NCBI (http://www.ncbi.nlm.nih.gov/entrez/), using accession number NM_000169.
To avoid amplification of residual genomic DNA, primers GLA/RT1-R and GLA/RT2-F were designed to pair with !Gal mRNA
sequences overlapping GLA exons 4–5 and exons 3–4, respectively. Therefore, the final cDNA RT-PCR products included a common
sequence in their respective 3¶ and 5¶ terminals, corresponding to a part of the exon 4. These two partially overlapping amplicons
together comprise 1309 nucleotides of the GLA cDNA, including the last 26 nucleotides of the mRNA 5¶ UTR. The full sequence of
the GLA cDNA has 1418 nucleotides. F: forward primer, R: reverse primer.
The RT-PCR conditions were as follows: cDNA synthesis at 50-C for 30 min and pre-denaturation at 94-C for 3 min; 40 cycles with
denaturation at 94-C for 1 min, annealing at 60-C for 1 min, and extension at 72-C for 1.5 min; terminal extension at 72-C for 10 min.
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20 pmol of each relevant primer, and SuperScript One-
Step RT-PCR with Platinum Taq (Invitrogen).
PCR and RT-PCR products purification
and sequencing
Amplified PCR and RT-PCR products were purified
with GFX PCR DNA and Gel Band Purification Kit
(Amersham Biosciences, Uppsala, Sweden). The puri-
fied amplicons were then sequenced in forward and
reverse directions, using the BigDye Terminator v1.1
Cycle Sequencing Kit (Applied Biosystems).
GLA nucleotide sequence data and in silico GLA
mRNA analyses
The canonical genomic and cDNA/mRNA GLA
sequences were obtained from the National Center
for Biotechnology Information. (NCBI; Bethesda,
MD, USA) CoreNucleotide database. In silico struc-
tural and functional analyses of the GLA 5¶ UTR
g.1170 mRNA allelic isoforms were respectively per-
formed with the FRNAstructure_ (Mathews et al 2004)
and the FUTRscan_ (Pesole and Liuni 1999) programs.
Multiplex ligation-dependent probe
amplification (MLPA)
SALSA P001 Trisomy MLPA (Schouten et al 2002) probe-
mix kit (MRC-Holland, Amsterdam, The Netherlands)
was used to rule out the presence of an extra X chromosome
in the index patient.
Enzyme analysis
Plasma and leukocyte activities of !-Gal were measured
using a fluorimetric assay with 4-methylumbelliferyl-D-
galactoside as substrate (Svennerholm et al 1979), in the
presence of 0.1 mol/L N-acetylgalactosamine (Mayes
et al 1981).
SDS-PAGE
Electrophoreses were carried out on a 12% polyacryl-
amide resolving gel, in Tris-glycine buffer. Fifty-
microgram aliquots of the leukocyte protein extracts,
and 5 ml (assay 1) or 1 ml (assay 2) of the rh-!-Gal
solution, were dissolved in 3 SDS loading buffer, and
the sample volumes were adjusted to 15 ml with water
for injection. Electrophoreses were run for 60 min at
20 mA.
Western blotting
Proteins were eluted onto Protran Nitrocellulose
Membranes (BA85, 0.45 mm; Schleicher & Schuell,
Dassel, Germany) by applying an electric current of
0.65 mA/cm2 gel surface for 2 h in a transfer buffer
containing 39 mmol/L glycine, 48 mmol/L Tris base,
0.037% SDS and 20% methanol.
Chemoluminescent identification of !-Gal
A rabbit polyclonal anti-human !-Gal antibody (Fabry
4, solution at 1.05 mg/ml; Genzyme Corporation) was
used as the primary antibody and a goat horseradish
peroxidase-labelled anti-rabbit IgG (H+L) (solution at
1 mg/ml; Vector Laboratories, Burlingame, CA, USA)
as the secondary antibody, at respective final concen-
trations of 1:200 and 1:5000.
Following reversible staining with Ponceau S, the
membranes were blocked with 5% non-fat dry milk and
incubated overnight with the primary antibody at 4-C.
After washing, the membranes were incubated with
the secondary antibody for 1 h at room temperature,
mounted in an autoradiography cassette and incubated
with SuperSignal West Pico Chemiluminescent Sub-
strate (Pierce Biotechnology, Rockford, IL, USA). The
autoradiography film was exposed for 3 min.
Chromogenic identification of b-actin
The blotting membrane of assay 2 was additionally used
for chromogenic identification of b-actin. After incuba-
tion in a stripping buffer at 60-C for 30 min and
washing, the immunoblotting protocol was repeated
with a mouse anti-actin IgM antibody (clone JLA20
DHSB, solution at 1 mg/ml; Developmental Studies
Hybridoma Bank, University of Iowa, IA, USA) as
primary antibody, and a biotin-conjugated goat isotype-
specific anti-mouse IgM (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) as secondary antibody, at re-
spective final volume ratios of 1:1000 and 1:5000. The
Vectastain ABC Kit (Vector Laboratories) was used
for staining.
Image analysis
The !-Gal autoradiogram of assay 2 and the chromo-
genically stained b-Actin western blot membrane were
digitally photographed and the optical density (OD) of
each blot was measured with a dedicated software
(details in Fig. 1),
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The !-Gal expression was normalized to b-actin
expression and quantitatively standardized to the 5 ng
rh-!-Gal blot, respectively by dividing the OD of each
!-Gal blot by the OD of the corresponding b-actin blot
or by the OD of the rh-!-Gal blot. The patient_s and
his daughter_s !-Gal expression ratios were compared
with their age- and sex-matched healthy controls.
Results
The g.1170C>T transition was the only GLA nucleo-
tide variant identified by sequencing all the patient_s
amplified exons and more than 350 nucleotides of the
promoter region, upstream of the 5¶ UTR sequence.
Sequencing of the RT-PCR amplicons further exclud-
ed the presence of splicing mutations. MLPA showed a
normal male electropherogram pattern. The exon 1
genotypes of the patient_s first-degree relatives are
shown in Table 3. None of the control subjects carried
the g.1170T allele.
The index patient and both his siblings had leuko-
cyte !-Gal activities below the lower limit of the
normal range, whereas their parents had normal values
(Table 3). The plasma !-Gal activity was within the
low-normal range in all, but the highest value was
observed in the father and the lowest values in the
male brothers, while the two females had intermediate
values (chance probability for all equivalent rankings
of values, assuming a co-dominant effect of the
g.1170C/T alleles on !-Gal expression: p = 0.03).
Results of the !-Gal western blot assay 2 are shown
in Fig. 1. Compared with controls, the patient_s and his
sister_s !-Gal/b-actin and !-Gal/rh-!-Gal expression
ratios were 5.3- and 3.9-fold, and 2.6- and 2.5-fold
lower, respectively.
Discussion
Male hemizygotes with classical AFD have !-Gal
activity levels below 1% of normal (Desnick et al
2001b). Higher enzyme activity levels are associated
with less severe clinical expression, and a Fcardiac
variant_ has been described in patients with !-Gal
activity as high as 30–35% of the normal mean
(Yoshitama et al 2001). However, the pathophysiolog-
ical consequences of leukocyte !-Gal activity de-
creased to 50% of the normal average, as in the
siblings presented here, have never been investigated.
In our patient, subnormal leukocyte !-Gal activity
levels (70–80% of the lower limit of normal) were
consistently observed several years apart. By the effect
of random X-chromosome inactivation, such slightly
decreased values are observed in many AFD hetero-
zygotes (Desnick et al 2001a) and might also be found
in AFD males with the XXY chromosome constitu-
tion. However, the presence of an X-chromosome
aneuploidy was excluded in our patient. In as much
as no GLA mutation affecting the protein sequence
was found, altered !-Gal physical or kinetic properties
are also very unlikely explanations for the observed
lower enzyme activity.
The assumption that the g.1170C>T SNP is a
biologically neutral polymorphism has never been
demonstrated by formal genotype-to-enzyme activity
correlation studies. In this family, the sibling concor-
dance for subnormal leukocyte !-Gal enzyme activity
Table 3 Leukocyte and plasma !-Gal enzyme activities in the index patient and in all his first-degree relatives, with corresponding
GLA g.1170 genotypes
Subject Age (years) GLA g.1170 allele(s) Leukocyte assays Plasma assay
!-Gal (nkat/L)
!-Gal (mkat/kg) b-Gal (mkat/kg)
Patient 20 T 19.0 70 2.61
Sister 23 C/T 18.1 77 2.83
Brother 17 T 18.4 68 2.39
Mother 45 C/T 31.6 101 2.99
Father 46 C 22.3 73 3.59
Subnormal values are shown in bold type.
Laboratory reference ranges (average; minimum–maximum):
!-galactosidase: in leukocytes = 28.5; 22–36 mkat/kg; in plasma = 4.63; 2.3–9.9 nkat/L.
b-galactosidase (measured as a control for sample quality): in leukocytes = 74; 50–108 mkat/kg.
These control values were established on a sample of 20 male and 20 female anonymous healthy adult blood donors.
Conversion factors (SI to conventional enzyme activity units):
nmol/h per mg protein = 3.6 mkat/kg protein.
nmol/h per ml plasma = 3.6 nkat/L plasma.
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suggests that a genetic factor, rather than normal
biological variation, is the most plausible cause. The
observed co-segregation of the g.1170T and subnormal
leukocyte !-Gal activity lends support to the hypoth-
esis that the g.1170C>T SNP exerts a quantitative
effect upon GLA expression at the transcription and/
or translation level. The decreased amount of intracel-
lular !-Gal protein in leukocytes of g.1170T carriers, as
demonstrated by the western blot assays, favours this
interpretation.
The rather different leukocyte !-Gal activities
observed in the patient_s mother and sister might be
simply due to spurious technical reasons, as the
mother_s leukocyte b-galactosidase activity control
level was also proportionately above the mean value
of her relatives. Alternatively, this finding could be
related to reverse proportions of g.1170C/T alleles
being inactivated in mother and sister. Indeed, given
the small size of the human haematopoietic progenitor
cell pool (Gale and Linch 1994), non-concordant X-
chromosome inactivation ratios in mother–daughter
pairs are not uncommon in leukocyte-based assays. In
addition, the mother_s higher leukocyte !-Gal activity
might be due to age-related reactivation of the GLA
gene, which has also been suggested as an explanation
for the higher leukocyte !-Gal activities not infre-
quently observed in older obligate AFD heterozygotes
(Desnick et al 2001a).
Every g.1170T male or female carrier in this family
showed plasma !-Gal activity values 50–60% below
the normal mean. Of note, the patient_s father, who
was the only g.1170C hemizygote, had the highest
value. Despite all enzyme activity values being within
the normal reference range, their ranking within the
family suggested a co-dominant dosage effect of the
GLA g.1170C/T alleles.
Since the circulating !-Gal protein pool most
probably has a multiplicity of cell sources of different
embryonic origins (Fitzmaurice et al 1997; Warnock
2005), it is not surprising that plasma !-Gal activity
may correlate only roughly with intracellular enzyme
activity, as measured in single cell types (Gale and
Linch 1994; Gale et al 1994). This is especially true in
females and could be the underlying reason for the
much lower sensitivity of the plasma !-Gal assay to
identify AFD heterozygotes, as compared with the
leukocyte assay (Wilcox et al 2008). The human
plasma !-Gal isozyme has a higher degree of sialyla-
tion than tissue isozymes (Brady et al 1973; Desnick
et al 1979). The substantially longer circulating half-
life of the more sialylated plasma !-Gal may addition-
ally be a reasonable explanation for the finding of low
normal plasma enzyme activities in subjects with
subnormal leukocyte !-Gal activities.
5¶ UTRs in mRNAs may have an important role in
the posttranscriptional regulation of gene expression,
and a number of structural features capable of
significantly modulating initiation of translation and
translation efficiency have been identified (Kozak
1991; Pickering and Willis 2005). Nevertheless, in silico
analyses did not identify any biologically relevant
difference in nucleotide sequence or secondary struc-
ture between j10C and j10T !-Gal mRNAs (Oliveira
et al 2008). This indirectly suggests that the effect of
the g.1170C>T SNP upon GLA expression might act at
the transcription level, rather than at the translation
level.
The g.1170C>T SNP is located in a putative binding
site for methylated DNA-binding protein (MDBP)
(Fitzmaurice et al 1997; Zhang et al 1989, 1990)
(Fig. 2), which is possibly involved in the repression
or attenuation of gene transcription, both through
cytosine methylation-dependent or independent
modes (Khan et al 1988; Wang et al 1986). In the
human cytomegalovirus, the substitution of thymine
for cytosine in the third position of a consensus
Fig. 2 Partial sequence of GLA exon 1, including the last 35
5¶ UTR nucleotides (lower-case letters) and the first 10
translated nucleotides (upper-case letters). The ATG start codon
is signalled by a horizontal line on top the corresponding upper-
case letters. Nucleotide positions j30 and j10, counting
backwards from the first nucleotide of the start codon, are
indicated above the DNA sequence. The three 5¶ UTR SNP sites
g.1150 (j30AUG), g.1168 (j12AUG) and g.1170 (j10AUG)
are depicted in bold letters, showing the most common allele.
The 14-nucleotide double-strand sequence is the MDBP binding
motif, which extends from position j12 to the thymine of the
start codon (Fitzmaurice et al 1997). The consensus sequence of
the MDBP binding motif is 5¶-RTMRYYAMRGMRAY-3¶
(Zhang et al 1995), where FR_ is any purine, FY_ is any
pyrimidine, FM_ is 5-methylcytosine or thymine. Also shown is
the Ets binding site, which includes the j30 position. The
transition of guanine to adenine at this location (g.1150G>A)
presumably decreases the binding of Ets and/or other negatively-
acting transcription factors, leading to enhanced GLA transcrip-
tion (Fitzmaurice et al 1997)
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MDBP-binding sequence (equivalent to the GLA
g.1170C>T transition) downstream of a cap site,
converted a low-affinity methylation-independent
MDBP site to a high-affinity site, resulting in a sig-
nificant increase in MDBP binding and a 10-fold
reduction of reporter gene expression (Zhang et al
1995). These latter findings are consistent with and
offer an attractive molecular explanation for the
observations in the family reported herein.
Ischaemic stroke is uncommon among adolescents
and young adults and the investigation of its causes
may lead to important insights regarding additional
mechanisms, beyond atherosclerosis, involved in the
pathogenesis of cerebrovascular disease. However,
despite a thorough diagnostic work-up, the aetiology
of ISVCD in our patient remained unclear. The
patient_s clinical and neuroradiological presentation
was similar to that of the classical AFD phenotype
(Fellgiebel et al 2005; Mitsias and Levine 1996; Moore
et al 2007), but his leukocyte !-Gal enzyme activity
was much higher than the residual levels observed in
males with classical AFD and unlikely to be associated
with endothelial GL-3 accumulation (Desnick et al
2001b), which is regarded as the major pathogenic
mechanism of major organ involvement in classic AFD
(Desnick et al 2001a, b). However, as enzyme replace-
ment therapy with rh-!-Gal does not seem to signi-
ficantly reduce the cerebrovascular risk associated
with AFD (Germain et al 2007; Moore et al 2007;
Schiffmann et al 2006), despite being highly efficient
in clearing GL-3 from endothelial cells (Germain et al
2007), the role of endothelial damage in the pathogen-
esis of stroke in patients with AFD needs further
elucidation.
A recent GLA SNP screening study among 100
healthy Portuguese males and females showed that the
mean leukocyte !-Gal activity was significantly lower
(õ25%) in unrelated hemizygous and heterozygous
carriers of the g.1170T allele than in individuals with
the standard 5¶ UTR gene sequence (Oliveira et al
2008). These data, in conjunction with the family data
presented here, suggest that the GLA g.1170C>T SNP
may be associated with a decreased expression of
!-Gal, which is particularly evident in leukocytes and
has a co-dominant effect upon plasma !-Gal activity.
Larger population studies are needed to confirm these
findings and to test the hypothesis that the GLA
g.1170C>T may contribute to the multifactorial risk of
ISVCD. In vitro gene transcription and translation
studies and electrophoretic mobility shift assays may
provide experimental confirmatory evidence and help
to clarify the putative role of the MDBP site in the
regulation of GLA gene expression.
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